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Abstract 
This study examined the potential significant differences in the distribution of adverse drug 
reactions (ADRs) by reporter (consumer versus physician) and patient outcome at case and event 
level. This study also contains exploratory questions to evaluate reporting of ADRs by consumers 
versus physician by system organ class (SOC) and reporter demographics within the United 
States Food & Drug Administration Adverse Event Reporting System (FAERS). The theoretical 
foundation applied in this quantitative study was the social amplification of risk framework. Data 
from the second quarter of 2016 were obtained from FAERS, and a total of 87,807 ADR reports 
corresponding to 143,399 ADRs were analyzed by utilizing the chi-square test, the odds ratio, and 
logistic regression. Cross-sectional design was employed to compare reporting of ADRs at the 
case and event level (case-based and event-based analyses, respectively) between reporters 
(consumer versus physician), specifically, for patient outcome, as well as SOC and reporter 
demographics. For both the case-based and event-based analyses, findings revealed that 
consumers reported more serious ADRs in comparison to physicians. Furthermore, findings 
confirmed a difference in ADR reporting between consumers and physicians depending on SOC 
groups. Additionally, consumers reported more nonserious ADRs in comparison to physicians. 
The results from this study may have implications for positive social change by augmenting 
pharmacovigilance systems at a national and international level to identify risks and risk factors 
spontaneously reported after drugs have been on the market. 
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Chapter 1: Introduction to the Study 
Introduction 
In this study, I examined the differences in reporting adverse drug reactions 
(ADRs) to the Food & Drug Administration (FDA) between consumers and physicians in 
the United States (US) at case and event level. ADRs are considered harmful effects 
arising from the use of medications (Abraham, & Ballinger, 2012). However, reporting 
differences may exist between consumers and physicians for different reporting 
categories resulting in a potential public health issue (Alatawi & Hansen, 2017). I 
addressed, in this study, those reporting differences between reporters (specifically, 
physicians and consumers) and the severity of ADRs based on patient outcome. 
Additionally, I evaluated the reporting of ADRs within different system organ classes 
(SOCs) and demographics. 
The under-reporting of ADRs is a limitation of current Pharmacovigilance (PV) 
systems within the US, thereby leading to the inability of regulators to estimate total 
safety risk (Alatawi & Hansen, 2017). The findings from this study determined whether 
consumer reporting was an important factor in ADR reporting, and if these reports (also 
used interchangeably referred to as “cases”) added value to the safety profile of a 
product. In addition, the results from this study have implications for positive social 
change in that may potentially be able to augment PV systems at a national and 
international level to identify risks and risk factors spontaneously reported after such 
drugs have been on the market (Pal, Duncombe, Falzon, & Olsson, 2013).  
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In this chapter, I first provide a background and the purpose of the study. Then, I 
identify the problem examined in the study, provide the theoretical framework of the 
study, describe the nature of the study and state the research questions and hypotheses. 
Last, I list the key definitions of terms used in the study, discuss the study assumptions, 
scope, delimitations, and limitations, and describe the significance of the study. 
Background 
PV is the science that serves as a crucial component in detecting, evaluating, and 
inhibiting ADRs or any other drug-related issues and/or effects (World Health 
Organization [WHO], 2017). The objective of PV is to facilitate the intake of medicines 
in a safe manner, evaluate and convey the risks and benefits of medicines on the market, 
and to disseminate information and educate consumers about drugs and other medicines 
(WHO, 2012). ADRs, which can be defined as harmful and involuntary responses 
resulting from doses used in humans, are deemed a limiting factor that arises from issues 
with patient compliance and medication adherence (Tadesse, Mekonnen, Tesfaye, & 
Tadesse, 2014). Researchers have discovered that nonadherence to medication stems 
from the following: patients (i.e., failure to comprehend essential health information 
regarding their own health); physicians (i.e., lack of communication with patients with 
regards to prescription of complex drug regimens); and, healthcare systems (i.e., office 
visit time limitations, limited access to care, and shortage of health information 
technology) (Brown & Bussell, 2011). 
Additionally, ADRs have continued to persist as a concern and public health 
issue, especially within underdeveloped countries in which sufficient drug toxicity 
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monitoring and reporting systems are virtually nonexistent (Sen, 2016). Researchers have 
revealed findings suggesting that, on national and international scales, more than 5% of 
hospital admissions were related to ADRs (Sultana, Cutroneo, & Trifirò, 2013), thereby 
responsible for nearly 20% of deaths annually among hospitalized patients (FDA, 2016a). 
Due to the nature of ADRs, public health agencies are faced with substantial 
economic consequences namely, on average, the medical expenditures of a hospital 
admission associated with an ADR ranges from circa $10,000 to $13,000 per 
person (Pillans, 2008). The US spends more than 30 billion dollars per year in managing 
ADRs, and these expenditures may be further magnified as a result of increased 
hospitalization, prolongation of hospital stay, and further clinical investigations in more 
serious cases (Sultana et al. 2013). Hence, ADRs have deleterious effects on the clinical, 
social, and economic aspects of society (Inácio, Cavaco, & Airaksinen, 2016). Therefore, 
to counteract the negative impact of ADRs, it is of paramount importance for regulatory 
agencies, such as the US FDA, to work in tandem with healthcare systems and 
pharmaceutical industries to constantly detect any drug safety issues and ensure a 
product’s label is current (Leroy, Dauxois, Théophile Haramburu, Tubert-Bitter, 2014). 
 To scrutinize and effectively manage the risks and adverse reactions related to 
drugs to which the public has access, regulatory agencies should enhance their 
postmarketing surveillance of drugs by implementing an efficient spontaneous reporting 
system (SRS) (Inácio et al., 2016). The objective of SRS during the postmarketing phase 
is the identification of new ADRs that may have otherwise gone undetected during 
clinical trials Phases I-III (WHO, 2012). The US FDA Adverse Event (AE) Reporting 
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System (FAERS), as a type of SRS, is a national postmarketing surveillance database that 
gathers data on ADRs, medication error reports, and product quality complaints leading 
to AEs submitted to the FDA by reporters, including consumers and physicians (FDA, 
2017). The FDA employs the FAERS database (the major postmarketing surveillance 
database used by the FDA for collecting ADRs reported by reporters) to detect safety 
signals (a new, potential causal association or a new aspect of a previously known 
relationship between an ADR and a drug or intervention) relating to ADRs and further 
assess additional potential safety concerns once they are discovered (Hauben & Aronson, 
2009). Hence, upon scrutinizing potential safety concerns from the FAERS system, the 
FDA can subsequently make informed regulatory decisions in an effort to ameliorate 
product safety and safeguard the health and well-being of the public, including, but not 
limited to, the following: updating the labeling information of a drug or product; limiting 
drug consumption or product usage; disseminating new safety information to the public; 
or, removing a product from the market (also known as product recall) (FDA, 2017). 
Healthcare systems need a system of spontaneous reporting of ADRs by 
consumers and physicians (and other healthcare professionals) to determine new 
reactions, record the rate of ADR occurrence, and present this information to prescribers 
to inhibit subsequent ADRs (Alatawi & Hansen, 2017; Pillans, 2008). Spontaneous 
reporting of ADRs during postmarketing (Phase IV) and approval by the FDA is a crucial 
strategy of ADR detection, thereby allowing the identification of serious, unpredicted, 
and uncommon ADRs that may not have been observed during clinical trials Phases I-III 
(Alatawi & Hansen, 2017; Pillans, 2008). Although one of the advantages of SRS, such 
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as FAERS, is its ability to detect ADRs in an economic manner, the major disadvantage 
of SRS is under-reporting of ADRs, which impedes the successful detection of signals 
and proper identification of safety issues and concerns (Sakaeda, Tamon, Kadoyama, & 
Okuno, 2013). Hence, given the significance of the reporting of ADRs, the under-
reporting of ADRs to the FDA by consumers and physicians is an impediment to 
ensuring the completeness of the safety profile of product. 
Researchers have estimated that more than 1 million serious ADRs are reported in 
the US on an annual basis (Maciejewski et al, 2017). Of these, 5 to 10% are fatal, while 
others lead to patient suffering, hospitalization, and increased health system burden 
(Lazarou, Pomeranz, & Corey, 1998). Furthermore, ADRs are one of the leading causes 
of mortality within the US, thereby comprising more than 40,000 deaths on an annual 
basis (Hoyert & Xu, 2012). Researchers have also estimated that only 6% of all ADRs 
are reported in the US (Alatawi & Hansen, 2017). This rather high rate of under-reporting 
hinders signal detection, which can be defined as the process of identifying a new, 
potential causal association (or a new aspect of a previously known relationship) between 
an ADR and a drug or intervention (Hauben & Aronson, 2009). Consequently, the failure 
to establish an association between an ADR and a drug can lead to more individuals at 
risk of developing an AE that results in potential patient outcomes like (a) death,  (b) life-
threatening (LT) situations, (c) initial or prolonged existing inpatient hospitalization, (d) 
persistent or significant disability or incapacity, (e) a congenital anomaly or birth defect, 
(f) necessary intervention to inhibit permanent damage, or (g) other (important) medical 
outcome, event, or reaction (FDA, 2016b). Hence, the under-reporting of ADRs has a 
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negative effect on public health due to the inability for healthcare professionals (HCPs) 
(particularly physicians) to detect and approximate the magnitude of drug risks, verify 
actionable issues, and ascertain potential action from regulatory agencies (Sen, 2016; 
Inácio et al., 2016). 
Typically, physicians have been almost entirely responsible for spontaneous 
reports of ADRs (WHO, 2012). However, the rather high rate of under-reporting has 
made it challenging for health authorities to protect the health and well-being of the 
public (Inácio et al., 2016). Researchers have discovered that insufficient knowledge 
about PV and ADR reporting, as well as apathetic attitudes on the part of HCPs are 
among the factors associated with under-reporting (Sen, 2016; Pillans, 2008). 
Furthermore, published findings suggest that the following factors may contribute to 
under-reporting by HCPs: reactions after drug consumption that are either unknown or 
well-known; an uncertainty regarding a causal association; lack of awareness of reporting 
requirements; lack of comprehension of the objective of spontaneous reporting schemes 
and the aim of SRSs; challenges in accessing report forms; and, an inadequate amount of 
reporting time (Biagi et al., 2013; Pillans, 2008). Moreover, results from qualitative 
research studies have suggested that the knowledge and attitudes of HCPs with regards to 
ADR reporting may be impacting under-reporting based on the survey responses of 
HCPs, who rationalized their lack of reporting ADRs via the following beliefs: serious 
adverse reactions will be extensively recorded when the medicine or product reaches the 
market; only safe medications or products may be related to ADR reporting; or, one case 
reported by a single physician will not contribute to medical knowledge (Herdeiro, 
7 
 
Figueiras, Polónia, & Gestal-Otero, 2005). Hence, researchers have concluded that it is 
essential to improve these factors to positively influence the quality and quantity of 
postmarketing surveillance data (Inácio et al., 2016; Sen, 2016; Biagi et al., 2013; Pillans, 
2008). 
In an effort to ameliorate the rate of under-reporting, public health authorities and 
PV centers require complete, accurate, and quality spontaneous reports. However, given 
the challenge of under-reporting of ADRs by physicians, public health authorities and PV 
centers have been recently relying upon consumer reporting, which is the reporting of 
suspected side effects of a drug by a consumer and not the HCP (WHO, 2012). 
Consumer reporting is a wider term that encompasses not only patients, but 
consumers as well (WHO, 2012). A patient may be defined as an individual who is 
receiving or is registered to receive medical treatment from physicians or other HCPs. 
The patient who was prescribed an analgesic from his/her physician, and the individual 
who purchases over-the-counter drugs at the pharmacy without a prescription are both 
consumers of a medicinal product (WHO, 2012). Hence, not all individuals who consume 
medicines are patients, but all patients are consumers. 
Although ADR reporting to national databases has typically been performed by 
HCPs, researchers have resorted to direct consumer reporting of ADRs to combat the 
persistent and negative consequences of ADRs, as well as to bolster the SRS (Aagaard & 
Hansen, 2013). Furthermore, although consumer reporting is not universally recognized 
in PV, it has been integrated within the PV systems in a select few countries, such as the 
US, Canada, the United Kingdom (UK), Australia, New Zealand, Sweden, Denmark, and 
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the Netherlands, which accept this form of reporting (Pillans, 2008). Moreover, there is 
scant evidence of the significance of spontaneous reporting by consumers. Consumers are 
being motivated to report ADRs to a SRS, and such organizations as the FDA, the WHO, 
and the European Commission, recognize the significance of the consumer in 
spontaneous reporting (European Medicines Agency, 2010). Hence, consumer reporting 
is gradually becoming more of a part of the PV process, especially concerning the relay 
of risk information (Sen, 2016; Van Grootheest, & de Graaf, 2003). 
Researchers have discovered that consumer reports are more comprehensive and 
specific than physicians’ reports, thereby detailing certain symptoms in a lucid manner 
(Sen, 2016). Consumer reports typically contain a detailed, direct, and personal account 
of the effects of ADRs from drug consumption in comparison to reports from physicians. 
Furthermore, consumer reporting possesses several advantages, including, but not limited 
to, the following: an increase in ADRs reported, especially new and previously 
unreported ADRs; early signal detection of ADRs; and, a potential strategy to prevent 
medication errors (Sen, 2016). Consumer reports describe the prevention of medication 
errors by identifying and describing new reactions to medications, as well as detailing 
patients’ reporting of their symptoms to their HCPs or to regulatory agencies (Britten, 
2009). According to Robertson and Newby (2003), direct and spontaneous consumer 
reporting provides greater insight for PV by facilitating the comprehension of ADRs, 
thereby potentially serving as a missing link for the issue of under-reporting of ADRs by 
physicians. Hence, researchers have determined the significance of the role of the 
consumer in spontaneous ADRs. 
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In this study, I evaluated the FAERS database in an effort to compare the 
differences between consumers and physicians in reporting ADRs to the FDA in the US 
at case and event level. Based on the research and analyses that was conducted, it was 
determined whether consumer reporting needed to be bolstered within PV in the US. A 
SRS that includes both consumer and HCP reporters has an increased chance of 
identifying ADRs at an early stage (Health Action International, 2015; Mitchell, Henry, 
Hennrikus, & O’Connell, 1994). Positive social change in overall patient safety was a 
major outcome of this study. For example, the combination of consumer reports with 
reports from HCPs yielded an increase in signal detection, which stimulated a more 
successful way to detect ADRs. Furthermore, it was determined that an increase in 
physician reporting, in combination with consumer reporting, reduced the rate of under-
reporting and this serves as a crucial factor in overall PV and drug safety (Health Action 
International, 2015). Hence, it was also determined that the combination of reports from 
both HCPs and consumers fostered the growth and progression of PV systems within the 
US and other countries as well. 
Problem Statement 
The problem I addressed in this study is the lack of reporting from different 
categories of reporters (consumer versus physician). The lack of reporting is a limitation 
of current PV systems within the US, thereby hindering regulators’ ability to quantify risk 
of under-reporting of ADRs (Alatawi & Hansen, 2017). In this study, I addressed the 
aforementioned problem by examining the potential significant difference in the 
distribution of ADRs by reporter (consumer versus physician) and patient outcome at 
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case and event level. I also evaluated the reporting of ADRs by consumers versus 
physician by SOC and demographics. 
Purpose of the Study 
In this quantitative study, I examined the statistical significance in the distribution 
of ADRs within the FAERS database by reporter (consumer versus physician) and patient 
outcome, and I also evaluated reporter differences in SOC and demographics. The factors 
explored and compared included the differences in under-reporting of consumer versus 
physician, thereby elucidating whether consumer reporting plays a pivotal role in AE 
reporting. It was anticipated that the outcome would have some bearing on the frequency 
of physician and consumer reporting and on differences in reporting rates between them. 
The reporter (consumer versus physician) was the independent variable, thereby 
consisting of two levels: consumer and physician. Patient outcome, SOC, and reporter 
demographics were the dependent variables. The unit of analysis was the total number of 
ADR cases and reported ADRs. In the severity of patient outcome analysis, I grouped 
patient outcomes into a dichotomous variable by severity and tested this first. Since the 
results turned out to be significant, I then went on to test specific dyads (e.g. fatal vs non-
fatal, LT vs non-LT, etc.) to further characterize the relationship.  Within the exploratory 
research questions, I also evaluated the total number of ADR cases and reported ADRs of 
reporters (consumer and physician; independent variable) versus patient outcome 
(dependent variable) and SOC (dependent variable), and I also evaluated the total number 
of cases and reported ADRs of reporters (consumer and physician) versus reporter 
demographics. 
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Research Questions and Hypothesis 
Primary Research Questions 
Research Question 1A: Is there a statistically significant difference in the 
distribution of ADRs by reporter (consumer versus physician) and patient outcome? 
H01A: There is no statistically significant difference in the distribution of ADRs 
by reporter (consumer versus physician) and patient outcome. 
Ha1A: There is a statistically significant difference in the distribution of ADRs by 
reporter (consumer versus physician) and patient outcome. 
Research Question 1B: Is there a statistically significant difference in the 
distribution of ADRs by reporter when comparing by severity of outcome? 
H01B: There is no statistically significant difference in the distribution of ADRs 
by reporter when comparing by severity of outcome. 
Ha1B: There is a statistically significant difference in the distribution of ADRs by 
reporter when comparing by severity of outcome. 
Exploratory Research Questions 
Research Question 2: Is there a statistically significant difference in the 
distribution of ADRs by reporter (consumer versus physician) and SOC? 
H02: There is no statistically significant difference in the distribution of ADRs by 
reporter (consumer versus physician) and SOC. 
Ha2: There is a statistically significant difference in the distribution of ADRs by 
reporter (consumer versus physician) and SOC. 
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Research Question 3: Is there a statistically significant difference in the 
distribution of ADRs by reporter (consumer and physician) and demographics? 
H03: There is no statistically significant difference in the distribution of ADRs by 
reporter (consumer versus physician) and demographics. 
Ha3: There is a statistically significant difference in the distribution of ADRs by 
reporter (consumer versus physician) and demographics. 
Theoretical Foundation 
The theoretical foundation most applicable to this study is known as social 
amplification of risk framework (SARF), which stems from the perception of risk 
framework. Risk comprises the likelihood and repercussions of the occurrence of an 
event (Adams, 1995). The theory holds that risk interrelates with the psychological, 
social, institutional, and cultural perceptions of individuals in a manner that may magnify 
or diminish individuals’ responses to the risk or risk event (Kasperson & Ratick, 1988). 
These changes in the perception of risk elicit behavioral responses from individuals that 
alter the social and economic aspects of society, thereby increasing or decreasing the 
actual physical risk (Kasperson & Ratick, 1988). The perception of risk as it applies to 
the present issue involves the premise that different groups (HCPs and non-HCPs, 
researchers and the public, or HCPs and consumers) hold different views on the possible 
risks associated with ADR reporting as described earlier. The results from Bongard et al. 
(2002), which will be given in greater detail in Chapter 2, bolstered the claim that risk 
perception of ADRs varies between consumers and healthcare professionals, which was 
crucial for this study and addressed the issue of under-reporting of ADRs by consumers 
13 
 
versus HCPS. Therefore, with respect to ADR reporting, consumers frequently have 
contrasting views in their perception of risk versus HCPs (Sen, 2016; Aronson, 2006). 
Nature of the Study 
This study was quantitative in nature, and secondary analysis of these data were 
performed by utilizing the chi-square test and the odds ratio (OR). This study was cross-
sectional and descriptive. The non-experimental research design (known as the cross-
sectional design) was employed to compare reporting of ADRs at case and event level 
between reporters (consumer versus physician), specifically, for patient outcome, as well 
as SOC and demographics. The independent variable was the reporter (consumer versus 
physician), whereas patient outcome, SOC and reporter demographics were the 
dependent variables. The unit of analysis was the total number of ADR cases and 
reported ADRs. The analysis focused on describing statistical relationships between the 
variables that were chosen for examination. This particular design enabled data collection 
without manipulating the independent variables (Field, 2013). Hence, the cross-sectional 
design enabled the examination of associations or relationships among variables by using 
statistical data analysis techniques (Frankfort-Nachmias, 2014). 
In this study, I analyzed secondary data (see Aagaard, Nielsen, & Hansen, 2009), 
specifically, ADRs that were submitted by consumers and physicians to the FDA, from 
the FAERS database, which contained quarterly data files that were extracted for analysis 
(FDA, 2016b). The data containing the spontaneous ADR reports from the FAERS 
database were accessed and downloaded from the quarterly data file data selection time 
period containing a quarter’s worth (3 months) of data: 01 April 2016 through 30 June 
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2016. Each quarterly data file within FAERS had variations in data due to the number of 
ADRs reported in the interval (3 months). Each data file was not representative of all four 
quarters for the year. In this study, my justification for selecting three-month’s worth of 
data was to provide a more specific perspective of AE reports received by the FDA and to 
be in alignment with the FDA website (Institute for Safe Medication Practices, 2015). In 
addition, without access to some licensed software tools, such as Empirica Signal®, more 
than 3 months would have been very cumbersome. Once the ADR data was collected, 
spontaneous reports from consumers and physicians were subsequently assessed for 
ADRs. 
Definitions 
According to WHO (2012), the following is a brief listing of key terms and 
phrases that were considered ambiguous, controversial, or operational terms used 
throughout this study: 
Adherence: The degree to which an individual’s behavior (consumption of 
medication, adherence to a diet and exercise regimen, and/or implementation of changes 
in lifestyle) is in conformity with the recommendations from a healthcare provider. 
Adverse drug reaction: Harmful and involuntary responses resulting from doses 
used in humans for preventive treatment, diagnosis, or for diseases and therapy. 
Adverse event: An unwanted outcome related to the consumption of any 
substance or combination of substances used for treating or preventing diseases in 
humans. 
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Anatomical Therapeutic Chemical Classification System: is used for the 
classification of active ingredients of drugs according to the organ or system on which 
they act and their therapeutic, pharmacological and chemical properties. 
"Direct" Case/Report: cases/reports voluntarily submitted to the FDA by non-
manufacturers. 
Expedited Case/Report: case/report expedited to the FDA within 15 days. 
FAERS: The US FAERS database is a national postmarketing surveillance 
database that gathers data on ADRs, medication error reports, and product quality 
complaints leading to AEs submitted to the FDA by reporters, including consumers and 
physicians. 
Periodic Case/Report: Non-Expedited cases/reports from manufacturers to the 
FDA. 
Pharmacovigilance: PV is the science that serves as a crucial component in 
detecting, evaluating, and inhibiting ADRs or any other drug-related issues and/or effects. 
Serious adverse event or serious suspected adverse reaction: An AE or suspected 
adverse reaction that is deemed “serious” if, from the perspective of the investigator or 
sponsor, it may result in any of the following patient outcomes: death; LT; persistent or 
significant disability or incapacity; a congenital anomaly or birth defect; initial or 
prolonged existing inpatient hospitalization; or, a medically significant outcome, event, 
or reaction. 
Side effect: any undesirable effect or problem resulting from medicinal product 
that occurs in addition to a desired therapeutic effect. 
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Signal: A new, potential causal association or a new aspect of a previously known 
relationship between an ADR and a drug or intervention. 
Spontaneous reporting: A voluntary submission of ADR reports by different types 
of reporters, including, HCPs, consumers, pharmacists, and lawyers, as well as 
pharmaceutical companies to national regulatory authority agencies. 
Spontaneous Reporting System: A SRS is a system that is employed during the 
postmarketing phase to identify new ADRs that may have otherwise gone undetected 
during clinical trials. 
 Under-reporting: Under-reporting of ADRs is the reporting of less than the actual 
amount of ADRs that are being reported. 
Assumptions 
It was assumed that the collection and synthesis of data from FAERS over the 
specified timeframe was adequate to conduct this study. Furthermore, it was also 
assumed that the FAERS database was sufficient to provide the appropriate amount of 
data. Moreover, in terms of quality, it was further assumed that the types of reports 
received from consumers were similar in content and presumed accuracy to those of 
physician reports (Blenkinsopp, Wilkie, Wang, & Routledge, 2007). Additionally, it was 
assumed that consumer reports yielded information on patient outcome, drug therapy and 
demographics in comparison to physician reports. 
Scope and Delimitations 
This quantitative study covered the potential significant difference in the 
distribution of ADRs by reporter (consumer versus physician) and patient outcome, as 
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well as SOC, and reporter demographics within the FDA FAERS database at case and 
event level. There were not any studies in which the FAERS database was employed to 
compare under-reporting of ADRs between consumers and physicians specifically with 
the aforementioned methods used in this study (Sakaeda et al., 2013). This particular 
focus was chosen due to the fact that there is a gap in the literature of the under-reporting 
of ADRs by consumers versus physicians in the FAERS safety database. 
This quantitative study did not cover the under-reporting of ADRs to the FDA by 
consumers and physicians since the data are limited to only ADRs that were actually 
reported. Moreover, since this study employed secondary data analysis, recruitment of the 
participants was not made, especially those in vulnerable populations, including, but not 
limited to the following: minors (age 17 and under); adult students of the researcher; 
subordinates of the researcher; patients of the researcher; nursing home residents; 
prisoners; mentally impaired or disabled individuals; emotionally impaired or disabled 
individuals; physically impaired or disabled individuals; individuals residing within the 
US who may not be fluent in English; undocumented immigrants; victims/witnesses of 
violent crime or other trauma (e.g. natural disasters); active duty military personnel; and, 
any other individuals who may not be able to protect their own rights or interest (Walden 
University, n.d.). 
Limitations 
Some anticipated limitations of the FAERS data, as well as the secondary data 
analysis in this study, must be acknowledged. For example, not all reports for every AE 
or medication error that occurred with a product were submitted to the FDA. Moreover, 
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duplicate reports existed in which the same report was submitted by a consumer and by 
another reporter (the physician). Hence, neither incidence rates nor an estimation of drug 
risk could be calculated from the FAERS data (FDA, 2017). 
Given that quantitative methods were employed, consumer perception of ADRs 
were not assessed, since the latter requires qualitative methods. Since the correlational 
cross-sectional research design was utilized, the secondary data led to under-reporting 
and recall bias, which yielded misclassification or information bias (Gualano, Gili, 
Scaioli, Bert, & Siliquini, 2015). Furthermore, the use of this particular design provided a 
rather limited amount of information of the sample (Gualano et al., 2015). The 
correlational cross-sectional research design presented challenges regarding the 
determination of causal relationships between the distribution of ADRs by reporter 
(consumer versus physician) and patient outcome, as well as SOC and reporter 
demographics. The correlational cross-sectional design contained several limitations that 
were significant to examine, including internal validity, which is only germane to such a 
design as experimental that attempts to establish a causal relationship (Frankfort-
Nachmias, 2014). Since researchers do not alter the independent variables, they must 
render logical or theoretical inferences in terms of the direction of the causation by taking 
into account that correlation between variables does not imply causation (Field, 2013). 
Hence, it is challenging for researchers to make causal inferences. 
To overcome several methodological limitations of correlational cross-sectional 
designs, researchers frequently employ statistical analyses, including cross-tabulation, for 
the purpose of organizing, describing, and summarizing their observations, as well 
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approximating some of the processes inherent within experimental designs (Frankfort-
Nachmias, 2014). When the data are categorized, researchers are able to make contrasts 
between the categorical groups (Frankfort-Nachmias, 2014). 
Significance of the Study 
To date, there have not been any studies within the US in which the FDA FAERS 
database was used to compare under-reporting of ADRs by reporter (consumers and 
physicians) and patient outcome, as well as SOC and reporter demographics at case 
and/or event level (see Sakaeda et al., 2013). Therefore, I examined in this study the 
statistical significance in the distribution of case and event level ADRs within the FAERS 
database by reporter (consumer versus physician) and patient outcome, as well as SOC 
and reporter demographics. This research fills a gap in the literature by focusing on 
whether consumers may report ADRs to the FDA more frequently than physicians may, 
and whether these differences may be tied in some way to the severity of the ADRs, 
especially within SOC (Blenkinsopp et al., 2007). This, in turn, enables greater 
comprehension of consumer and physician perceptions, as well as determine if there was 
a need for a better safety reporting system in the US (Blenkinsopp et al., 2007). 
Consumer reports could enhance the overall drug safety system by providing additional 
information not reported by HCPs or other professional reporters (Health Action 
International, 2015). A SRS that can divulge the proportion of reports that arise from both 
consumers and physicians has a greater likelihood of early signal detection of ADRs that 
were not observed and reported in premarketing clinical trials (Health Action 
International, 2015; Mitchell et al., 1994). 
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By integrating consumer reports within HCP reports, signal detection may 
considerably increase, thereby yielding a more comprehensive ADR detection strategy. 
Based on the results from this study, my findings identified areas where reporting by one 
kind of reporter or the other is less meaningful, and these findings identified situations 
where efforts to increase education and awareness might be especially helpful to the 
public health community. The findings from this study will lead to recommendations for 
future research, including ameliorating existing PV systems to employ methods that 
detect and measure medicine safety, recognize certain risk factors and high-risk groups, 
classify ADRs linked to certain drugs or medications and in certain groups or 
communities, and pinpoint issues stemming from medication errors and medications 
with low or suboptimal quality (Pal et al., 2013). Hence, the results from this study have 
implications for positive social change surely enhance PV systems at the national and 
global scales to detect risks and risk factors in a rapid fashion after medications or drugs 
have been marketed to potentially inhibit ADRs, thus ultimately enabling patients to 
receive optimal treatment and quality of care at a fraction of the cost to the healthcare 
system (Pal et al., 2013).  
Summary 
In essence, given the relatively high rate of under-reporting by physicians, an 
urgent need exists to revolutionize the surveillance system for pharmaceutical drugs 
during the postmarketing phase, as evidenced by the amount of ADRs that were 
experienced by consumers (Lazarou et al., 1998). The inclusion of consumer reports to an 
SRS influences the validity of safety surveillance systems, thereby potentially yielding 
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considerable amelioration of the existing PV surveillance system (Jarernsiripornkul, 
Krska, Capps, Richards, & Lee, A. 2002). As a crucial component in PV, consumers may 
contribute to new and serious ADRs that can be identified in an expeditious manner via 
consumer reporting in comparison to physician reporting (Jarernsiripornkul et al., 2002). 
Furthermore, consumers may also report unforeseen or unanticipated benefits. This new 
additional information may lead to the enhancement of safety signals, as well as influence 
the awareness and implications of ADRs (Hammond, Rich, & Gibbs, 2007). Although 
consumer reports should never be deemed as a substitute for HCP reports, consumer 
reports may nonetheless serve as a counterpart to HCP reports. Hence, by obtaining 
reports on ADRs directly from consumers, the issue of under-reporting may ultimately be 
diminished. 
In Chapter 2, I provide a literature review of consumer versus physician reporting, 
identify the existing gap in the literature, and discuss the theoretical framework most 
applicable to this study. In Chapter 3, I provide a review of the research methods that 
were employed for performing the secondary data analysis of the data in the FAERS 
database. In Chapter 4, I provide the results of the study. Lastly, in Chapter 5, I provide a 
discussion of the results, study limitations, recommendations for future research, and the 
implications for social change. 
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Chapter 2: Literature Review 
Introduction 
ADRs are a grave issue to the health and well-being of the public, particularly in 
less developed nations in which adequate drug toxicity monitoring and reporting systems 
are often lacking (Sen, 2016). Researchers have shown that, on a national and global 
level, greater than 5% of hospital admissions resulted from ADRs (Sultana et al., 2013), 
thereby responsible for close to 20% of deaths per year among patients who are 
hospitalized (FDA, 2016a). Consequently, a considerable economic burden is placed on 
the health of the public, as evidenced by public health costs of a hospital admission 
ranging from roughly $10,000 to $13,000 per hospitalized patient (Pillans, 2008). The US 
spends more than 30 billion dollars per year in managing ADRs, and these expenditures 
may be further magnified as a result of increased hospitalization, prolongation of hospital 
stay, and further clinical investigations in more serious cases (Sultana et al., 2013). 
Therefore, ADRs have a negative influence on the clinical, social, and economic aspects 
of society (Inácio et al., 2016). Therefore, to counteract the negative impact of ADRs, it 
is of paramount importance for regulatory agencies to work with marketing authorization 
holders to ensure a product’s safety profile is current (Leroy et al., 2014). 
 The problem that I addressed in this study was the differences in the proportion of 
case and event level ADR reporting, from different reporting categories with a focus on 
patient outcome, as well as SOC, and reporter demographics within the US. The potential 
statistical significance in the distribution of case and event level ADRs within the FAERS 
database by reporter (consumer versus physician) and patient outcome, as well as SOC, 
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and reporter demographics, was examined. I anticipated that the findings of this study 
could provide information regarding variability in the proportions of ADR reporting 
between consumers and physicians and that the outcome might be further balanced in 
ADR reporting. 
In the previous chapter, ADRs were discussed as a common problem within 
society. First, I addressed the under-reporting of ADRs by consumers and physicians as a 
recurring issue that continues to plague the well-being of the public.  Second, I discussed 
the necessity of integrating consumer reporting alongside physician reporting as 
necessary to transform the surveillance system. In this chapter, I provide a history of 
ADR reporting in the US and the relevant SRS (FAERS), a history of ADR reporting in 
international countries and a literature review of consumer versus physician reporting. In 
doing so, I identified an existing gap in the literature, and discuss the theoretical 
framework most applicable to this study. The following literature review shows evidence 
that consumers may report some ADRs more frequently than physicians, and these 
differences may be tied in some way to the severity of the ADRs (Blenkinsopp et al., 
2007). 
Literature Search Strategy 
The databases of MEDLINE and Google Scholar were reviewed. ADRs, under-
reporting of ADRs by consumers versus HCPs, and related terms as keywords were 
searched. The following key search terms were employed: ADRs; direct consumer 
reporting; direct patient reporting; under-reporting of ADRs; under-reporting of ADRs 
by consumers, patients, physicians, HCPs; PV; drug safety; spontaneous, healthcare 
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professional, patient, and physician. The date range of reviewed published literature falls 
within the years of 2004 to 2017, inclusive. 
History of ADR Reporting in the US and Overview of FAERS SRS 
Circa the end of the 19th century and beginning of the 20th century, the mandate 
for the safety and efficacy of medicines and drugs was not implemented and enforced, 
thereby precluding the FDA from maintaining and exercising any official control or 
power to render legal decisions and judgments (Cobert, 2011). Consequently, unsafe or 
hazardous products infiltrated the US market, claiming hundreds of fatalities. 
The number of mass poisonings is exemplified by the release of an elixir of 
sulfanilamide in 1937 by a company within the US (Cobert, 2011). Given that the 
mandate for drug safety testing was nonexistent during that time, the company failed to 
conduct any safety and efficacy testing of this product. The following year, the Federal 
Food, Drug and Cosmetic Act was enacted, thus prompting the safety testing of drugs and 
products to the FDA via a New Drug Application to protect the public’s health (Cobert, 
2011). 
In the early 1960s, more than 20 years after the Federal Food, Drug and Cosmetic 
Act, the thalidomide disaster occurred during which thousands of infants all over the 
world were born with malformed limbs after the thalidomide drug was internationally 
marketed as a sleeping pill safe for pregnant women (Science Museum, n.d.). While this 
drug was never released on the market within the US,  due to the opposition of the FDA’s 
drug examiner Dr. Frances Kelsey, thalidomide was nonetheless used in clinical trials in 
the US. During the late 1950s, GlaxoSmithKline had conducted clinical trials with 
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thalidomide involving more than 800 study participants, including pregnant women 
(Bren, 2001). Consequently, 17 babies were born in the US with severely deformed arms 
and legs as a result of thalidomide (Bren, 2001). Due to this worldwide recognition of the 
lack of safety when using thalidomide, in 1962 the Kefauver-Harris Amendment was 
legislated, marking the advent of a new age of drug regulation. Hence, pharmaceutical 
companies were obligated to prove to the FDA the safety and efficacy of a new drug prior 
to its inception on the market (Cobert, 2011).  
 For the purpose of collecting information about the safety and efficacy of new 
drugs, in 1969, a SRS of suspected ADRs, now known as FAERS, was launched. This 
system was created as a repository of drug surveillance data for more than 6,000 
marketed drugs, thereby enabling the FDA to render regulatory decisions regarding the 
safety and efficacy of these drugs. Since 1993, the FDA has been accepting direct 
consumer ADR reports electronically, by phone, or mail (FDA, 2015). Between the late 
1990s to the mid-2000s, the number of ADRs reported to the FDA increased from 
approximately 100,000 per quarter to 300,000 per quarter in 2015 (Mezher, 2017). 
Presently, FAERS contains more than 8 million reported ADRs, thereby showing its 
exponential growth rate (Mezher, 2017). In 2016, the FDA has received more than 1.6 
million ADR reports directly from consumers, physicians, manufacturers, and other 
reporter types (FDA, n.d.). 
Despite the strengths inherent within the FAERS database, the limitations are also 
worthy to describe. The correct assessment of FAERS data are complicated by the fact 
that multiple drug compositions bear different names and various drug substances, as 
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exemplified by the active ingredient fluoxetine found in the drug Prozac for which 
researchers (Maciejewski et al., 2017) discovered nearly 400 “synonyms” (Mezher, 
2017). The ability for researchers to make correlations between drugs and their adverse 
effects and render causal associations can be obfuscated by numerous drug synonyms 
associated with each drug in FAERS. On average, researchers determined 16 synonyms 
per one active ingredient within the FAERS database (Mezher, 2017), thereby impeding 
the ability to cluster ADRs to determine whether ADR reporting patterns differed across 
anatomical therapeutic classes (ATC) (Maciejewski et al., 2017). To correct this 
shortcoming, researchers suggested to consolidate drugs by their active component, 
which may enable easier detection of drug-ADR signals versus combining drugs based 
solely on synonym grouping (Mezher, 2017). 
The researchers discovered an additional limitation within the FAERS database, 
namely, reporters misinterpreting adverse reactions as an indication of a drug (Mezher, 
2017). The researchers stated that nearly 5% of all reports describe a drug’s indication as 
an AE. According to the researchers, some reports classified diabetes as a side effect for 
the drug rosiglitazone used to treat type 2 diabetes. To ameliorate the FAERS system, the 
researchers encouraged proper reporter education for the purpose of minimizing the 
number of reports in which misinterpretations between indication and side effect occur 
(Mezher, 2017). 
Despite the limitations of the FAERS SRS, submitted ADR reports assist in the 
detection of serious AE (SAE)s that are subsequently included in the labeling information 
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of a drug. However, additional regulations, such as removing the product from the 
market, can be imposed in extreme circumstances. 
European Union Countries in Which Direct ADR Reporting Is Accepted 
 ADRs are considered a serious issue to the health of the public not only on the 
terrain of the US, but on the international arena as well. Researchers have conjectured 
that ADRs are responsible for circa 5% of all hospitalizations in the European Union 
(EU) countries (Van-Lierop & Bunyan, 2008). Furthermore, ADRs are the fifth leading 
cause of mortality in a hospital setting, thereby comprising almost 200,000 mortalities on 
an annual basis (Van-Lierop & Bunyan, 2008). Researchers have stated that between 1% 
to 10% of serious ADRs are reported in EU countries, thereby defining under-reporting to 
be prevalent not only in the US, but internationally as well (Prescrire International, 2015). 
The history of ADR reporting in the EU is newer in comparison to that of the US. 
Denmark and the Netherlands were among the pioneering nations that began to accept 
ADR reporting by patients and consumers circa 2003. Italy, the UK, and Sweden 
followed their lead in 2004, 2005, and 2008, respectively (Herxheimer, Crombag, & 
Alves, 2010). Although many other countries have been currently accepting direct 
consumer ADR reporting, including, but not limited to, Bulgaria, France, Portugal, 
Romania, and Norway, this literature review will only discuss Denmark, the Netherlands, 
and Sweden, which are the most experienced countries in consumer reporting (Health 
Action International, 2015). 
 Since 2003, Denmark has been accepting consumer reporting directly to the 
Danish Health and Medicines Authority (Danish Medicines Agency [DHMA], 
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Sundhedsstyrelsen). Given that under-reporting is a considerable issue in Denmark, the 
DHMA has implemented and launched several information campaigns for the purpose of 
promoting spontaneous ADR reporting. In 2007, pharmacies and healthcare providers 
were issued brochures containing information on how to better consumer reporting 
electronically. Analogously, in 2010, the DHMA organized programs for health 
institutions’ phone counseling services in an effort to provide additional information on 
ADRs and direct consumer ADR reporting (Blenkinsopp et al., 2007). In 2013, the 
DHMA initiated an awareness-raising campaign entitled “Not everybody reacts the 
same” in which pharmacies and health centers partnered with patient organizations in an 
effort to further stimulate consumer reporting (Blenkinsopp et al., 2007). Thanks to the 
efforts of DHMA initiatives and awareness-raising campaigns, the surveillance system 
used in Denmark has markedly improved, as evidenced by an increase in the number of 
ADR reports submitted to the DHMA. In 2013, the DHMA received 6,681 reports of 
suspected ADRs, which indicated an increase of 35% versus those in 2012 (Blenkinsopp 
et al., 2007). Additionally, in 2014, the DHMA directed its attention to increasing ADR 
reporting not only among consumers, but also among family members and physicians 
within the mental health sector. 
Similar to Denmark, the Netherlands established its direct consumer reporting to 
regulatory authorities in April 2003 via the Lareb Center, which is a specialized national 
center and an independent source of SRS in the Netherlands (WHO, 2002). Lareb accepts 
ADR reports directly submitted by patients, consumers, HCPs, and other reporter types 
and subsequently examines reports to determine the impact of patient reports on PV. 
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Since 2013, Lareb has been appointed by the WHO Collaborating Center for PV in 
Education and Patient Reporting to aid WHO providing training workshops to Member 
Countries on the process of managing consumer reports (WHO, 2002). Analogous to the 
DHMA in Denmark, Lareb in the Netherlands has also been actively involved in 
launching awareness campaigns designed to provide education to consumers regarding 
submitting ADR reports electronically. Consequently, direct consumer reporting in the 
Netherlands has been enhanced, as evidenced by the number of total ADR reports 
submitted. In 2013 and 2014, Lareb collected more than 17,000 reports, and circa one-
fourth of them were submitted by patients/consumers. Moreover, according to the 2014 
data from Lareb, 95% of direct ADR reports were submitted electronically (Health 
Action International, 2015). 
In 2008, Sweden has implemented direct patient reporting to the Swedish Medical 
Product Agency (Medical Products Agency [MPA], Läkemedelsverket), which, similar to 
Denmark and the Netherlands, has launched campaigns and information sessions 
designed to raise awareness on consumer reporting and educate consumers on directly 
submitting ADR reports electronically. As a result, direct consumer reporting in Sweden 
(in addition to improvements in online reporting mechanisms) has been heightened, as 
exemplified by the increase in the total number of ADR reports submitted to the MPA. In 
2013, more than 6,000 ADR reports were submitted to the MPA, and circa 18% and 83% 
of those reports were directly submitted by consumers and HCPs, respectively. 
Furthermore, in 2014, nearly 7,000 ADR reports were received by the MPA, and nearly a 
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quarter of those reports were submitted electronically by consumers (Health Action 
International, 2015).  
Medical Dictionary for Regulatory Activities Overview 
In an effort to further safeguard the health and well-being of patients and 
consumers on a global scale, a set of standardized, harmonized, and universal medical 
terminology was needed to enable the electronic dissemination of medical information 
and suspected ADRs among regulatory officials and agencies, pharmaceutical companies, 
clinical research organizations, biotechnology firms, HCPs, academics, and other 
researchers on an international level (International Council for Harmonisation [ICH], 
2013). Circa March 1999, the International Council for Harmonisation of Technical 
Requirements for Pharmaceuticals for Human Use (ICH) created an international, 
clinically validated medical dictionary, known as The Medical Dictionary for Regulatory 
Activities (MedDRA), which contains a standardized set of terms pertaining to medical 
conditions, medical products and devices, and medicines that can be transmitted to 
regulatory agencies and pharmaceutical companies (ICH, 2013). 
MedDRA can be employed for signal monitoring and detection, data input, 
coding, and retrieval, and assessment of products. Furthermore, MedDRA is crucial 
during the pre- and postmarketing phase of products, including, but not limited to, 
pharmaceuticals, biologics, vaccines, and drug-device combination products (ICH, 2013). 
MedDRA also contains standardized terminology for the classification and 
characterization of AEs, as well as the following medical information: symptoms, signs, 
diseases, syndromes and diagnoses; problems with a system, organ, or etiology (i.e., 
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Infections); errors and failures in medical devices and products; medication errors; 
medical, social, and family history information; application, implant, and injection sites; 
medical and surgical procedures; approved uses for medications and medical devices; 
and, types of investigations (i.e., liver function analyses, metabolism tests) (ICH, 2013). 
One of the chief advantages of MedDRA is its ability to group and analyze AEs 
according to its own hierarchical structure (ICH, 2013). MedDRA is organized into five 
levels ranging from very specific to very general (ICH, 2013). The most specific level is 
known as the “Lowest Level Terms” (LLTs), which contain greater than 70,000 terms 
that describe medical information. These LLTs depict the manner in which an 
observation or case can be reported (ICH, 2013). The next level, known as “Preferred 
Terms” (PTs), contains more than 20,000 terms, which are single medical concepts that 
characterize a symptom, sign, disease diagnosis, therapeutic indication, investigation, 
surgical or medical procedure, and medical social or family history characteristic (ICH, 
2013). Each LLT is linked to only one PT, while each PT has at least one LLT (itself) in 
addition to synonyms (different terms for the same concept) and lexical variants (i.e., 
abbreviations, different word forms for the same expression). Related PTs are combined 
into more than 1,700 “High Level Terms” (HLTs) on the basis of anatomy, pathology, 
physiology, etiology, or function (ICH, 2013). Subsequently, HLTs are linked to 330 
“High Level Group Terms”, which are finally grouped into 26 “SOCs”, which form the 
most general level of the MedDRA hierarchy. SOCs are groupings by etiology 
(e.g. Infections and infestations), manifestation site (e.g. Gastrointestinal disorders) or 
purpose (e.g. Surgical and medical procedures). In addition, there is a SOC relating to 
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products and one to contain social circumstances. SOCs are comprised of more specific 
subgroups that combine single medical concepts and equal terms used for codifying 
clinical information associated with AEs and ADRs (ICH, 2013). 
Given the significance of MedDRA in the coding of AEs and ADRs based on its 
five-level hierarchical structure, especially SOC, MedDRA will be employed for coding 
ADRs reported by consumers and physicians in this study. Hence, SOCs will be 
identified via this method and compared according to reporter. 
Theoretical Foundation 
The theoretical foundation that is the most applicable to this study is known as 
SARF, which stems from the perception of risk framework. Risk comprises the likelihood 
and repercussions of the occurrence of an event (Adams, 1995). Researchers have 
theorized that individuals tend to differ between their attitude toward a likelihood or 
repercussion (Drottz-Sjöberg, 1991). A majority of definitions of risk include a 
probability estimate for the occurrence of a negative event (Brun, 1994). Adams (1995) 
explained risk (as per the definitions contained within medical and drug safety literature) 
as the likelihood that an AE occurring in the future is multiplied by its magnitude 
(Adams, 1995). 
The theory holds that risk interrelates with the psychological, social, institutional, 
and cultural perceptions of individuals in a manner that may magnify or diminish 
individuals’ responses to the risk or risk event (Kasperson & Ratick, 1988). These 
changes in the perception of risk elicit behavioral responses from individuals that alter 
the social and economic aspects of society, thereby increasing or decreasing the actual 
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physical risk (Kasperson & Ratick, 1988). Researchers have identified variations between 
HCPs and consumers in terms of reporting ADRs (Aagaard et al., 2009). SARF may be 
employed to elucidate the differences between HCPs and consumers’ reporting of ADRs. 
The perception of risk as it applies to the present issue involves the premise that different 
groups (HCPs and non-HCPs, researchers and the public, or HCPs and consumers) hold 
different views on the possible risks associated with some action or environment. 
Researchers have discovered that several factors contribute to the perception of risk, 
including factors related to the individual, the presentation of the risk, and the attributes 
of the risk (Association of Reproductive Health Professionals, 2006). Hence, with respect 
to ADR reporting and drug therapy, consumers frequently have contrasting views in their 
perception of risk versus HCPs (Aronson, 2006). Therefore, the SARF framework is 
appropriate for this study with regards to identifying under-reporting of ADRs since it is 
assumed that the consumer’s perception of risk differs from that of the physician. 
The studies conducted by Bongard et al. (2002) and Durrie, Hurault, Damase-
Michel, & Montastruc (2009) employ a similar theoretical foundation in relation to this 
study. The results from these studies have revealed how consumer’s perception of risk 
differs from that of the physician, thereby justifying the use of the SARF framework. To 
determine whether perceived risk differs between HCPs and non-HCPs (consumers), 
researchers Bongard et al. (2002) conducted a study on 400 HCPs (consisting of general 
practitioners, pharmacists, and PV professionals) and 153 non-HCPs. To comprehend the 
risk perception of ADRs within the medical arena in comparison to the public, the 
researchers requested study participants to evaluate their risk perception of ADRs related 
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to 13 different drug classes via visual analogue scales, which were utilized to define a 
score of perceived risk of ADRs related to each drug class (ranking from 0 to 10). Based 
on the results from the study conducted by Bongard et al. (2002), the authors claimed that 
the risk perception of ADRs varied between both groups. HCPs gave the highest and 
second highest ranking to anticoagulants and nonsteroidal anti-inflammatory drugs 
(NSAIDs), respectively, thereby claiming that these drugs were most hazardous to the 
health and safety of patients and consumers. Contrarily, consumers gave a lower ranking 
to anticoagulants and NSAIDs, thereby claiming that these drugs posed a lesser threat. 
Moreover, non-HCPs gave the lowest ranking to aspirin, thereby stating that this drug 
posed the least threat. However, the ADRs related to the aforementioned drugs are 
significant, especially gastrointestinal (GI)-related ones. This perception of the safety of 
aspirin by the consumer may partially be attributed to the dearth of information presented 
on the risk of aspirin and the excess of information presented to the consumer through 
advertisements, Internet, and commercials (Durrie et al., 2009). Hence, the authors 
concluded that the public was incognizant of such ADRs and, therefore, underrated the 
risk associated with NSAIDs (Bongard et al., 2002). Additional findings from the study 
by Bongard et al. (2002) revealed that consumers gave the highest rank to sleeping pills, 
followed by tranquillizers and antidepressant drugs. Additionally, consumers highly 
ranked psychotropic drugs, thereby asserting that these drugs posed the greatest risk. 
Bongard et al. (2002) acknowledged that mass media’s linking of psychotropic drugs 
with frequent suicide attempts may have influenced the public’s perception of high-risk 
regarding these drugs. Since consumers and HCPs perceived the dangers of one drug 
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class over another drug class differently, the authors concluded that HCPs and non-HCPs 
possess differing risk perceptions of ADRs. Hence, the results from the study conducted 
by Bongard et al. (2002) bolster the claim that risk perception of ADRs varies between 
consumers and HCPs, which is crucial for this study and which may explain why HCPs 
report ADRs less frequently in comparison to non-HCPs. 
Durrie et al. (2009) conducted a study that assessed the perceived risk of ADRs 
among 92 medical students (63 females and 29 males) and examined whether the 
perceived risk of ADRs differs before and after taking pharmacology courses and found 
this to be the case. The authors requested the medical student study participants to assess 
their risk perception of ADRs related to 13 different drug classes prior and subsequent to 
the pharmacology courses via a visual analogue scale, which was employed to define a 
score of perceived risk of ADRs related to each drug class (ranking from 0 to 10). The 
following drug classes were assessed: antibiotics; anticoagulants; antidepressants; aspirin; 
contraceptive pill; corticosteroids; drugs for arterial hypertension; drugs for diabetes 
(other than insulin); hypnotics; hypocholesterolaemic drugs; NSAIDs; postmenopausal 
hormone replacement therapy; and, tranquilizers. The findings from the study conducted 
by Durrie et al. (2009) revealed that the perceived risk of ADRs by medical students was 
different after taking pharmacology courses. Based on the results from the authors’ study, 
the authors claimed that, prior to the pharmacology courses, medical students ranked 
hypnotics as the most hazardous drug (followed by antidepressants and anticoagulants) 
and contraceptive pills as the least hazardous. After pharmacology courses, 
antidepressants were ranked as the most dangerous drugs by medical students, followed 
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by anticoagulants and hypnotics. The authors claimed that, aside from several classes of 
drugs (antidiabetics, antihypertensive drugs, tranquillizers, corticosteroids, and 
hypnotics), upon completion of the pharmacology courses, there was a statistically 
significant increase in perceived risk for other classes of drugs. The highest increases 
were observed for contraceptive pills, NSAIDs, and aspirin, while the lowest increases 
were observed for hypocholesterolaemic and antidepressant drugs. The authors concluded 
that after completion of the pharmacology courses, medical students became more 
cognizant of potentially serious ADRs that are associated with drugs deemed relatively 
safe by non-HCPs, such as NSAIDs and aspirin. Hence, the findings from the study 
conducted by Durrie et al. (2009) are critical to this study and may explain the need for 
efficacious training and preparation, as well as adequate information for HCPs on ADRs, 
which may explain the under-reporting of ADRs by HCPs. 
Literature Review of Consumer Versus Healthcare Professional ADR Reporting 
In a published review that compared patient and physician reporting of suspected 
ADRs, the authors of Health Action International (2015) claimed that although HCPs are 
an essential element of evidence regarding the safety and efficacy of medicine and 
pharmaceutical drugs, they do not report ADRs as frequently as they should (Health 
Action International, 2015). To the author’s opinion, one of the greatest challenges to 
reporting ADRs by physicians is the shortage of time. The same authors argue that 
physicians see many patients during their clinical visits per day and are often preoccupied 
with completing medical records and forms, as well as attending to other clinical 
priorities within the office or hospital setting. Consequently, HCPs only report the ADRs 
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they deem the most serious, as well as ADRs they may ascertain as associated with the 
usage of medicines or drugs. Moreover, although patients consider certain ADRs to be 
highly important with regards to affecting their quality-of-life, HCPs tend to not view 
such ADRs in the same aspect. The same authors of stated that patients’ reports of their 
personal reactions to the drugs and the drugs’ impact on their quality-of-life are typically 
more detailed than physicians’ reports of their patients’ ADRs. Hence, the same authors 
argued that if patients can collaborate with their physicians and discuss the ADRs 
experienced by patients, both parties may contribute to delivering effective reports of 
prospective safety issues of the drugs. Therefore, the authors of Health Action 
International (2015) contended that it is essential to combine the reports from HCPs and 
patients, as such a procedure may foster the growth and progression of systems of PV 
within Europe. 
Parrella et al. (2014) performed computer assisted telephone interviews of 191 
South Australian parents who reported an AE following immunization (AEFI) of their 
children. The authors compared parents reporting their children’s AEFI to either HCPs or 
surveillance authorities with those who did not report their children’s AEFI based on the 
following factors: awareness of surveillance, vaccine safety opinions, and demographics. 
Based on the findings from their study, Parrella et al. (2014) claimed that reporting an 
AEFI to an HCP or a surveillance authority was not statistically significantly related to an 
awareness of a surveillance system. Furthermore, the authors stated that there was a 
statistically significant relationship between AEFI reporters and the perception that a 
serious reaction was more likely to occur at their children’s last immunization. Based on 
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their findings, the authors claimed that while reporting an AEFI was not statistically 
significantly related to an awareness of surveillance or socio-demographic factors, the 
findings revealed some differences in safety opinions. Parrella et al. (2014) concluded 
that additional research is needed to determine if these differences have existed or have 
occurred at a date earlier than the incidence of an AEFI or whether these differences are a 
result of the AEFI. The authors emphasized the significance of consumer reporting for 
postmarketing vaccine safety surveillance. 
The aim of the descriptive-cross-sectional study performed by Vural, Ciftci, and 
Vural (2014) was to examine the knowledge, attitudes, and behaviors of 112 nurses 
employed in a public hospital regarding PV, ADRs, and AE reporting via a questionnaire. 
Based on the findings of their study, the authors claimed that nearly 74% of the nurses 
were cognizant of the definition of “severe adverse effect” of drug therapy. Almost 35% 
of nurses were aware that ADRs are reported to a contact individual working in the 
Turkish PV Center (TÜFAM). The same authors stated that while circa 70% of nurses 
had knowledge of the importance of ADR reporting, only 8% of the nurses actually 
reported ADRs to the TÜFAM. Based on these results, the authors stated that ADR event 
reporting was low among nurses. The authors concluded that the findings from their 
study revealed a deficit in knowledge regarding PV and ADR reporting. Vural et al. 
(2014) stressed the need for additional research to ameliorate the rate of reporting and to 
enhance the knowledge and understanding of PV not only among nurses, but also other 
healthcare practitioners. 
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Alatawi et al. (2017) compared reporting rates in FAERS to expected rates of 
known adverse drug events (ADEs). The authors chose three groups of drugs, including 
statins, biologics, and narrow therapeutics index drugs (NTI) to determine the difference 
in sensitivity to reporting. The results from the authors’ research revealed that most drug-
ADE pairs were statistically significantly under-reported by both consumers and 
physicians. The authors contended that the reporting differences between consumers and 
providers potentially stem from their perceptions of the seriousness of an ADE, which 
subsequently necessitates whether an event report needs to be made and submitted to the 
FDA. The authors claimed that circa 20% to 33% of the minimum number of expected 
serious AEs were reported with biologics and NTI drugs. The authors stated that under-
reporting by both consumers and physicians significantly differs by the types of drug and 
perceived severity of ADRs, and an understanding of this difference in under-reporting is 
necessary when interpreting safety signals. The authors concluded that their study 
explains the rate of under-reporting of ADEs in spontaneous reporting data within the 
FAERS database. 
The objectives of the study conducted by Di Maio et al. (2015) were to: compare 
reporting by patients and HCPs of six toxicities (anorexia, nausea, vomiting, constipation, 
diarrhea, and hair loss) occurring during anticancer treatment based on data prospectively 
collected in three randomized trials; determine the agreement between patients’ and 
physicians’ reports; and, calculate the rate of possible under-reporting of AEs by 
physicians. The authors calculated toxicity rates for each toxicity, as well as computed 
the agreement between patients and physicians (via inter-rater reliability scores) and the 
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under-reporting rate by HCPs. The results of their study revealed that the agreement 
between patients and physicians was rather low for all toxicities. Moreover, toxicity rates 
reported by HCPs were lower in comparison to those reported by patients. For patients 
who reported any severity of toxicity level (based on their responses of either “not at all,” 
“a little,” “quite a bit,” or “very much” on a quality-of-life questionnaire), under-
reporting by physicians ranged from 40.7% to 74.4%. For patients who reported “very 
much” toxicity, under-reporting by physicians ranged from 13.0% to 50.0%. The authors 
concluded that subjective toxicities were highly under-reported by physicians, even when 
prospectively gathered within randomized trials. Based on the findings from their study, 
the authors accentuated the need for patient reporting and encouraged the inclusion of 
patient-reported outcomes into toxicity reporting within clinical trials. 
Medawar and Herxheimer (2004) conducted research in the UK comparing the 
reports from patients and primary care physicians regarding suspected reactions to an 
antidepressant drug called paroxetine. The doctors’ reports were submitted via the 
Yellow Card (YC) scheme – an information-collecting UK system for suspected ADRs to 
medicines and drugs (Yellowcard, 2017). Based on the results from the research of 
Medawar and Herxheimer (2004), in comparison to reports from the YC, reports from 
patients were more comprehensive and specific, thereby detailing suicidality and 
withdrawal symptoms, including, but not limited to, weight gain, suicidal behavior, 
and/or loss of libido, in a lucid manner. Hence, the authors argued that reports from 
patients conveyed important information regarding ADRs that medical professionals 
were unable to deliver. Thus, the same authors concluded that an increase in physician 
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reporting, in conjunction with patient reporting, especially patients who directly report to 
physicians, would decrease the rate of under-reporting and ultimately play a potent role in 
PV and drug safety. 
The objective of the study conducted by Farquhar et al. (2015) was to determine 
the proportion of maternal and perinatal death and illness cases due to SAEs by 
comparing the case reports from the Perinatal and Maternal Mortality Review Committee 
(PMMRC) to those from the Health Quality and Safety Commission (HQSC) in New 
Zealand. Based on the results from the study, the authors stated that less than 9% of 
maternal and perinatal SAEs were identified by the HQSC SAE reporting system. 
Farquhar et al. (2015) claimed that the proportion of maternal and perinatal AE reporting 
to the HQSC is low in comparison to that of PMMRC reporting of AEs. The authors 
concluded that these SAEs were not undergoing sufficient scrutiny at the local level and, 
consequently, the reporting of SAEs to the HQSC may not be a valid method to detect or 
ameliorate the quality of maternity services offered in New Zealand. 
Moore and Bennett (2012) employed incidence studies that have been previously 
published to compute reporting rates for hemorrhage, emergency hospitalization, and 
venous thromboembolism (VTE) associated with four drugs: warfarin, clopidogrel, 
ticlopidine, and thalidomide. The AEs were reported by healthcare providers to the 
FDA’s FAERS system. The authors discovered the following annual reporting rates with 
an associated AE: 1.15% for more than 33,000 emergency hospitalizations linked to 
warfarin for patients aged 65 years or older; 0.98% for greater than 13,000 
hospitalizations attributed to clopidogrel and ticlopidine; and, 1.02% for more than 
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67,000 hemorrhage cases associated with warfarin. Moreover, the results from their 
research revealed a 9-year reporting rate of 2.33% for 48,000 VTE AEs linked to 
thalidomide. Based on these findings, Moore and Bennett (2012) stated that the incidence 
of these hematologic AEs is considerably high and reporting rates are rather low (near the 
lower boundary of the 1 to 15% range evident for other events). The same authors 
concluded that given the low reporting rates of AEs, the FDA FAERS system should be 
examined. 
Goldsmith, Aikin, Encinosa, & Nardinelli (2012) studied AE reports for 123 
drugs that originated directly from patients prior and subsequent to the 2007 US federal 
mandate of the print direct-to-consumer advertisement, which provides consumers with 
information to directly contact the FDA (via phone or agency’s website) in order to report 
any AEs experienced following the consumption of medicines. The authors assessed the 
impact of this mandate via statistical model simulations and discovered that, if monthly 
expenditures on print direct-to-consumer advertising increased from 0 to $7.7 million per 
drug, patient-reported AEs would increase by three times (versus patient-reported AEs 
prior to the mandate). However, based on their findings, the authors claimed that the 
absolute increase per month was less than 0.24 reports per drug, thereby suggesting that 
the influence of the increase on the health of the public was rather small and that the AE 
reporting rate was still considerably low. The same authors concluded that additional 
measures, including a greater awareness of FDA FAERs, in addition to an increase in 
consumer education, is encouraged to stimulate patient reporting of AEs. 
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Blenkinsopp et al. (2007), examined literature on international experience from 
six countries, as well as seven studies that surveyed patients in hospital or primary care. 
According to the authors, published research has divulged findings suggesting that 
patients are inclined to detect and report more ADRs in comparison to HCPs. However, 
some patients neither discuss their ADRs with their HCPs nor do they report to healthcare 
authorities and regulatory agencies. The same authors admitted that although the root 
cause of patients failing to disclose all their ADRs to their physicians has not been 
elucidated, the results from their research can nonetheless provide some evidence of 
under-reporting of ADRs by patients due to patients’ viewpoint that there was insufficient 
communication with their primary care physicians. Hence, Blenkinsopp et al. (2007) 
concluded that it is essential for patients concerns to be expressed and reported to health 
authorities. 
Van Hunsel, Passler, & Grootheest (2009) compared ADR reports from patients 
and medical professionals regarding the advantages and jeopardies of statins. Based on 
the findings from the authors’ research, a majority of the patients claimed that they did 
not receive proper knowledge about the drug, as well as adequate guidance from their 
physicians regarding the side effects from the drug. Consequently, patients, rather than 
HCPs, reported more frequently musculoskeletal and connective tissue disorders relating 
to statins. The same authors believed that HCPs refrained from reporting these ADRs to 
PV agencies due to them being specified in the Summary of Product Characteristics of 
statins. The results from the authors’ research suggested that patient reports may yield 
insight into ADRs, especially those that have not been previously known. Hence, 
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Van Hunsel et al. (2009) concluded that patients’ apprehensions regarding ADRs should 
be acknowledged in reports to national PV agencies. 
The study by Golomb, McGraw, Evans, & Dimsdale (2007) examined patients’ 
viewpoint of the patient-physician relationship, as well as physicians’ acknowledgment 
of their patients’ reporting of suspected ADRs resulting from statins, a class of drugs that 
lower the cholesterol level in the body. The findings from the study showed that 87% of 
patients instigated the conversation with their physicians regarding their condition after 
being treated with statins. Physicians were more inclined to refute than confirm the 
potential association between ADRs and statins by disregarding their patients’ symptoms 
and possibility of those symptoms’ relationship to statin use. Hence, Golomb et al. 
(2007) argued that physicians’ failure to properly communicate with their patients might 
be the cause of under-reporting of ADRs by primary care physicians. Therefore, the same 
authors suggested an all-encompassing active postmarketing surveillance undertaking to 
target patients to report ADRs may contribute to an amelioration of ADR reporting 
systems. 
The studies conducted by Aagaard et al. (2009) and de Langen, van Hunsel, 
Passier, de Jong-van den Berg, & Van Grootheest (2008) employ a similar type of data 
collection and/or data analysis methods in relation to this study. Aagaard et al. (2009) 
conducted a retrospective study by employing the Danish ADR database to compare 
ADR reports between consumers and other sources, including physicians, pharmacists, 
lawyers, pharmaceutical companies and other HCPs. Aagaard et al. (2009) examined 
6,319 ADR reports containing 15,531 ADRs from 2004 to 2006 and analyzed the data 
45 
 
from these reports with regards to the reporter category, severity of the ADRs, the 
category of ADRs by SOC, and the suspected medicines on level 1 of the ATC 
classification system. The same authors computed chi-square and ORs to determine the 
relationship between the type of reporter and reported ADRs (classified by ATC or SOC). 
The confidence interval (95%) was calculated for all the ORs. Based on the results from 
the study of Aagaard et al. (2009), consumers reported 11% of the ADRs. Consumers’ 
reporting of serious ADRs was analogous to that of physicians (approximately 45%), 
though lower than that of pharmacists and other HCPs. Consumers provided a different 
perspective of the ADRs, especially for the disorders of the nervous system. Furthermore, 
the same authors discovered that consumer reports provided greater detail on the 
prospective diagnosis made by the consumers themselves, which is a finding that HCPs 
do not typically anticipate from non-HCPs. In comparison to other sources, consumers 
were more likely to report ADRs from the following SOCs: nervous system disorders 
(OR = 1.27); psychiatric disorders (OR = 1.70); and, reproductive system and breast 
disorders (OR = 1.27). Moreover, compared with other sources, consumers were less 
likely to report ADRs from the SOCs blood and lymphatic system disorders (OR = 0.22) 
and hepatobiliary system disorders (OR = 0.14). Aagaard et al. (2009) stated that, in 
comparison to other sources, consumers were more likely to report ADRs from the 
following ATC groups: N (nervous system) (OR = 2.72); P (antiparasitic products) (OR = 
2.41); and, S (sensory organs) (OR = 4.79). Additionally, compared with other sources, 
consumers were less likely to report ADRs from the following ATC groups: B (blood and 
blood-forming organs) (OR = 0.04); J (anti-infective for systemic use) (OR = 0.44); L 
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(antioneoplastic and immunomodulating agents) (OR = 0.19); and, V (various) (OR = 
0.03). In the SOC ‘nervous system disorders’, consumers reported seven categories of 
ADRs, two of which were dysgraphia and parosmia, that were not reported by the other 
sources. Aagaard et al. (2009) claimed that, in comparison to other sources, consumers 
reported different categories of ADRs for different types of SOCs and ATC groups. 
Hence, the authors concluded that consumers should be active participants within 
systematic drug surveillance systems, including clinical settings, and their reports should 
be treated with as much importance as those from other sources. The study conducted by 
Aagaard et al. (2009) revealed significant findings suggesting that, in comparison to other 
sources, consumers reported different categories of ADRs for different types of drugs. 
Similar to this study’s quantitative methodology (Chapter 3), the chi-square and the OR 
in the study by Aagaard et al. (2009) were computed to determine the relationship 
between the type of reporter and seriousness, as well as type of reporter and type of 
reported ADRs (classified by ATC or SOC). Although this study will not be focusing on 
ATC, the authors’ statistical framework will nonetheless be beneficial to use in an effort 
to compare and contrast the results from this study. 
de Langen et al. (2008) performed a study that compared ADR reports between 
consumers and HCPs from the Netherlands PV Center Lareb within a three-year time 
period from April 2004 to April 2007. Consequently, my study will focus on the US and 
the FDA FAERS database and focus solely on physician versus consumer, unlike Langen 
et al. (2008). This is important to be studied, as the lack of AE reporting is a limitation of 
current PV systems within the US, thereby hindering regulators’ ability to quantify risk of 
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under-reporting of ADRs. My study will ultimately see if the FDA FAERS database is 
lacking in reporting of ADRs by consumers and/or physicians, thereby determining if 
FAERS needs improvement in this area. The authors examined 2,522 ADR reports 
comprising 5,401 ADRs that were submitted by consumers, and 10,635 reports 
comprising 16,722 ADRs that were submitted by HCPs. The authors analyzed the data 
from these reports with regards to the age and gender of the reporters, the attributes of the 
most frequently reported drugs, and the attributes of the most frequently reported ADRs, 
their seriousness, and their outcome. de Langen et al. (2008) computed chi-square to 
determine the relationship between the type of reporter (patient versus HCP), the number 
of reports submitted by type of reporter, patient characteristics, and information regarding 
the reported drugs and ADRs. Furthermore, the authors employed the t-test to determine 
statistically significant differences in the male to female ratio among reports from 
patients and HCPs. 
de Langen et al. (2008) discovered statistically significant differences between 
patient reports and reports from HCPs with regards to the seriousness and outcome of 
reported ADRs in the Netherlands. In comparison to HCPs, patients reported a 
significantly higher number of LT ADRs (5.2% vs 2.7%) and disability (2.3% vs 0.4%). 
Moreover, patients reported significantly fewer ADRs leading to death (0.6% vs 1.5%) 
and hospitalization or prolongation of hospitalization (9.8% vs 12.0%). The authors also 
determined statistically significant differences in the outcome of the reported ADRs 
between patients and HCPs (87% vs 68%). Patients reported non-recovery (35.4%) from 
the ADR significantly more often than HCPs (16.7%). Contrarily, the same authors 
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claimed that no statistically significant differences were determined between patient 
reports and reports from HCPs with regards to the following attributes: patient 
characteristics (age and gender); most frequently reported ADRs from the five most 
involved organ systems (nervous system disorders, psychiatric disorders, gastrointestinal 
disorders, musculoskeletal disorders and general disorders/administration site 
conditions); and, most frequently reported drugs from the five most reported drug 
categories (HMG Co-A reductase inhibitors (“statins”), selective serotonin reuptake 
inhibitors, B-adrenoceptor antagonists (“B-blockers”), anticoagulants, and proton pump 
inhibitors). In addition to the aforementioned findings, de Langen et al. (2008) also 
discovered that patient reports offered an entirely different perspective in comparison to 
those of HCPs, especially in terms of recovery (full versus non-recovery). 
The authors accentuated that although patient reporting should not substitute HCP 
reporting, (as HCPs are a reliable source for ADR reporting), patient reporting may 
nonetheless serve as a crucial component in healthcare, thereby placing patient safety and 
greater access to efficacious drugs at the forefront of PV. The authors encouraged the 
recognition and acknowledgment of patient reports, which they claimed will increase the 
number of reported ADRs received within a certain timeframe, thereby ultimately 
augmenting the statistical power for signal detection in an effort to yield signal detection 
of new ADRs. Hence, the same authors concluded that patient reporting in SRSs is 
advantageous, thereby fostering a valid PV. 
The study conducted by de Langen et al. (2008) revealed significant findings 
suggesting that patients reported ADRs differently from HCPs with respect to the 
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seriousness and outcome of reported ADRs. Similar to the quantitative methodology in 
this study, the chi-square in the study by de Langen et al. (2008) was calculated to 
determine the relationship between the type of reporter (patient versus HCP) and 
seriousness and outcome of reported ADRs, patient characteristics, and attributes of the 
most frequently reported ADRs. 
Summary and Conclusions 
The findings from the literature review suggested that consumer reporting is 
imperative to successful PV. Researchers have argued that consumer reporting would 
increase the number of spontaneous reports submitted, which would subsequently 
enhance SRSs (Aagaard et al., 2009; de Langen et al., 2008; Blenkinsopp et al., 2007; 
van Hunsel et al., 2009). Within their reports, consumers may provide an in-depth 
account of their symptoms while consuming medication, thereby unveiling potential and 
new ADRs that may otherwise have been unknown and undetected (WHO, 2012). Based 
on the results from the literature review, the quality of reports from consumers is akin to 
or even higher than that of reports from HCPs, especially in terms of identifying potential 
new ADRs that had not previously been reported by HCPs (Blenkinsopp et al., 2007). 
The findings from the study conducted by Aagaard et al. (2009) and de Langen et al. 
(2008) revealed that, in comparison to physician reports, consumers reported different 
categories of ADRs for different types of medicines, thereby providing a unique 
perspective of their experiences with ADRs (Aagaard et al., 2009). By combining the 
reports from consumers with those of HCPs, the SRSs may be filled with a plethora of 
new information regarding ADRs, thereby accelerating signal detection (Health Action 
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International, 2015). Hence, the reports from consumers can deliver an understanding and 
awareness of ADRs in greater detail (Herxheimer et al., 2010). 
The results from the literature review revealed that a majority of ADRs are under-
reported since ADRs comprise more than 5% of all hospital admissions, and 10% of all 
hospitalized patients. Findings have also shown that the overall reporting rate of ADRs is 
circa 1%, although the rate considerably fluctuates due to the severity and type of 
reaction, as well as the characteristics of the drug. Furthermore, reporting rates of 
suspected ADRs by medical professionals is substantially low (Medawar & Herxheimer, 
2004). Published research has shown that patients are inclined to detect and report more 
ADRs in comparison to HCPs. However, findings have also suggested that spontaneous 
reports from patients comprise a small proportion of total official reports, thereby 
emphasizing the importance of encouraging patient reporting of suspected ADRs and 
incorporating such reports into official systems (Blenkinsopp et al., 2007). While a 
scarcity of research has been published to assess the spontaneous reporting of suspected 
ADRs by patients, considerable and noteworthy experience from several countries in 
which patient reporting has progressed has divulged evidence that patients have detected 
potential new ADRs (Blenkinsopp et al., 2007; Medawar & Herxheimer, 2004). The 
select few countries that have released the reported experience of patients confirmed that 
such a patient reporting system will enable greater comprehension of consumer 
perceptions, which will ultimately lead to ameliorations in patient reporting. Thus, the 
advent of patient reporting should be taken into consideration by other countries 
(Blenkinsopp et al., 2007). 
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To date, there are no studies that compared and contrasted consumer reports with 
those of HCPs based on patient outcome in the US. Therefore, I will examine in my study 
the statistical significance in the distribution of case and event level ADRs within the 
FAERS database by non-HCPs (consumers) and HCPs (physicians) and patient outcome 
in an effort to fill the gap in the literature. In Chapter 3, I provide the research methods 
that will be employed for performing the secondary data analysis of the data contained in 
the FAERS database. In Chapter 4, I provide the results of the study. Lastly, in Chapter 5, 
I provide a discussion of the results, study limitations, recommendations for future 
research, and the implications for social change. 
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Chapter 3: Research Method 
Introduction 
In the previous chapter, I provided a literature review of consumer versus 
physician under-reporting, identified the existing gap in the literature, and discussed the 
theoretical framework that is the most applicable to this study. Specifically, in this study, 
I assessed whether a statistically significant difference existed in the distribution of case 
and event level ADRs by reporter (consumer versus physician) and patient outcome, as 
well as SOC and reporter demographics. The differences in under-reporting of physicians 
versus consumers were explored and compared to determine whether consumer reporting 
is imperative in AE reporting. It was anticipated that the outcome would impact 
frequency of physician and consumer reporting, as well as the differences in reporting 
rates between them. The independent variable was the reporter (consumer versus 
physician), whereas patient outcome, SOC, and reporter demographics were the 
dependent variables. The unit of analysis was the total number of ADR cases and 
reported ADRs. This chapter provides a description of the statistical methodology that 
was employed to compare consumer and physician reporting of ADRs. The essential 
elements of this study, including the research design, setting and sample, materials, data 
collection and analysis, threats to validity, and measures taken for protection of 
participants’ rights, are discussed in this chapter. 
Research Design and Rationale 
In this study, I followed the design employed by Aagaard et al. (2009) in their 
analysis of the Danish ADR database known as The Danish Medicines Agency (Aagaard 
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et al., 2009). My study was cross-sectional and descriptive, and the non-experimental 
research design (known as the cross-sectional design) was employed to compare case and 
event level ADRs between reporters (consumer and physician), specifically, for the total 
number of case and event level ADRs reported and patient outcome, as well as SOC and 
reporter demographics. The independent variable was the reporter (consumer and 
physician), whereas patient outcome, SOC, and reporter demographics were the 
dependent variables. The unit of analysis was the total number of ADR cases and 
reported ADRs. The analysis focused on describing statistical relationships between the 
variables that have been chosen for examination. This particular design enabled data 
collection without manipulating the independent variables (see Field, 2013). Hence, the 
cross-sectional design enabled the examination of associations or relationships among the 
aforementioned variables by using statistical data analysis techniques (see Frankfort-
Nachmias, 2014). 
In this study, I employed quantitative methods, which are frequently used to 
analyze spontaneous data (see Aagaard et al., 2009). Chi-square test and ORs, as the most 
appropriate statistical methods, were conducted to investigate the relationship between 
reporter and reported ADRs. The test for association or dependence between the reporter 
and the total number of reported ADRs, as well as patient outcome, SOC, and reporter 
demographics, were conducted using the chi-square test and/or logistic regression (unless 
specified otherwise). 
The chi-square test, as the most appropriate analytical strategy to employ in this 
study, was used to test for association between two categorical variables (see Gerstman, 
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2008). The statistical significance in association between reporter and total number of 
case and event level reported ADRs, as well as patient outcome, SOC, and reporter 
demographics, were shown with a p-value of less than 0.05. Given the number of 
comparisons of a similar nature, the issue of multiple comparisons arose. Furthermore, 
since multiple hypotheses were tested, the chance of incorrectly rejecting a null 
hypothesis (Type I error) was increased (Mittelhammer, Judge, & Miller, 2000). 
Therefore, to counteract these issues, I employed the Bonferroni correction, which tested 
each individual hypothesis at a significance level of α/m, where α was the desired overall 
alpha level and m was the number of hypotheses (see Miller, 1966). In this study, I 
adjusted for multiple comparisons by dividing my criterion of significance (0.05) by the 
number of tests (8), which yielded 0.006 (i.e. 0.05/8=0.006). Subsequently, I employed 
this number (0.006) as a benchmark to determine whether any comparison was 
statistically significant. 
The OR, which is another measure of association for categorical data, as well as 
an additional appropriate method to employ in this study, was also used in conjunction 
with logistic regression models (see Gertsman, 2008). The chi-square test illustrated that 
an association exists, while the OR displayed the strength of the association. The 
confidence intervals were calculated at 95% for each OR. Statistical analysis were 
performed using a statistical software package (SPSS v25). 
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Methodology 
Population 
In this study, the target population were the reporters, consumers and physicians, 
who both submitted ADR reports (cases) to the FDA. ADRs voluntarily reported by 
consumers and physicians can be made directly to the market authorization holders of the 
product, which is mandated by law to subsequently report these events to the FDA (FDA, 
2017). ADRs reported by consumers can also be made directly to such regulatory 
agencies as the FDA without making the initial report to their physicians (Health Action 
International, 2015). 
Sampling and Sampling Procedures 
I hypothesized that the two groups, consumers and physicians, were independent, 
and that the sample size of physician and consumer groups were unequal. Moreover, I 
hypothesized that the number of ADRs at case and event level reported by consumers and 
physicians were not the same. Furthermore, I hypothesized that physicians would report a 
lower number of ADRs at case and event level in comparison to consumers. To ascertain 
that the reporting differences between consumers and physicians were statistically 
significant and were not due to chance, the difference between two independent 
proportions (with unequal sample size per group) sample size calculation was performed. 
Hence, the following sample size formula was employed: n1= [√p(1-p) (1 + 1/k) zα/2 + √ 
p1(1-p1) + p2(1-p2)/k zß]2 /(p1-p2)2, n2=kn1 (see Ott & Longnecker, 2008), where 
zα/2 corresponds to a two-tailed significance level and is the critical value of the Normal 
distribution at α/2 (for a confidence level of 95%, α is 0.05 and the critical value is 
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1.96); Zβ corresponds to power and is the critical value of the Normal distribution at β 
(for a power of 80%, β is 0.2 and the critical value is 0.84); p1 and p2 were the expected 
sample proportions of the two groups of participants (consumer versus physician); and, 
k = ratio of larger group (consumers) to smaller group (physicians) of participants (see 
Ott & Longnecker, 2008). 
A total of 87,807 ADR reports and 143,399 ADRs (consumer [83,009 ADRs] and 
physician [60,390 ADRs]) for the 2nd quarter of the year 2016 were analyzed. 
Spontaneous ADRs were reported by consumers and physicians with α = 0.05 (two-
tailed) and the minimum required power level β = 0.80. For the difference between two 
independent proportions (with unequal sample size per group) analysis, G*Power was 
used to calculate the appropriate sample size based on the following criteria: z-test (a 
two-tailed test); proportion for group 2 (consumers = 83,009/143,399 =.58); proportion 
for group 1 (physicians = 60,390/143,399 =.42); an allocation ratio of n2/n1, which is the 
ratio of larger group (consumers) to smaller group (physicians) of participants 
(83,009/60,390 = 1.37); an 80% power; and, an alpha level of .05. Based on the 
aforementioned assumptions, the appropriate total sample size needed for this particular 
test was 312, with 132 and 180 sample sizes needed for each consumer and physician 
group, respectively. Hence, the total sample size of 312 represented the minimum sample 
size needed for sufficient power. 
Data Collection Procedures 
This study included ADRs at case and event level that were submitted by 
consumers and physicians to the FDA via the FDA’s FAERS database, which contains 
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the latest quarterly data files that were extracted for analysis. Data were collected 
subsequent to Institutional Review Board (IRB) approval in April 2018. The data 
containing the spontaneous ADR reports from the FAERS database were accessed and 
downloaded from the quarterly data file data selection time period: 01 April 2016 through 
30 June 2016. The quarterly data files were available in two different formats: ASCII and 
SGML. In the ASCII files, the data elements were separated from each other by a “$” 
sign (“$ delimited”) (FDA, 2016b). The SGML files conform to the ICH guidelines 
regarding transmission of individual case safety reports (FDA, 2016b). The data files 
included, but were not limited to, the following data: demographic and administrative 
information and the initial report image identification (ID) number; drug information 
from the case reports; reaction information from the reports; patient outcome information 
from the reports; information on the source of the reports; and, a “README” file 
containing a description of the files (FDA, 2016). 
The spontaneous ADR reports were initially collected in the form of raw data via 
the MedWatch program, which is the FDA’s Safety Information and AE Reporting 
Program that gathers reports of ADRs, medication or product use errors, and quality 
issues associated with human medical products, medical devices, vaccines and other 
biologics, dietary supplements, and cosmetics (FDA, 2017). Under MedWatch, HCPs, 
including physicians, and consumers may voluntarily submit reports to the FDA when 
they discover an issue or an adverse reaction with a drug, medical device, biologic, or 
other FDA-regulated products. Subsequently, these data were thoroughly cleaned, 
recorded, recoded, redacted, and stored as an electronic file in the FAERS database by 
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the FDA for accessibility (Hyman, 2000). Since the data had been previously coded and 
redacted, the data were anonymously encrypted in form, with no personal identifiers 
present. The data were in a line listing format in which a unique number known as the 
individual safety report (ISR) was assigned for identifying an AER report (FDA, 2015). 
A case number, which consists of one or more ISR, was assigned for identifying an 
AERS case, and served as a link to the necessary variables for research. Once the ADR 
data had been collected, spontaneous reports from consumers and physicians were 
compared for ADRs at case and event level. 
Instrumentation and Operationalization of Constructs 
ADRs were coded using MedDRA, and ADRs at case and event level were 
determined by the Council for International Organizations of Medical Sciences criteria 
(EMEA, 1995). All ADR terms had been previously coded to the PT within FAERS, and 
the PT was used to obtain the correct SOC. The codes for outcomes in the FAERS ASCII 
files were as follows: DE = Death; LT = Life-Threatening; HO = Hospitalization−Initial 
or Prolonged; DS = Disability; CA = Congenital Anomaly; RI = Required Intervention to 
Prevent Permanent Impairment/Damage; and, OT = Other. SOC was retrieved from the 
quarterly output and the PT was entered into the MedDRA database (if necessary) to 
determine SOC category. Reporter demographics were coded M= male and F= female or 
NR= Not Reported. 
The reporters in this study were consumers (non-HCPs) and physicians, and the 
codes for reporter’s type of occupation in the AERS ASCII files were as follows: MD = 
Physician and CN = Consumer. 
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Data Analysis Plan 
In this study, I analyzed secondary data, specifically, ADRs that were submitted 
by consumers and physicians to the FDA, from the FAERS database, which contains 
quarterly data files that were extracted for analysis (FDA, 2016b). The data containing 
the spontaneous ADR reports from the FAERS database were accessed and downloaded 
from the quarterly data file data selection time period: 01 April 2016 through 30 June 
2016. Once the ADR data had been collected, spontaneous reports from consumers and 
physicians were assessed. A total of 87,807 ADR reports (cases) and 143,399 ADRs 
(events) (consumer [83,009 ADRs] and physician [60,390 ADRs]) reported by consumers 
and physicians for the 2nd quarter of the year 2016 (01 April 2016 through 30 June 2016) 
were analyzed. The distinction between ADR reports and ADRs could be made in the 
following manner: ADR reports (or cases) are singular and can have multiple ADRs (or 
events) within them. In my study, 87,807 ADR cases referred to the number of cases that 
contain 143,399 events. The numbers in brackets signifies that consumers reported 
83,009 events while physicians reported 60,390 events (please note: the remaining 
number of events that were reported from other sources that are not relevant to this study 
include, but are not limited to, pharmacists, other HCPs, and lawyers). Spontaneous US 
ADRs were analyzed in an effort to compare consumer and physician reporting of ADRs. 
These reports were examined on the basis of the reporter type and patient outcome 
(which determines the severity of the event). 
The FAERS reporting system data contained seven files. The element that 
connected the files data was the Primary ID. The files were as follows: Demographic, 
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Outcome, Drug, Reaction, Report Sources, Indication, and Therapy. The “Outcome” file 
contains all outcomes, in other words “all” events, that occurred to a patient after drug 
administration and reported by a medical doctor or a consumer. The “Demographic” file 
contained and described the cases, which were identified through IDs (every case had a 
single ID). As for a single patient (a case) could be reported with one or more outcomes 
(events), there were IDs that were associated with more than one outcome. In an analysis 
focused on cases and outcomes simultaneously, only those IDs that had a single outcome 
could be used (FDA, n.d.). 
Prior to commencing secondary data collection, approval from the IRB was 
sought and obtained (04-18-18-0523354). Upon receipt of approval, the quarterly data 
file data as described above were extracted from the FDA’s FAERS database (April 
2018). 
The following research questions will be addressed: 
 
Primary Research Questions 
Research Question 1A: Is there a statistically significant difference in the 
distribution of ADRs by reporter (consumer versus physician) and patient outcome? 
H01A: There is no statistically significant difference in the distribution of ADRs 
by reporter (consumer versus physician) and patient outcome. 
Ha1A: There is a statistically significant difference in the distribution of ADRs by 
reporter (consumer versus physician) and patient outcome. 
Research Question 1B: Is there a statistically significant difference in the 
distribution of ADRs by reporter when comparing by severity of outcome? 
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H01B: There is no statistically significant difference in the distribution of ADRs 
by reporter when comparing by severity of outcome. 
Ha1B: There is a statistically significant difference in the distribution of ADRs by 
reporter when comparing by severity of outcome. 
Exploratory Research Questions 
Research Question 2: Is there a statistically significant difference in the 
distribution of ADRs by reporter (consumer versus physician) and SOC? 
H02: There is no statistically significant difference in the distribution of ADRs by 
reporter (consumer versus physician) and SOC. 
Ha2: There is a statistically significant difference in the distribution of ADRs by 
reporter (consumer versus physician) and SOC. 
Research Question 3: Is there a statistically significant difference in the 
distribution of ADRs by reporter (consumer and physician) and demographics? 
H03: There is no statistically significant difference in the distribution of ADRs by 
reporter (consumer versus physician) and demographics. 
Ha3: There is a statistically significant difference in the distribution of ADRs by 
reporter (consumer versus physician) and demographics. 
The primary objective in this study was to test the association between the type of 
reporter reporting the ADR and patient outcome, with exploratory objectives of 
evaluating total ADRs (events) and total ADR cases (reports) reported by consumers and 
physicians versus SOC and reporter demographics. Once data were downloaded from the 
FDA’s FAERS database, they were analyzed for type of reporter and patient outcome, as 
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well as SOC, and reporter demographics. This study contains several tables, specifically 
for the distribution of ADRs based on patient outcome, as well as SOC and reporter 
demographics. The independent variable was the reporter (consumer versus physician 
whereas patient outcome, SOC, and reporter demographics was the dependent variables. 
The unit of analysis was the total number of ADR cases and reported ADRs. A statistical 
software package (SPSS v.25) was employed to manage and set up the data, as well as to 
perform bivariate and multivariate analyses. Bivariate analyses, specifically, the chi-
square test for independence, OR, and logistic regression was conducted to assess 
statistically significant differences between the categorical independent variable (the 
reporter) and the seven different levels of the categorical dependent variable (patient 
outcome) (see Ott & Longnecker, 2008). The seven different levels of the patient 
outcome variable were as follows: death (DE); LT; initial or prolonged existing inpatient 
hospitalization (HO); persistent or significant disability or incapacity (DS); a congenital 
anomaly or birth defect (CA); necessary intervention to inhibit permanent damage (RI); 
or, other (important) medical outcome, event, or reaction (OT) (FDA, 2016b). As 
previously mentioned, SOC was categorized by PT within MedDRA. Reporter 
demographics were categorized as male versus female since this information was readily 
available within the dataset. 
In this study, I employed quantitative methods, which are frequently used to 
analyze spontaneous data (see Aagaard et al., 2009). Chi-square test and ORs, as the most 
appropriate statistical methods, were conducted unless otherwise specified to investigate 
the relationship between reporter and reported ADRs. The chi-square test, as the most 
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appropriate analytical strategy to employ in this study, was used to test for association 
between two categorical variables (see Gerstman, 2008). The statistical significance in 
association between reporter and total number of reported ADRs, as well as patient 
outcome, were shown with a p-value of less than 0.006. The OR, which is another 
measure of association for categorical data, as well as an additional appropriate method to 
employ in this study, was also used in conjunction with logistic regression models (see 
Gertsman, 2008). The chi-square test illustrated that an association existed, while the OR 
displayed the strength of the association. The confidence intervals were calculated at 95% 
for each OR. 
After bivariate analyses were conducted, the results were presented via tables. It is 
important to mention that the tables presented had to be clear and concise. Table titles 
had to be understandable without reading the chapter text (see Diether, 2016). All 
relevant results were noted, even those that were contrary to the alternative hypotheses, 
or those that tended to distract from clear determinations. Furthermore, statements of the 
results were rendered without any implication, speculation, assessment, evaluation, or 
interpretation (see van Hunsel et al., 2009). In conducting research for this study, the area 
of examination and the research questions allowed me to determine the research method 
that was be followed. The research method entailed the manner in which the researcher 
gathered, assessed, and deciphered the data in this study (see Creswell, 2014). One of the 
most important aspects of secondary data analysis is the implementation of theoretical 
knowledge and conceptual skills within existing data in an effort to address the research 
questions. Since a secondary data analysis was performed, which is a systematic method 
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with procedural and evaluative steps, this process was commenced with the development 
of the research questions, which enabled identification of datasets for analysis (see 
Creswell, 2014). 
The main research question was as follows: is there a statistically significant 
difference in the distribution of ADRs by reporter (consumer versus physician) and 
patient outcome? To address this research question, seven logistic regression analyses 
were conducted in which the dependent variable, patient outcome, were dichotomized for 
seven distinct categories: fatal and non-fatal; LT and non-LT; hospitalized and non-
hospitalized; with and without the outcome of initial or prolonged disability; with and 
without the outcome of congenital anomaly; with and without the outcome of required 
intervention to prevent permanent impairment/damage; and, with and without the 
outcome of other (important medical event). The results were presented in a tabular 
fashion, thereby producing several tables comparing consumer versus physician to the 
aforementioned seven distinct categories of the dependent variable patient outcome. 
Secondary questions included reporter versus SOC and reporter demographics. 
Threats to Validity 
Since the correlational cross-sectional research design was utilized, the secondary 
data led to under-reporting and recall bias, which yielded misclassification or information 
bias (see Gualano et al., 2015). Furthermore, the use of this particular design only 
provided a rather limited amount of information of the sample (see Gualano et al., 2015). 
The correlational cross-sectional research design presented challenges regarding the 
determination of causal relationships between the distribution of case and event level 
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ADRs by reporter (consumer versus physician) and patient outcome, SOC, and reporter 
demographics. The correlational cross-sectional design contained several limitations that 
were significant to examine, including internal validity, which was only germane to such 
a design as experimental that attempts to establish a causal relationship (see Frankfort-
Nachmias, 2014). Since researchers do not alter the independent variables, they must 
render logical or theoretical inferences in terms of the direction of the causation by taking 
into account that correlation between variables does not imply causation (see Field, 
2013). Hence, it is challenging for researchers to make causal inferences. 
To overcome several methodological limitations of correlational cross-sectional 
designs, researchers frequently employ statistical analyses, including cross-tabulation, for 
the purpose of organizing, describing, and summarizing their observations, as well 
approximating some of the processes inherent within experimental designs (see 
Frankfort-Nachmias, 2014). When the data are categorized, researchers are able to make 
contrasts between the categorical groups (see Frankfort-Nachmias, 2014). 
Despite the disadvantages of correlational cross-sectional research designs, in 
particular, the threat to internal validity, these designs have advantages inherent within 
them. Despite this design’s internal weaknesses, it manages the threats to external 
validity (see Campbell & Stanley, 1963). However, researchers using the cross-sectional 
design must sacrifice internal validity in order to achieve greater generalizability or 
external validity (see Research Design, n.d.). Correlational cross-sectional designs 
usually have a high level of external validity, which enables researchers to generalize 
their findings to a larger population (see Carlson & Morrison, 2009). Furthermore, these 
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designs enable the researchers to perform studies in natural, real-life settings utilizing 
probability samples, thereby increasing the external validity of their studies (see 
Frankfort-Nachmias, 2014). 
Additionally, correlational cross-sectional designs do not require the random 
assignment of individual cases to comparison groups, which is particularly useful in 
situations where the random assignment of individuals to a treatment or control group 
may be unethical or improbable (see Frankfort-Nachmias, 2014). Although correlational 
cross-sectional designs prevent researchers from making causal inferences, these non-
experimental designs nonetheless play a pivotal role in research efforts by allowing 
researchers to establish a statistical relationship between variables and, subsequently, 
paving the way for future studies in which researchers can utilize experimental designs to 
confirm the statistical relationship as a causal one (Price, 2012). 
Ethical Procedures 
Given that the ADR data from the FDA’s FAERS database have been de-
identified, it is not possible to trace back to the consumers and physicians from whom the 
data were originally collected. Since these data will no longer identifiable, the subsequent 
use of these data would not constitute research on human subjects (University of 
Chicago, 2014). Moreover, since this study employed secondary data analysis, 
recruitment of the participants were not made, especially those in vulnerable populations, 
including, but not limited to the following: minors (age 17 and under); adult students of 
the researcher; subordinates of the researcher; patients of the researcher; nursing home 
residents; prisoners; mentally impaired or disabled individuals; emotionally impaired or 
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disabled individuals; physically impaired or disabled individuals; individuals residing 
within the US who may not be fluent in English; undocumented immigrants; 
victims/witnesses of violent crime or other trauma (e.g. natural disasters); active duty 
military personnel; and, any other individuals who may not be able to protect their own 
rights or interest (Walden University, n.d.). 
Furthermore, this study did not involve the following sensitive topics, which 
would pose ethical challenges in doctoral research and, consequently, entail early ethics 
consultation with the Walden University IRB: questions about professional work that 
might lead to disclosure of behavior(s) or standpoints that may lead to someone being 
terminated from their position or passed over for promotion (e.g., lack of compliance 
with policy, disagreement with leadership decisions, etc.); questions regarding substance 
use, mental state, or violence that may necessitate a referral or intervention to eschew 
violence to the participant (addiction, severe depression, suicidality, eating disorders, 
bullying, physical threats, etc.); illicit activities in which the participant may inculpate 
him or herself via research data (e.g. illegal drug use, illegal immigration, child neglect, 
insider trading, harassment, assault, bullying, cyberbullying, etc.); personal issues that 
may cause anxiety to an individual if framed in a judgmental, non-inclusive, dismissive, 
or otherwise insensitive fashion (ethnicity, body image, religion, etc.); race or ethnicity as 
a variable or inclusion criterion; and, outcomes of a new intervention or program in an 
education, psychological, or clinical environment (Walden University, n.d.). 
While doctoral research and other projects that necessitate secondary data analysis 
do not entail interactions or interventions with humans, they still require IRB review, as 
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per the Code of Federal Regulations 45 CFR 46.102(f), which defines ‘human subject’ as 
a living individual about whom a researcher collects data via intervention or interaction 
with the individual or identifiable private information for the purpose of research (U.S. 
Department of Health & Human Services, 2010). The secondary data analysis does not 
require IRB review when it falls outside of the regulatory definition of research involving 
human subjects (University of Chicago, 2014). Although secondary data analysis in this 
study will not jeopardize the privacy of the participants in the manner that primary data 
collection and analysis may (Purdue Online Writing Lab, 2016), the rights of participants 
will still need to be protected by ensuring that all identifiers have been removed from the 
dataset (Walden University, n.d.). Furthermore, since the data from the FAERS database 
was readily available to the public, no additional approval (other than Walden University 
IRB approval) was needed. Hence, prior to commencing secondary data collection, 
approval from the Walden University IRB was sought and obtained (04-18-18-0523354). 
Summary 
This study was quantitative in nature, and the cross-sectional research design was 
employed. Secondary analysis of these data was performed by utilizing the chi-square 
test, as well as the OR. I discussed the methodology and analytical strategies in this 
chapter and provided greater insight into the significance of including consumer reports 
within SRSs, as well as comparing the rates of case and event level ADR reporting 
between consumers and physicians for the purpose of increasing awareness of the rate of 
under-reporting. The ADR data was obtained from the FDA’s FAERS database in order 
to assess ADRs submitted as reports by consumers and physicians and patient outcome, 
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SOC, and reporter demographics. Chi-square test of association, OR, and logistic 
regression analyses was employed for comprehending the nature of these categorical 
secondary data. Statistical analysis was conducted via a statistical software package 
(SPSS v.25). Next, in Chapter 4, I provide the results of the study. Lastly, in Chapter 5, I 
provide a discussion of the results, study limitations, recommendations for future 
research, and the implications for social change. 
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Chapter 4: Results 
Introduction 
The purpose of this quantitative study was to examine whether a statistically 
significant difference exists in the distribution of ADRs within the FAERS database by 
reporter (consumer versus physician) and patient outcome, while also evaluating reporter 
differences in SOC and reporter demographics. The reporter was the independent variable 
consisting of two levels: consumer and physician. Patient outcome, SOC, and reporter 
demographics were the dependent variables. The unit of analysis was the total number of 
ADR cases and reported ADRs. Within the exploratory research questions, I evaluated 
the total number of ADR cases and reported ADRs of reporters (consumer and physician; 
independent variable) compared to SOC (dependent variable), and I also evaluated the 
total number of ADR cases and reported ADRs of reporters (consumer and physician) 
compared to demographics. The findings of this study are represented in tables in this 
chapter. The following research questions and hypotheses were addressed during the 
analysis: 
Primary Research Questions 
Research Question 1A: Is there a statistically significant difference in the 
distribution of ADRs by reporter (consumer versus physician) and patient outcome? 
H01A: There is no statistically significant difference in the distribution of ADRs 
by reporter (consumer versus physician) and patient outcome. 
Ha1A: There is a statistically significant difference in the distribution of ADRs by 
reporter (consumer versus physician) and patient outcome. 
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Research Question 1B: Is there a statistically significant difference in the 
distribution of ADRs by reporter when comparing by severity of outcome? 
H01B: There is no statistically significant difference in the distribution of ADRs 
by reporter when comparing by severity of outcome. 
Ha1B: There is a statistically significant difference in the distribution of ADRs by 
reporter when comparing by severity of outcome. 
Exploratory Research Questions 
Research Question 2: Is there a statistically significant difference in the 
distribution of ADRs by reporter (consumer versus physician) and SOC? 
H02: There is no statistically significant difference in the distribution of ADRs by 
reporter (consumer versus physician) and SOC. 
Ha2: There is a statistically significant difference in the distribution of ADRs by 
reporter (consumer versus physician) and SOC. 
Research Question 3: Is there a statistically significant difference in the 
distribution of ADRs by reporter (consumer and physician) and demographics? 
H03: There is no statistically significant difference in the distribution of ADRs by 
reporter (consumer versus physician) and demographics. 
Ha3: There is a statistically significant difference in the distribution of ADRs by 
reporter (consumer versus physician) and demographics. 
Data Collection 
 I conducted the analysis by using data publicly available from the FAERS 
database. The AEs and medication error were coded in the FAERS database to terms in 
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the MedDRA terminology. The FAERS database contained its data in seven tables linked 
through cases reports identifications (IDs), which could be found within the following 
data tables: Demographic, Outcome, Report sources, Reaction, Drug, and Therapy and 
Indication (FDA, n.d.). 
The data employed in the current analysis covered the cases of AEs reported or 
updated in the second quarter of 2016 (from 01 April 2016 to 30 June 2016), and the 
analysis was performed from the case perspective (case-based analysis) and events 
perspective (event-based analysis). This type of approach was necessary due to the fact 
that a significant number of cases are associated with multiple events. Consequently, the 
analysis based on ADR cases was performed using only those case IDs that were 
associated with only one event. Therefore, the samples used in the analysis of cases and 
events had different sizes. Furthermore, since the number of events is greater than the 
number of cases, the set of case IDs that was used to build the dataset with all necessary 
variables and observations for the statistical analyses (along with the associated events 
from the “outcome” table) was used as a starting point in the development of the dataset. 
With regards to the analysis of ADRs by reporter and SOC, the drug consumption 
outcomes and, more precisely, their associated reactions, were grouped according to the 
SOC by matching the PTs for reactions from the FAERS “Reaction” table. Subsequently, 
the matched terms were coded using the MedDRA terminology with the outcomes from 
FAERS “Outcome” table based on the case identifiers (IDs). The conversion of the 
existent PTs into SOCs was made using the 2016 release, which covers the first half of 
the year, from The Protect Adverse Drug and Product Reaction Database, which is 
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provided by The European Medicines Agency and PROTECT Partners (FDA, n.d.). The 
above-mentioned database contains drugs names (trade and active ingredient name), the 
PTs for reactions (coded via MedDRA), and the SOC group for each PT. Given that not 
all PTs from the “Reaction” table could be matched with a SOC group based on the PTs 
from The Protect Adverse Drug and Product Reaction Database, and since the manual 
matching may lead to bias (systematic or random), the analysis was limited to those PTs 
for which the exact SOC group can be identified. Concurrently, since the intended 
analysis was event outcome-based and multiple reactions (PTs) could be associated with 
one or more outcomes, the analysis was also limited to only those case IDs associated 
with a single reaction (PT) reported. Hence, this particular analysis was based on 
approximately 25% of the total reported ADRs, namely, cases (IDs) with a single 
reaction (PT) and one or more events. 
All p-values were calculated using the chi-square (χ2) test and a significance level 
of .006. Given the number of comparisons of a similar nature, the issue of multiple 
comparisons arose. Furthermore, since multiple hypotheses were tested, the chance of 
incorrectly rejecting a null hypothesis (Type I error) was increased (see Mittelhammer, 
Judge, & Miller, 2000). Therefore, to counteract these issues, I employed the Bonferroni 
correction, which tested each individual hypothesis at a significance level of α/m, where 
α was the desired overall alpha level and m was the number of hypotheses (see Miller, 
1966). In this study, I adjusted for multiple comparisons by dividing my criterion of 
significance (0.05) by the number of tests (8), which yielded 0.006 (i.e. 0.05/8=0.006). 
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Subsequently, I employed this number (0.006) as a benchmark to determine whether any 
comparison was statistically significant. 
The same significance level was used for OR confidence intervals. The p-value 
from the chi-square test was calculated for only the categorical data contained in the 2x2 
contingency tables. Therefore, the test was conducted to determine whether statistically 
significant differences exist between two groups. A significant p-value (less than .006) 
indicated that a statistically significant difference exists between consumers and 
physicians in reporting of an ADR case or event. The OR represented how much more 
likely consumers were to report an ADR case or event in comparison to physicians. A 
post-hoc power analysis was also computed. For the difference between two independent 
proportions analysis, G*Power was used to calculate the power based on the following 
criteria: z-test (a two-tailed test); a medium effect size of 0.33; proportion for group 1 
(physicians = 60,390/143,399 = .42); an alpha level of .05; a sample size of 60,390 for 
group 1, which represents physicians; and, a sample size of 83,009 for group 2, which 
represents consumers. Based on the aforementioned criteria, the post-hoc power for this 
analysis was 1.0. 
 
Results 
Research Question 1A 
The first part of the research question, I examined whether a statistically 
significant difference exists in the distribution of ADRs based on reporter (consumer 
versus physician) and patient outcome. The case-based and event-based analyses were 
performed, and the chi-square test was conducted for both types of analyses. Since the 
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response variable (patient outcome) contains seven categories, a reference category is 
needed to compute ORs and compare reporter and patient outcome. Therefore, other 
medical event (OME) was selected as a reference category; the results are shown in 
Tables 1 and 2. As can be seen in Table 1, for the case-based analysis, the results from 
the chi-square test revealed a statistically significant association between reporter and 
patient outcome, χ2 (6, N = 87,807) = 406.74, p <.001, φC = .07. Cramer’s V value of .07, 
which was less than a value of .20, signified a relatively weak relationship between 
reporter and patient outcome. The ORs for the six categories of patient outcome 
(congenital, fatal, disability, hospitalization, intervention, and LT) were computed and 
compared to the reference category of OME. 
For the patient outcome category of congenital, the odds ratio for reporter (OR = 
0.39) was less than 1, thereby indicating a negative relationship between reporter and 
patient outcome category of congenital. The odds of consumers reporting congenital 
ADR reports versus OME ADR reports were 0.39 times the same odds among 
physicians. 
For the patient outcome category of fatal, the odds ratio for reporter (OR = 0.86) 
was less than 1, thereby indicating a negative relationship between reporter and patient 
outcome category of fatal. The odds of consumers reporting fatal ADR reports versus 
OME ADR reports were 0.86 times the same odds among physicians. 
For the patient outcome category of disability, the odds ratio for reporter (OR = 
0.77) was less than 1, thereby indicating a negative relationship between reporter and 
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patient outcome category of disability. The odds of consumers reporting disability ADR 
reports versus OME ADR reports were 0.77 times the same odds among physicians. 
For the patient outcome category of hospitalization, the odds ratio for reporter 
(OR = 0.87) was less than 1, thereby indicating a negative relationship between reporter 
and patient outcome category of fatal. The odds of consumers reporting hospitalization 
ADR reports versus OME ADR reports were 0.87 times the same odds among 
physicians. 
For the patient outcome category of intervention, the odds ratio for reporter (OR = 
0.13) was less than 1, thereby indicating a negative relationship between reporter and 
patient outcome category of intervention. The odds of consumers reporting intervention 
ADR reports versus OME ADR reports were 0.13 times the same odds among 
physicians. 
For the patient outcome category of LT, the odds ratio for reporter (OR = 0.29) 
was less than 1, thereby indicating a negative relationship between reporter and patient 
outcome category of LT. The odds of consumers reporting LT ADR reports versus OME 
ADR reports were 0.29 times the same odds among physicians. Based on these results, 
the null hypothesis would be rejected in favor of the alternative hypothesis. 
Table 1 also illustrates the distribution of ADR reports (cases) by reporter and the 
seven categories of patient outcome. A total of 87,807 reports were received for the 01 
April 2016 through 30 June 2016 period of the quarterly data file data selection time 
period: 01 April 2016 through 30 June 2016. According to Table 1, in comparison to 
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physicians, consumers reported more ADR reports for the following categories of patient 
outcome: death, disability, hospitalization, and OME. 
 
Table 1 
 
Distribution of Adverse Drug Reactions (ADRs) Reports in the US (01 April 2016 
through 30 June 2016) by Reporter and Patient Outcome 
Reporter 
Type 
Congenital 
N 
Death 
N 
Disability 
N 
Hospitalization 
N 
Intervention 
N 
Life-
threatening 
N 
Other 
Medical 
Event 
N 
Total 
N 
Both 
Reporters 
181 7,903 978 26,416 12 753 51,564 87,807 
 
Consumer 
 
70 
(38.7) 
 
4,564 
(57.8) 
 
539 
(55.1) 
 
15,362 
(58.2) 
 
2 
(16.7) 
 
236 
(31.3) 
 
3,1683 
(61.4) 
 
52,456 
(59.7) 
 
Physician 
 
111 
(61.3) 
 
3,339 
(42.2) 
 
439 
(44.9) 
 
11,054 
(41.8) 
 
10 
(83.3) 
 
517 
(68.7) 
 
19,881 
(38.6) 
 
3,5351 
(40.3) 
Note. χ2 = 406.74, df = 6, p <.001. Numbers in parentheses indicate column percentages. 
p <.006 
 
As can be seen in Table 2, for the event-based analysis, the results from the chi-
square test revealed a statistically significant association between reporter and patient 
outcome, χ2 (6, N = 143,399) = 1,299.37, p <.001, φC =.09. The Cramer’s V value of .09, 
which was less than a value of .20, signified a relatively weak relationship between 
reporter and patient outcome. The ORs for the six categories of patient outcome 
(congenital, fatal, disability, hospitalization, intervention, and LT) were computed and 
compared to the reference category of OME. 
For the patient outcome category of congenital, the odds ratio for reporter (OR = 
0.58) was less than 1, thereby indicating a negative relationship between reporter and 
patient outcome category of congenital. The odds of consumers reporting congenital 
ADRs versus OME ADRs were 0.58 times the same odds among physicians. 
78 
 
For the patient outcome category of fatal, the odds ratio for reporter (OR = 0.89) 
was less than 1, thereby indicating a negative relationship between reporter and patient 
outcome category of fatal. The odds of consumers reporting fatal ADRs versus OME 
ADRs were 0.89 times the same odds among physicians. 
For the patient outcome category of disability, the odds ratio for reporter (OR = 
0.76) was less than 1, thereby indicating a negative relationship between reporter and 
patient outcome category of disability. The odds of consumers reporting disability ADRs 
reports OME ADRs were 0.76 times the same odds among physicians. 
For the patient outcome category of hospitalization, the odds ratio for reporter 
(OR = 0.85) was less than 1, thereby indicating a negative relationship between reporter 
and patient outcome category of fatal. The odds of consumers reporting hospitalization 
ADRs versus OME ADRs were 0.85 times the same odds among physicians. 
For the patient outcome category of intervention, the odds ratio for reporter (OR = 
0.12) was less than 1, thereby indicating a negative relationship between reporter and 
patient outcome category of intervention. The odds of consumers reporting intervention 
ADRs versus OME ADRs were 0.12 times the same odds among physicians. 
For the patient outcome category of LT, the odds ratio for reporter (OR = 0.33) 
was less than 1, thereby indicating a negative relationship between reporter and patient 
outcome category of LT. The odds of consumers reporting LT ADRs versus OME ADRs 
were 0.33 times the same odds among physicians. Based on these results, the null 
hypothesis would be rejected in favor of the alternative hypothesis. 
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Table 2 also shows the distribution of ADRs (events) by reporter and patient 
outcome. A total of 143,399 ADRs were received for the 01 April 2016 through 30 June 
2016 period of the quarterly data file data selection time period: 01 April 2016 to 30 June 
2016. According to Table 2, in comparison to physicians, consumers reported more 
ADRs for the following categories of patient outcome: death, disability, hospitalization, 
and OME. 
Table 2 
 
Distribution of Adverse Drug Reactions (ADRs) in the US (01 April 2016 through 30 
June 2016) by Reporter and Patient Outcome 
Reporter 
Type 
Congenital 
N 
Death 
N 
Disability 
N 
Hospitalization 
N 
Intervention 
N 
Life-
threatening 
N 
Other 
Medical 
Event 
N 
Total 
N 
Both 
Reporters 
507 16,178 2,866 46,149 19 4,154 73,526 143,399 
 
Consumer 
 
237  
(46.7) 
 
 
8,346 
(57.8) 
 
1,535 
(53.6) 
 
26,074 
(56.5) 
 
3 
(15.8) 
 
1,394 
(33.6) 
 
44,420 
(60.4) 
 
83,009 
(57.9) 
 
Physician 
 
270 
(53.3) 
 
6,832 
(42.2) 
 
1,331 
(46.4) 
 
20,075 
(43.5) 
 
16 
(84.2) 
 
2,769 
(66.4) 
 
29,106 
(39.6) 
 
60,390 
(42.1) 
Note. χ2 = 1,299.37, df = 6, p <.001. Numbers in parentheses indicate column percentages. 
p <.006 
 
Research Question 1B 
The second part of the research question, I examined whether a statistically 
significant difference exists in the distribution of ADRs based on reporter (consumer 
versus physician) and severity of patient outcome. For the severity of patient outcome 
analysis, I grouped patient outcomes into a dichotomous variable by severity (serious 
versus nonserious) and tested this first.  For this particular analysis, the seven categories 
of the patient outcome variable were grouped into a dichotomous variable by severity 
(serious versus nonserious) and the relationship was first tested. The reason for grouping 
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the seven categories of patient outcome variable into two categories is to create a severity 
variable consisting of two levels: serious and nonserious in order to determine whether 
there is a statistically significant association between reporter and severity of patient 
outcome. 
As shown in Tables 3 and 4, the serious outcomes (“Serious” column) were 
grouped as death and LT ADRs, and the nonserious outcomes (“Nonserious” column) 
were grouped as hospitalization, disability, congenital anomaly, intervention (required to 
prevent permanent impairment/damage), and OME. The case-based and event-based 
analyses were performed and the chi-square test was conducted for both types of 
analyses; the results are shown in Tables 3 and 4. As can be seen in Table 3, for the case-
based analysis, the results from the chi-square test revealed a statistically significant 
association between reporter and patient outcome severity, χ2 (1, N = 87,807) = 73.39, p 
<.001, φC =.03. The Cramer’s V value of .03, which was less than a value of .20, signified 
a relatively weak relationship between reporter and severity of patient outcome. The odds 
ratio for reporter (OR = 0.82) was less than 1, thereby indicating a negative relationship 
between reporter and patient outcome severity. The odds of consumers reporting serious 
ADR reports versus nonserious ADR reports were 0.82 times the same odds among 
physicians. Based on these results, the null hypothesis would be rejected in favor of the 
alternative hypothesis. 
Table 3 also illustrates the distribution of ADR reports (cases) by reporter and 
patient outcome severity. A total of 87,807 reports were received for the 01 April 2016 
through 30 June 2016 period of the quarterly data file data selection time period: 01 April 
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2016 through 30 June 2016. Of these, consumers reported 52,456 (59.7%) ADR reports 
and physicians reported 35,351 (40.3%) ADR reports. Of the total ADR reports, 8,656 
reports were serious and 79,151 reports were nonserious. Of the 8,656 serious reports, 
consumers reported 4,800 (55.5%) serious reports and physicians reported 3,865 (44.5%) 
serious reports. Therefore, consumers reported more ADR reports and more serious ADR 
reports in comparison to those reported by physicians. 
Table 3 
 
Distribution of Adverse Drug Reactions (ADRs) Reports in the US (01 April 2016 
through 30 June 2016) by Reporter and Patient Outcome Severity 
Patient 
Outcome 
Severity 
Serious 
 
N=8,656 
 Nonserious 
 
N= 79,151 
 Total 
 
N= 87,807 
Consumer 4,800 
(55.5) 
 47,656 
(60.2) 
 52,456 
(59.7) 
Physician 3,856 
(44.5) 
 31,495 
(39.8) 
 35,351 
(40.3) 
Note. χ2 = *73.39, df = 1, OR = 0.82. p <.001. Numbers in parentheses indicate column  
percentages. p <.006 
 
According to Table 4, for the event-based analysis, the results from the chi-square 
test revealed a statistically significant association between reporter and patient outcome 
severity, χ2 (1, N = 143,399) = 249.18, p <.001, φC =.04. The Cramer’s V value of .04, 
which was less than a value of .20, signified a relatively weak relationship between 
reporter and severity of patient outcome. The odds ratio for reporter (OR = 0.79) was less 
than one, thereby indicating a negative relationship between reporter and patient outcome 
severity. The odds of consumers reporting serious ADRs versus nonserious ADRs were 
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0.79 times the same odds among physicians. Based on these results, the null hypothesis 
would be rejected in favor of the alternative hypothesis. 
Table 4 also shows the distribution of ADRs (events) by reporter and patient 
outcome severity. A total of 143,399 ADRs were received for the 01 April to 30 April 
2016 period of the quarterly data file data selection time period: 01 April 2016 to 30 June 
2016. Of these, consumers reported 83,009 (57.9%) ADRs and physicians reported 
60,390 (42.1%) ADRs. Of the total ADRs, 20,332 ADRs were serious and 123,067 
ADRs were nonserious. Of the 20,332 serious ADRs, consumers reported 10,740 (52.8%) 
serious ADRs, and physicians reported 9,592 (47.2%) serious ADRs. Therefore, 
consumers reported more ADRs and more serious ADRs in comparison to those reported 
by physicians. 
Table 4 
 
Distribution of Adverse Drug Reactions (ADRs) in the US (01 April 2016 through 30 
June 2016) by Reporter and Patient Outcome Severity 
Patient Outcome 
Severity 
Serious 
 
N=20,332 
 Nonseriou
s 
N= 
123,067 
 Total 
 
N= 143,399 
Consumer 10,740 
(52.8) 
 72,269 
(58.7) 
 83,009 
(57.9) 
Physician 9,592 
(47.2) 
 50,798 
(41.3) 
 60,390 
(42.1) 
Note. χ2 = 249.18*, df = 1, OR = 0.79. p <.001. Numbers in parentheses indicate column  
percentages. p <.006 
 
 Given that the results from the severity of patient outcome analysis were 
statistically significant, I subsequently proceeded to test specific dyads (e.g. fatal versus 
non-fatal, LT versus non-LT, etc.) to further characterize the relationship between 
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reporter and patient outcome. For both the case-based and event-based analyses, seven 
separate standard logistic regression models (thereby totaling 14 standard logistic 
regression models for both types of analyses) were generated and run to determine 
whether reporter was a statistically significant predictor of patient outcome. The results 
from the logistic regression analyses as shown in Tables 5-18. 
 As can be seen in Table 5, for the case-based analysis, the results from the logistic 
regression analysis revealed that reporter was a statistically significant predictor of 
patient outcome of fatal (Wald χ2 = 14.3, p <.001). The odds ratio for the patient outcome 
of fatal (OR =.91) was less than one, thereby indicating a negative relationship between 
reporter and patient outcome of fatal. The odds of consumers reporting fatal ADR cases 
versus non-fatal ADR cases were 0.91 times the same odds among physicians. Based on 
these results, the null hypothesis would be rejected in favor of the alternative hypothesis. 
Table 5 
 
Logistic Regression Predicting Reporting Cases of Patient Outcome of Fatal versus Non-
Fatal 
 B 
 
SEB OR 95% CI 
Reporters (all) -.09 .02 .91 [.87,.96] 
Note. CI = confidence interval for odds ratio (OR). N =87,807, p <.001. 
p <.006 
 
As can be seen in Table 6, for the event-based analysis, the results from the 
logistic regression analysis revealed that reporter was not a statistically significant 
predictor of patient outcome of fatal (Wald χ2 = .10, p = .75). The odds ratio for the 
patient outcome of fatal (OR = 1.00) was equal to one, thereby indicating that as reporter 
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changes from 0 (physician) to 1 (consumer), the odds of consumers reporting fatal ADRs 
versus non-fatal ADRs were no different than the odds among physicians. Based on these 
results, the null hypothesis would be retained. 
Table 6 
 
Logistic Regression Predicting Reporting ADRs Resulting in Patient Outcome of Fatal 
versus Non-fatal 
 B 
 
SEB OR 95% CI 
Reporters (all) -.005 .02 1.00 [.96, 1.03] 
Note. CI = confidence interval for odds ratio (OR). N = 143,399, p =.75. 
p <.006 
 
For testing the relationship between reporting and patient outcome of LT, the 
ADR cases and events were partitioned into two groups: LT or non-LT. ADR cases and 
events that resulted in death were excluded for this particular analysis. Therefore, the 
analysis was limited to only the non-fatal outcomes. 
As can be seen in Table 7, for the case-based analysis, the results from the logistic 
regression analysis revealed that reporter was a statistically significant predictor of 
patient outcome of LT (Wald χ2 = 230.73, p <.001). The odds ratio for the patient 
outcome of LT (OR = .30) was less than one, thereby indicating a negative relationship 
between reporter and patient outcome of LT. The odds of consumers reporting LT ADR 
cases versus non-LT ADR cases were 0.30 times the same odds among physicians. Based 
on these results, the null hypothesis would be rejected in favor of the alternative 
hypothesis. 
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Table 7 
 
Logistic Regression Predicting Reporting Cases of Patient Outcome of Life-Threatening 
versus Non-Life-Threatening 
 B 
 
SEB OR 95% CI 
Reporter (all) -1.20 .08 .30 [.26,.35] 
Note. CI = confidence interval for odds ratio (OR). N = 79,904, p <.001. 
p <.006 
 
As can be seen in Table 8, for the event-based analysis, the results from the 
logistic regression analysis revealed that reporter was a statistically significant predictor 
of patient outcome of LT (Wald χ2 = 963.39, p <.001). The odds ratio for the patient 
outcome of LT (OR = .36) was less than one, thereby indicating a negative relationship 
between reporter and patient outcome LT. The odds of consumers reporting LT ADRs 
versus non-LT ADRs were 0.36 times the same odds among physicians. Based on these 
results, the null hypothesis would be rejected in favor of the alternative hypothesis. 
Table 8 
 
Logistic Regression Predicting Reporting ADRs Resulting in Patient Outcome of Life-
Threatening versus Non-Life-Threatening 
 B 
 
SEB OR 95% CI 
Reporter (all) -1.04 .03 .36 [.33,.38] 
Note. CI = confidence interval for odds ratio (OR). N = 127,221, p <.001. 
p <.006 
 
 
As can be seen in Table 9, for the case-based analysis, the results from the logistic 
regression analysis revealed that reporter was a statistically significant predictor of 
patient outcome of hospitalization (Wald χ2 = 39.5, p <.001). The odds ratio for the 
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patient outcome of hospitalization (OR = .91) was less than one, thereby indicating a 
negative relationship between reporter and patient outcome of hospitalization. The odds 
of consumers reporting hospitalization ADR cases versus non-hospitalization ADR cases 
were 0.91 times the same odds among physicians. Based on these results, the null 
hypothesis would be rejected in favor of the alternative hypothesis. 
Table 9 
 
Logistic Regression Predicting Reporting ADR Cases of Patient Outcome of 
Hospitalization versus Non-Hospitalization 
 B 
 
SEB OR 95% CI 
Reporter (all) -.09 .02 .91 [.88,.94] 
Note. CI = confidence interval for odds ratio (OR). N = 87,807, p <.001. 
p <.006 
 
As can be seen in Table 10, for the event-based analysis, the results from the 
logistic regression analysis revealed that reporter was a statistically significant predictor 
of patient outcome of hospitalization (Wald χ2 = 53.7, p <.001). The odds ratio for the 
patient outcome of hospitalization (OR = .92) was less than one, thereby indicating a 
negative relationship between reporter and patient outcome of hospitalization. The odds 
of consumers reporting ADRs resulting in hospitalization versus those not resulting in 
hospitalization were 0.92 times the same odds among physicians. Based on these results, 
the null hypothesis would be rejected in favor of the alternative hypothesis. 
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Table 10 
 
Logistic Regression Predicting Reporting ADRs Resulting in Patient Outcome of 
Hospitalization versus Non-Hospitalization 
 B 
 
SEB OR 95% CI 
Reporter (all) -.08 .01 .92 [.90,.94] 
Note. CI = confidence interval for odds ratio (OR). N = 143,399, p <.001. 
p <.006 
 
As can be seen in Table 11, for the case-based analysis, the results from the 
logistic regression analysis revealed that reporter was a statistically significant predictor 
of patient outcome of disability (Wald χ2 = 8.8, p = .003). The odds ratio for the patient 
outcome of disability (OR = .83) was less than one, thereby indicating a negative 
relationship between reporter and patient outcome of disability. The odds of consumers 
reporting disability ADR cases versus non-disability ADR cases were 0.83 times the 
same odds among physicians. Based on these results, the null hypothesis would be 
rejected in favor of the alternative hypothesis. 
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Table 11 
 
Logistic Regression Predicting Reporting ADR Cases of Patient Outcome of Disability 
versus Non-Disability 
 B 
 
SEB OR 95% CI 
Reporter (all) -.19 .07 .83 [.73,.94] 
Note. CI = confidence interval for odds ratio (OR). N = 87,807, p <.001. 
p <.006 
 
As can be seen in Table 12, for the event-based analysis, the results from the 
logistic regression analysis revealed that reporter was a statistically significant predictor 
of patient outcome of disability (Wald χ2 = 22.4, p <.001). The odds ratio for the patient 
outcome of disability (OR = .84) was less than one, thereby indicating a negative 
relationship between reporter and patient outcome of disability. The odds of consumers 
reporting ADRs resulting in disability versus those not resulting in disability were 0.84 
times the same odds among physicians. Based on these results, the null hypothesis would 
be rejected in favor of the alternative hypothesis. 
Table 12 
 
Logistic Regression Predicting Reporting ADRs Resulting in Patient Outcome of 
Disability versus Non-Disability 
 B 
 
SEB OR 95% CI 
Reporter (all) -.18 .04 .84 [.78,.90] 
Note. CI = confidence interval for odds ratio (OR). N = 143,399, p <.001. 
p <.006 
 
As can be seen in Table 13, for the case-based analysis, the results from the 
logistic regression analysis revealed that reporter was a statistically significant predictor 
of patient outcome of congenital (Wald χ2 = 31.5, p <.001). The odds ratio for the patient 
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outcome of congenital (OR = .42) was less than one, thereby indicating a negative 
relationship between reporter and patient outcome of congenital. The odds of consumers 
reporting congenital ADR cases versus non-congenital ADR cases were 0.42 times the 
same odds among physicians. Based on these results, the null hypothesis would be 
rejected in favor of the alternative hypothesis. 
Table 13 
 
Logistic Regression Predicting Reporting ADR Cases of Patient Outcome of Congenital 
versus Non-Congenital 
 B 
 
SEB OR 95% CI 
Reporter (all) -.86 .15 .42 [.31,.57] 
Note. CI = confidence interval for odds ratio (OR). N = 87,807, p <.001. 
p <.006 
 
As can be seen in Table 14, for the event-based analysis, the results from the 
logistic regression analysis revealed that reporter was a statistically significant predictor 
of patient outcome of congenital (Wald χ2 = 25.5, p <.001). The odds ratio for the patient 
outcome of congenital (OR = .64) was less than one, thereby indicating a negative 
relationship between reporter and patient outcome of congenital. The odds of consumers 
reporting ADRs resulting in congenital versus those not resulting in congenital were 0.64 
times the same odds among physicians. Based on these results, the null hypothesis would 
be rejected in favor of the alternative hypothesis. 
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Table 14 
 
Logistic Regression Predicting Reporting ADRs Resulting in Patient Outcome of 
Congenital versus Non-Congenital 
 B 
 
SEB OR 95% CI 
Reporter (all) -.45 .09 .64 [.54,.76] 
Note. CI = confidence interval for odds ratio (OR). N = 143,399, p <.001. 
p <.006 
 
 As can be seen in Table 15, for the case-based analysis, the results from the 
logistic regression analysis revealed that reporter was not a statistically significant 
predictor of patient outcome of intervention (Wald χ2 = 6.7, p =.01). The odds ratio for 
the patient outcome of intervention (OR = .14) was less than one, thereby indicating a 
negative relationship between reporter and patient outcome intervention. The odds of 
consumers reporting intervention ADR cases versus non-intervention ADR cases were 
0.14 times the same odds among physicians. Based on these results, the null hypothesis 
would be retained. 
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Table 15 
 
Logistic Regression Predicting Reporting ADR Cases of Patient Outcome of Intervention 
versus Non-Intervention 
 B 
 
SEB OR 95% CI 
Reporter (all) -2.00 .78 .14 [.03,.62] 
Note. CI = confidence interval for odds ratio (OR). N = 87,807, p =.01. 
p <.006 
 
As can be seen in Table 16, for the event-based analysis, the results from the 
logistic regression analysis revealed that reporter (Wald χ2 = 10.03, p = .002) was a 
statistically significant predictor of patient outcome of intervention. The odds ratio for the 
patient outcome of intervention (OR = .14) was less than one, thereby indicating a 
negative relationship between reporter and patient outcome of intervention. The odds of 
consumers reporting ADRs resulting in intervention versus those not resulting in 
intervention were 0.14 times the same odds among physicians. Based on these results, the 
null hypothesis would be rejected in favor of the alternative hypothesis. 
Table 16 
 
Logistic Regression Predicting Reporting ADRs Resulting in Patient Outcome of 
Intervention versus Non-Intervention 
 B 
 
SEB OR 95% CI 
Reporter (all) -2.00 .63 .14 [.04,.47] 
Note. CI = confidence interval for odds ratio (OR). N = 143,399, p =.002. 
p <.006 
 
 
As can be seen in Table 17, for the case-based analysis, the results from the 
logistic regression analysis revealed that reporter was a statistically significant predictor 
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of patient outcome of OME (Wald χ2 = 150.7, p <.001). The odds ratio for the patient 
outcome of OME (OR = 1.19) was greater than one, thereby indicating a positive 
relationship between reporter and patient outcome of OME. The odds of consumers 
reporting OME ADR cases versus non-OME ADR cases were 1.19 times higher than the 
odds among physicians. Based on these results, the null hypothesis would be rejected in 
favor of the alternative hypothesis. 
Table 17 
 
Logistic Regression Predicting Reporting ADR Cases of Patient Outcome of OME versus 
Non-OME 
 B 
 
SEB OR 95% CI 
Reporter (all) .17 .01 1.19 [1.16, 1.22] 
Note. CI = confidence interval for odds ratio (OR). N = 87,807, p <.001. 
p <.006 
 
 
As can be seen in Table 18, for the event-based analysis, the results from the 
logistic regression analysis revealed that reporter was a statistically significant predictor 
of patient outcome of OME (Wald χ2 = 394.95, p <.001). The odds ratio for the patient 
outcome of OME (OR = 1.24) was greater than one, thereby indicating a positive 
relationship between reporter and patient outcome of OME. The odds of consumers 
reporting ADRs resulting in OME versus those not resulting in OME were 1.24 times 
higher than the odds among physicians. Based on these results, the null hypothesis would 
be rejected in favor of the alternative hypothesis. 
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Table 18 
 
Logistic Regression Predicting Reporting ADRs Resulting in Patient Outcome of OME 
versus Non-OME 
 B 
 
SEB OR 95% CI 
Reporter (all) .21 .01 1.24 [1.21, 1.26] 
Note. CI = confidence interval for odds ratio (OR). N = 143,399, p <.001. 
p <.006 
 
Research Question 2 
The second research question examined whether a statistically significant 
difference exists in the distribution of ADRs between reporters and SOC. The event-
based analysis was performed, and the chi-square test was conducted; the results are 
shown in Table 19. As can be seen in Table 19, the results from the chi-square test 
revealed a statistically significant association between reporter and SOC (25, N = 36, 
665) = 3,157.04, p <.001)). Based on these results, the null hypothesis would be rejected 
in favor of the alternative hypothesis. 
To further characterize the relationship between reporter and SOC, 26 separate 
logistic regression analyses were performed to determine whether a statistically 
significant relationship exists between the reporter and each individual SOC. The results 
from the event-based analyses can be seen in Table 19. According to the results in Table 
19, there was a statistically significant difference between the reporter and the ADRs 
(events) grouped by the SOCs of their associated reactions. Hence, reporter was a 
predictor for a majority of the SOCs that were analyzed. Moreover, there are ADRs 
grouped by SOCs that were more frequently reported by consumers in comparison to 
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those reported by physicians. The odds of consumers reporting ADRs were higher than 
the odds of physicians for the following six SOCs: Gastrointestinal disorders (OR = 2.85, 
p <.001); General disorders and administration site conditions (OR = 1.99, p <.001); 
Injury, poisoning and procedural complications (OR = 1.36, p =.001); Psychiatric 
disorders (OR = 1.26, p = .001); Reproductive system and breast disorders (OR = 3.30, p 
<.001); and, Vascular disorders (OR = 1.44, p <.001). 
However, the odds of consumers reporting ADRs were lower than the odds of 
physicians for the following 14 SOCs: Blood and lymphatic system disorders (OR = .23, 
p <.001); Cardiac disorders (OR = .74, p <.001); Endocrine disorders (OR = .30, p 
<.001); Hepatobiliary disorders (OR =.30, p <.001); Immune system disorders (OR =.61, 
p <.001); Infections and infestations (OR = .85, p <.001); Investigations (OR = .83, p = 
0.005); Metabolism and nutrition disorders (OR = .52, p <.001); Musculoskeletal and 
connective tissue disorders (OR = .50, p <.001); Neoplasms benign, malignant and 
unspecified (OR = .61, p <.001); Nervous system disorders (OR = .78, p <.001); Renal 
and urinary disorders (OR = .62, p <.001); Respiratory, thoracic and mediastinal 
disorders (OR = .61, p <.001); and, Skin and subcutaneous tissue disorders (OR = .30, p 
<.001). 
An evaluation was not made for the SOC Social circumstances due to the fact that 
a single event was reported by the consumers and zero events were reported by the 
physicians. Out of the 25 evaluable SOCs, a statistically significant difference between 
reporter and SOC was not found for the following five SOCs: Congenital, familial and 
genetic disorders (p = .11); Ear and labyrinth disorders (p = .79); Eye disorders (p = .37); 
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Pregnancy, puerperium and perinatal conditions (p = .81); and, Surgical and medical 
procedures (p = .07). 
Table 19 also shows the distribution of ADRs (events) by reporter and SOC. A 
total of 36,665 ADRs were received for the quarterly data file data selection time period: 
01 April 2016 to 30 June 2016. 
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Table 19 
 
Analysis of Adverse Drug Reactions in the United States (01 April to 30 April 2016) by 
System Organ Class (SOC) and Reporter 
SOC Consumers 
 
Physicians *p OR 95% CI 
Blood and lymphatic system disorders 300 (25.2) 891 (74.8) <.001 .23 [.21, .27] 
 
Cardiac 
disorders 
 
1,149 (50.7) 
 
1,118 (49.3)  
 
<.001 
 
.74 
 
[.68, .80] 
 
Congenital, familial and genetic 
disorders 
 
5 (35.7) 
 
9 (64.3) 
 
.11 
 
.40 
 
[.14, 1.20] 
 
Ear and labyrinth disorders 
 
68 (56.7) 
 
52 (43.3) 
 
.79 
 
.95 
 
[.66, 1.37] 
 
Endocrine disorders 
 
24 (28.9) 
 
59 (71.1) 
 
<.001 
. 
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[.18, .48] 
 
Eye disorders  
 
367 (56.1) 
 
 
287 (43.9) 
 
.37 
 
.93 
 
[.79, 1.09] 
 
Gastrointestinal disorders 3,797 (77.6) 1,099 (22.4) <.001 2.85 [2.65, 3.06] 
 
General disorders and administration 
site conditions 
 
5,743 (70.3) 
 
2,430 (29.1) 
 
<.001 
 
1.99 
 
[1.89, 2.10] 
 
Hepatobiliary disorders 
 
213 (29.8) 
 
502 (70.2) 
 
<.001 
 
.30 
 
[.25, .35] 
 
Immune system disorders 
 
203 (45.9) 
 
239 (54.1) 
 
<.001 
 
.61 
 
[.51, .74] 
 
Infections and infestations 
 
1,624 (54.4) 
 
1,364 (45.6) 
 
<.001 
 
.85 
 
[.79, .93] 
 
Injury, poisoning and procedural 
complications 
 
327 (65.0) 
 
176 (35.0) 
 
.001 
 
1.36 
 
[1.13, 1.64] 
 
Investigations 
 
468 (53.2) 
 
411 (46.8) 
 
.005 
 
.83 
 
[.73, .94] 
 
Metabolism and nutrition disorders 
 
358 (42.2) 
 
490 (57.8) 
 
<.001 
 
.52 
 
[.46, .60] 
 
Musculoskeletal and connective tissue 
disorders 
 
441 (41.0) 
 
635 (59.0) 
 
<.001 
 
.50 
 
[.44, .56] 
 
Neoplasms benign, malignant and 
unspecified (incl. cysts and polyps) 
 
832 (46.2) 
 
967 (53.8) 
 
<.001 
 
.61 
 
[.56, .67] 
 
Nervous system disorders 
 
1,715 (52.2) 
 
1,568 (47.8) 
 
<.001 
 
.78 
 
[.73, .84] 
 
Pregnancy, puerperium and perinatal 
conditions 
 
15 (55.6) 
 
12 (44.4) 
 
.81 
 
.91 
 
[.43, 1.96] 
 
Psychiatric disorders 
 
580 (63.2) 
 
337 (36.8) 
 
.001 
 
1.26 
 
[1.10, 1.45] 
 
Renal and urinary disorders 
 
475 (46.4) 
 
549 (53.6) 
 
<.001 
 
.62 
 
[.55, .70] 
 
Reproductive system and breast 
disorders 
 
327 (81.1) 
 
73 (18.3) 
 
<.001 
 
3.30 
 
[2.56, 4.26] 
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Respiratory, thoracic and mediastinal 
disorders 
846 (46.2) 986 (53.8) <.001 .61 [.56, .67] 
 
Skin and subcutaneous tissue disorders 
 
282 (29.7) 
 
667 (70.3) 
 
<.001 
 
.30 
 
[.26, .34] 
Social circumstances 
 
1 (100) 
 
0 (0) 
 
1.00 
 
NE 
 
NE 
Surgical and medical procedures 
 
17 (77.3) 
 
5 (22.7) 
 
.07 
 
2.48 
 
[.91, 6.72] 
 
Vascular disorders 
 
1,032 (66.1) 
 
530 (33.9) 
 
<.001 
 
1.44 
 
[1.29, 1.60] 
Note. χ2 = *3,157.04, df = 25, *p <.006. Numbers in parentheses indicate column percentages. CI = confidence interval 
for odds ratio (OR). NE= Not Evaluable. 
 
Research Question 3 
The third research questions examined whether a statistically significant 
difference exists in the distribution of ADRs by reporter (consumer versus physician) and 
reporter demographics (gender). The case-based and event-based analyses were 
performed and the chi-square test was conducted for both types of analyses; the results 
are shown in Tables 20 and 21. As can be seen in Table 20, for the case-based analysis, 
the results from the chi-square test revealed a statistically significant association between 
the reporter and the reporter gender (male versus female) (χ2 = 118.48, p <.001, N = 
77,025). The odds ratio for the reporter gender (OR = 1.18) was greater than one, thereby 
indicating a positive relationship between reporter and reporter gender. The odds of 
consumers reporting ADR cases were 1.18 times higher for females versus males than the 
odds of physicians. Moreover, the odds of physicians reporting ADR cases were 1.18 
times higher for males versus females than the odds of consumers. Based on these results, 
the null hypothesis would be rejected in favor of the alternative hypothesis. 
Table 20 also illustrates the distribution of ADR reports (cases) by reporter and 
reporter gender. A total of 77,025 ADR reports were received from the quarterly data file 
data selection time period: 01 April 2016 to 30 June 2016. Of these, 32,534 reports were 
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reported by male reporters and 44,491 reports were reported by female reporters. Of the 
32,534 reports from male reporters, male consumers reported 18,529 (57%) ADR reports 
and male physicians reported 14,005 (43%) ADR reports. Of the 44,491 reports from 
female reporters, female consumers reported 27,075 (60.9%) ADR reports and female 
physicians reported 17,416 (39.1%) ADR reports. Regardless of gender, consumers 
reported more ADR reports in comparison to those reported by physicians (59.2% vs 
40.8%, respectively). 
Table 20 
 
Distribution of Adverse Drug Reactions (ADRs) Reports in the US (01 April 2016 
through 30 June 2016) by Reporter and Gender 
Reporter Male 
N= 32,534 
Female 
N= 44,491 
Total 
N= 77,025 
Consumer 18,529 (57.0) 27,075 (60.9) 45,604 (59.2) 
Physician 14,005 (43.0) 17,416 (39.1) 31,421 (40.8) 
Note. χ2  = *118.48, df = 1, OR = 1.18. p <.001. Numbers in parentheses indicate column percentages. 
p <.006 
 
As can be seen in Table 21, for the event-based analysis, the results from the chi-
square test revealed a statistically significant association between reporter and the 
reporter gender (χ2 = 258.47, p <.001, N = 128,100). The odds ratio for the reporter 
gender (OR = 1.20) was greater than one, thereby indicating a positive relationship 
between reporter and reporter gender. The odds of consumers reporting ADRs were 1.20 
times higher for females versus males than the odds of physicians. Moreover, the odds of 
physicians reporting ADRs were 1.20 times higher for males versus females than the 
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odds of consumers. Based on these results, the null hypothesis would be rejected in favor 
of the alternative hypothesis. 
Table 21 also illustrates the distribution of ADRs (events) by reporter and reporter 
gender. A total of 128,100 ADRs (events) were received from the quarterly data file data 
selection time period: 01 April 2016 to 30 June 2016. Of these, 56,841 ADR were 
reported by male reporters and 71,259 ADRs were reported by female reporters. Of the 
56,841 ADRs reported by male reporters, male consumers reported 31,212 (54.9%) 
ADRs and male physicians reported 25,629 (45.1%) ADRs. Of the 72,259 ADRs 
reported by female reporters, female consumers reported 42,315 (59.4%) ADRs and 
female physicians reported 28,944 (40.6%) ADRs. Regardless of gender, consumers 
reported more ADR reports in comparison to those reported by physicians (57.4% vs 
42.6%, respectively). 
Table 21 
 
Distribution of Adverse Drug Reactions (ADRs) in the US (01 April 2016 through 30 
June 2016) by Reporter and Gender 
Reporter  Male 
N=56,841 
Female 
N= 71,259 
Total 
N= 128,100 
Consumer 31,212 (54.9) 42,315 (59.4) 73,527 (57.4) 
Physician 25,629 (45.1) 28,944 (40.6) 54,573 (42.6) 
Note. χ2  = *258.47, df = 1, OR = 1.20. p <.001. Numbers in parentheses indicate column percentages. 
p <.006 
 
Summary 
For the quarterly data file data selection time period: 01 April 2016 to 30 June 
2016, a total of 87,807 ADR reports with 143,399 ADR events were examined in this 
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study. For the case and event-based analyses, the findings from the study revealed that 
consumers reported more ADR reports and more ADRs in comparison to those reported 
by physicians. Moreover, consumers reported more serious ADR reports and more 
serious ADRs in comparison to those reported by physicians. For the first research 
question, the results from both the case- and event-based analyses revealed statistically 
significant differences between consumers and physicians with regards to the distribution 
of ADR cases and events by patient outcome, as well as by the severity of patient 
outcome in the US. For the second research question, the results from the event-based 
analysis showed a statistically significant difference between consumers and physicians 
with regards to the distribution of ADR events by SOC. For the third research question, 
the results from both the case- and event-based analyses revealed a statistically 
significant difference between consumers and physicians with regards to the distribution 
of ADR cases and events by reporter gender. Female consumers and male physicians 
were more likely to report ADR cases and events in comparison to their respective 
opposite gender counterparts. For the case-based analysis, the findings from the study 
revealed that female consumers reported more ADR cases than female physicians. Next, 
in Chapter 5, I provide a discussion of these results, study limitations, recommendations 
for future research, and the implications for social change. 
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Chapter 5: Discussion, Conclusions, and Recommendations 
Introduction 
To date, no studies have been conducted within the US in which the FDA FAERS 
database was employed to compare reporting of ADRs by reporter (consumers and 
physicians) and patient outcome, as well as by SOC and reporter demographics at case 
and/or event levels (Sakaeda et al., 2013). In this quantitative study, in an effort to fill the 
gap in the literature, I examined the statistical difference in the distribution of case and 
event level ADRs within the FAERS database by reporter (consumers and physicians) 
and patient outcome, while also evaluating reporter differences in SOC and 
demographics. The factors explored and compared included the differences in under-
reporting of consumers compared to physicians, thereby elucidating whether consumer 
reporting played a pivotal role in AE reporting. 
In this study, I analyzed secondary data, specifically, ADRs that were submitted 
by consumers and physicians to the FDA from the FAERS database, which contained 
quarterly data files that were extracted for analysis (FDA, 2016b). The data containing 
the spontaneous ADR reports from the FAERS database were accessed and downloaded 
from the quarterly data file data selection time period containing one quarter of data: 01 
April 2016 through 30 June 2016. Once the ADR data were collected, spontaneous 
reports from consumers and physicians were assessed for ADRs. The reporter was the 
independent variable and consisted of two levels: consumer and physician. Patient 
outcome, SOC, and reporter demographics were the dependent variables. The unit of 
analysis was the total number of ADR cases and reported ADRs. Because this study was 
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quantitative in nature, secondary data analysis was performed by utilizing the chi-square 
test, the OR, and logistic regression.  
For both the case- and event-based analyses, the findings from the study revealed 
that consumers reported significantly more ADR reports (59.7% versus 40.3%, 
respectively) and more serious ADR reports (55.5% versus 44.5%, respectively) in 
comparison to those reported by physicians. Moreover, consumers reported significantly 
more ADRs (57.9% versus 42.1%, respectively) and more serious ADRs (52.8% versus 
47.2%, respectively) in comparison to those reported by physicians. 
Furthermore, the results from the event-based analysis showed that a statistically 
significant difference exists between consumers and physicians with regards to the 
distribution of ADR events by SOC. Additionally, the results from both the case- and 
event-based analyses revealed a statistically significant difference between consumers 
and physicians with regards to the distribution of ADR cases and events by reporter 
gender. Based on these findings, I provide in this chapter a discussion, recommendation 
for action and further research, and implications for positive social change. 
Interpretation of Findings 
In an effort to assess ADRs and ADR reports from physicians and consumers, as 
well as to compare the findings among those from other studies, researchers from 
European countries and the US have conducted studies using their respective databases 
for collecting ADRs. The findings from such studies suggest the significance of including 
ADR reports from consumers. Alatawi and Hansen (2017) also evaluated the FAERS 
database. However, the aforementioned study involved the comparison of reporting rates 
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in the FAERS database to expected rates of known ADEs by examining three groups of 
drugs (statins, biologics, and narrow therapeutic index drugs) in order to determine the 
difference in sensitivity to reporting. The results from the authors’ research revealed that 
most drug-ADE pairs were statistically significantly under-reported by both consumers 
and physicians. 
In my study, I did not aim at determining the statistical significance of under-
reporting of drug-ADE pairs by consumers and physicians. Rather, I focused on the 
comparison of the two reporter types, thereby showing that consumers reported more 
ADRs and ADR reports in comparison to those reported by physicians, similar to the 
findings from the European studies conducted by Aagaard et al. (2009) and de Langen, et 
al. (2008). Currently, no studies have been conducted within the US in which the FDA 
FAERS database was employed to compare under-reporting of ADRs by reporter 
(consumers and physicians) and patient outcome, as well as by SOC and reporter 
demographics at case and/or event level (Sakaeda et al., 2013).  
The studies performed by Aagaard et al. (2009) and de Langen et al. (2008) used 
a similar type of data collection and/or data analysis methods in relation to my study. 
Aagaard et al. (2009) utilized the Danish ADR database to compare ADR reports 
between consumers and other sources, including physicians, pharmacists, lawyers, 
pharmaceutical companies and other HCPs. The same authors analyzed the data from 
these reports in terms of the reporter category, severity of the ADRs, the category of 
ADRs by SOC, and the suspected medicines on level 1 of the ATC classification system. 
Based on the results from the study of Aagaard et al. (2009), statistically significant 
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differences existed between reporter types and distribution of ADRs. Consumers 
reporting of serious ADRs was analogous to that of physicians (approximately 45%), 
although lower than that of pharmacists and other HCPs. 
Similar to the study by Aagaard et al. (2009), my study involved the analysis of 
data from the ADR reports collected by FAERS database with respect to the following: 
the distribution of ADR cases and events by patient outcome and reporter (consumer 
versus physician); the distribution of ADR cases and events by the severity of patient 
outcome (serious versus nonserious) and reporter; the distribution of ADR events by SOC 
and reporter; and, the distribution of ADR cases and events by reporter and reporter 
gender (male versus female). However, unlike the study by Aagaard et al. (2009), my 
study did not analyze data with regards to ATC. 
In my study, the results from both the case- and event-based analyses revealed 
statistically significant differences between consumers and physicians with regards to the 
distribution of ADR cases and events by patient outcome as well as by the severity of 
patient outcome in the US. The results of ADR reporting by consumers and physicians 
from my study differed from those reported by Aagaard et al. (2009) due to the 
characteristics of the sample and methodology. The study by Aagaard et al. (2009) was 
conducted in Denmark with a significantly smaller sample size in comparison to that of 
my study. Moreover, the same authors did not investigate patient outcome or sample 
demographics. 
With regards to reporting ADRs and serious ADRs, for the case-based analysis, 
the findings from my study have revealed that consumers reported more ADR cases than 
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physicians. The results have shown that consumers reported nearly 60% of ADR cases, 
while physicians reported about 40% of ADR cases. Furthermore, consumers reported 
nearly 56% of serious ADR cases, while physicians reported nearly 45% of serious ADR 
cases. Therefore, consumers reported more ADR reports and more serious ADR reports 
in comparison to those reported by physicians. 
With regards to SOC, the results from the study by Aagaard et al. (2009) revealed 
a statistically significant difference between reporter types in terms of the distribution of 
ADRs by SOC. The same authors claimed that, in comparison to other sources, 
consumers were more likely to report ADRs from the following SOCs: Nervous system 
disorders (OR = 1.27); Psychiatric disorders (OR = 1.70); and, Reproductive system and 
breast disorders (OR = 1.27). In my study, the findings from the event-based analysis also 
showed a statistically significant difference between consumers and physicians with 
regards to the distribution of ADR events by SOC. Similar to the results from the 
Aagaard et al. (2009) study, the findings from my study have revealed that the odds of 
consumers reporting ADRs were higher than those of physicians for the SOCs Psychiatric 
disorders (OR = 1.26, p = .001) and Reproductive system and breast disorders (OR = 
3.30, p <.001). Unlike the results from Aagaard et al. (2009), the results from my study 
have also shown that the odds of consumers reporting ADRs were higher than those of 
physicians for the following SOCs: Gastrointestinal disorders (OR = 2.85, p <.001); 
General disorders and administration site conditions (OR = 1.99, p <.001); Injury, 
poisoning and procedural complications (OR = 1.36, p =.001); and, Vascular disorders 
(OR = 1.44, p <.001). 
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According to Aagaard et al. (2009), compared with other sources, consumers were 
less likely to report ADRs from the SOCs Blood and lymphatic system disorders (OR = 
.22) and Hepatobiliary system disorders (OR = .14). Similar to the findings from my 
study, the odds of consumers reporting ADRs were lower than those of physicians for the 
SOCs Blood and lymphatic system disorders (OR = .23, p <.001) and Hepatobiliary 
disorders (OR = .30, p <.001). Additionally, unlike the findings from Aagaard et al. 
(2009), the results from my study have also shown that the odds of consumers reporting 
ADRs were lower than those of physicians for the following SOCs: Cardiac disorders 
(OR = .74, p <.001); Endocrine disorders (OR = .30, p <.001); Immune system disorders 
(OR = .61, p <.001); Infections and infestations (OR = .85, p <.001); Investigations (OR 
=.83, p = 0.005); Metabolism and nutrition disorders (OR = .52, p <.001); 
Musculoskeletal and connective tissue disorders (OR = .50, p <.001); Neoplasms benign, 
malignant and unspecified (OR = .61, p <.001); Nervous system disorders (OR = .78, p 
<.001); Renal and urinary disorders (OR = .62, p <.001); Respiratory, thoracic and 
mediastinal disorders (OR = .61, p <.001); and, Skin and subcutaneous tissue disorders 
(OR = .30, p <.001). 
The study conducted by Aagaard et al. (2009) revealed statistically significant 
findings suggesting that, in comparison to other literature reviewed, consumers reported 
different categories of ADRs for different types of SOC and ATC groups. Similarly, the 
findings from my study have revealed that consumers had also reported different 
categories of ADRs for different types of SOCs in comparison to physicians (although 
my study did not focus on ATC). Therefore, when comparing and contrasting the results 
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from Aagaard et al. (2009) and those from my study, it can be concluded that consumers 
should be active participants within systematic drug surveillance systems, including 
clinical settings, and their reports should be treated with as much importance as those 
from other sources. 
The study conducted by de Langen et al. (2008) involved the comparison of ADR 
reports between patients and HCPs collected from the Netherlands database. The authors 
analyzed the data from these reports with regards to the age and gender of the reporters, 
the attributes of the most frequently reported drugs and the attributes of the most 
frequently reported ADRs, their seriousness, and their outcome. Although this study is 
very similar to mine, I focused on the US and the FDA FAERS database as well as on 
consumers and physicians. de Langen et al. (2008) discovered statistically significant 
differences between patient reports and reports from HCPs with regards to the 
seriousness and outcome of reported ADRs in the Netherlands. In comparison to HCPs, 
patients reported a significantly higher number of LT ADRs (5.2% vs 2.7%) and 
disability (2.3% vs 0.4%). Conversely, the findings from my study have shown that, for 
the case-based analysis, the odds of consumers reporting ADR cases were lower than 
those of physicians corresponding to the following patient outcomes: death (OR = .91, p 
<.001); LT (OR = .30, p <.001); hospitalization (OR = .91, p <.001); disability (OR = .82, 
p = .003); and, congenital (OR = .42, p <.001). However, unlike the results from de 
Langen et al. (2008), the results from my study have demonstrated that the odds of 
consumers reporting ADR cases corresponding to OME were higher than those of 
physicians (OR = 1.19, p <.001). 
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The findings from de Langen et al. (2008) have shown that patients reported 
significantly fewer ADRs leading to death (0.6% vs 1.5%) and hospitalization or 
prolongation of hospitalization (9.8% vs 12.0%). Similarly, the findings from my study 
have shown that, for the event-based analysis, the odds of consumers reporting LT ADRs 
(OR = .36, p <.001) and those resulting in hospitalization (OR = .92, p <.001) were lower 
than those of physicians. Additionally, unlike the findings from de Langen et al. (2008), 
the results from my study have demonstrated that, in comparison to physicians, 
consumers were less likely to report the following patient outcomes: disability (OR = .84, 
p <.001); congenital (OR = .64, p <.001); and, intervention (OR = .14, p =.002). 
However, unlike the results from de Langen et al. (2008), the results from my study have 
demonstrated that the odds of consumers reporting ADRs resulting in OME were higher 
than the odds of physicians (OR = 1.24, p <.001). 
The findings from the same authors revealed that no statistically significant 
differences were determined between patient reports and reports from HCPs with regards 
to patient characteristics (age and gender). Conversely, the findings from my study from 
both the case- and event-based analyses have shown a statistically significant difference 
between consumers and physicians with regards to the distribution of ADR cases and 
events by reporter gender. Female consumers and male physicians were more likely to 
report ADR cases and events in comparison to their respective opposite gender 
counterparts. Prior research has divulged findings suggesting that females are 1.5 to 1.7 
times more susceptible to ADRs in comparison to males (Rademaker, 2001; Luca, 
Ramesh, & Ram, 2017). Researchers have discovered that possible risk factors attributed 
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to pharmacokinetics, pharmacodynamic, pharmacogenetics, and immunological and 
hormonal factors are responsible for females’ predisposition to ADRs. Furthermore, 
researchers have determined an additional risk factor linked to the difference in 
prescribed drug consumption between females and males Rademaker, 2001; Luca et al., 
2017). Therefore, female consumers may be more inclined to report ADRs in comparison 
to their male counterparts.  
Results from previous literature have shown that the rate of burnout for female 
physicians is twice as high as that of male physicians within the US (Medscape, 2017). 
Moreover, the suicide rate among US female physicians is 2.5 to 4 times as high in 
comparison to that of the general US population (Schernhammer & Colditz, 2004). 
Additionally, high ranking leadership positions within hospital and academic settings in 
the US are occupied by male physicians given that only 15% of medical school dean-
level (decanal) positions are held by female physicians (Schor, 2018). Findings from 
prior research have also demonstrated a salary gap between male and female physicians 
in the US, thereby suggesting that female physicians earn less than their male 
counterparts (Jagsi et al., 2012; Jenna, Olenski, & Blumenthal, 2016). Researchers have 
discovered that, even after controlling for such factors as faculty ranking, years in 
practice, and graduation from a top medical university, female physicians earned nearly 
$20,000 less in comparison to male physicians (Jenna et al., 2016). Therefore, female 
physicians may be less inclined to report ADRs compared to male physicians. 
For the case-based analysis, the findings from my study revealed that female 
consumers reported more ADR cases than female physicians (61% versus 39%, 
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respectively). The odds of consumers reporting ADR cases were higher for females 
versus males than the odds of physicians (OR = 1.18, p <.001). For the event-based 
analysis, the findings from my study showed that female consumers reported more ADRs 
than female physicians (60% versus 40%, respectively). The odds of consumers reporting 
ADRs were higher for females versus males than the odds of physicians (OR = 1.20, p 
<.001). Therefore, irrespective of gender, from both the case- and event-based analyses, 
consumers reported more ADR reports and more ADRs in comparison to those reported 
by physicians. 
de Langen et al. (2008) also stated that no statistically significant differences were 
determined between patient reports and reports from HCPs with regards to the most 
frequently reported ADRs from the following five most involved SOCs: Nervous system 
disorders, Psychiatric disorders, Gastrointestinal disorders, Musculoskeletal disorders, 
and General disorders/administration site conditions. Conversely, the results from my 
study have revealed statistically significant differences between consumer reports and 
reports from physicians with regards to the ADRs that were reported for the 
aforementioned SOC categories. 
The study conducted by de Langen et al. (2008) revealed statistically significant 
findings suggesting that patients reported ADRs differently from HCPs with respect to 
the seriousness and outcome of reported ADRs. Similarly, the findings from my study 
have revealed that consumers have reported ADRs in a different manner than that 
reported by physicians with regards to the patient outcome and the severity of patient 
outcome. Therefore, when comparing and contrasting the results from de Langen et al. 
111 
 
(2008) and those from my study, it can be concluded that consumer reporting should not 
substitute physician reporting (as physicians are a reliable source for ADR reporting). 
Hence, consumer reporting may nonetheless serve as a crucial component in healthcare, 
thereby placing patient safety and greater access to efficacious drugs at the forefront of 
pharmacovigilance. 
The theoretical foundation that was employed this study is known as SARF, 
which stems from the perception of risk framework. The theory maintains that risk 
interconnects with the psychological, social, institutional, and cultural viewpoints of 
individuals in a way that may increase of decrease individuals’ responses to the risk or 
risk event (Kasperson & Ratick, 1988). These variations in the perception of risk evoke 
behavioral responses from individuals that change the social and economic aspects of 
society, thereby magnifying or diminishing the actual physical risk (Kasperson & Ratick, 
1988). 
Similar to the theoretical framework used in this study, Bongard et al. (2002) and 
Durrie et al. (2009) conducted studies in which the SARF theoretical framework was 
used. The findings from both studies have shown the difference in risk perception 
between consumers and physicians. In the study conducted by Bongard et al. (2002), 
study participants consisting of 400 HCPs and 153 non-HCPs were requested to assess 
their risk perception of ADRs related to 13 different drug classes. Based on the findings 
from the study, anticoagulants and NSAIDs were ranked by HCPs as the first and second 
most dangerous drugs, respectively. Contrarily, aspirin, anticoagulants, and NSAIDs 
were ranked by consumers as the least dangerous drugs, with aspirin ranking as the least 
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harmful. Moreover, sleeping pills, tranquillizers, and antidepressant drugs were ranked by 
consumers as the most dangerous, with psychotropic drugs ranking as the most harmful. 
The consumer’s perception of the safety of aspirin may in part be linked to the 
insufficient information regarding the risk of aspirin and the abundance of information 
given to the consumer via advertisements, Internet, and commercials (Durrie et al., 2009). 
Hence, the authors concluded that the consumer was unaware of such ADRs and, 
therefore, underestimated the risk related to NSAIDs (Bongard et al., 2002). 
Bongard et al. (2002) claimed that the mass media’s portrayal of psychotropic 
drugs and its association with frequent suicide attempts may have greatly affected the 
public’s high-risk perception of these drugs. Given the difference in the drug class 
perception between the consumers and HCPs, the authors concluded that consumers and 
HCPs have differing risk perceptions of ADRs. Hence, the results from the study 
conducted by Bongard et al. (2002) bolster the claim that risk perception of ADRs varies 
between consumers and HCPs, which is crucial for my study and which may explain why 
physicians reported ADRs less frequently than consumers. 
In the study performed by Durrie et al. (2009), study participants comprised of 92 
medical students were asked to evaluate their risk perception of ADRs related to 13 
different drug classes before and after taking pharmacology courses. Based on the 
findings from the study, before taking pharmacology courses, hypnotics were ranked by 
medical students as the most dangerous drug, followed by antidepressants and 
anticoagulants, while contraceptive pills were ranked as the least dangerous. After taking 
pharmacology courses, antidepressants were ranked by medical students as the most 
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dangerous drugs, followed by anticoagulants and hypnotics. Furthermore, Durrie et al. 
(2009) discovered a statistically significant increase in perceived risk for other classes of 
drugs. The highest increases were observed for contraceptive pills, NSAIDs, and aspirin, 
while the lowest increases were observed for hypocholesterolaemic and antidepressant 
drugs. The authors concluded that after completion of the pharmacology courses, medical 
students became more aware of potentially serious ADRs that are associated with drugs 
deemed relatively safe by non-HCPs, such as NSAIDs and aspirin. Therefore, the 
findings from the study conducted by Durrie et al. (2009) revealed that the perceived risk 
of ADRs by medical students was different after taking pharmacology courses. The lack 
of adequate training and education for physicians can greatly influence their risk 
perception with regards to different drug classes and the various levels of risk associated 
with each drug class. Hence, the findings from the study conducted by Durrie et al. 
(2009) are critical to this study and may explain the need for efficacious training and 
preparation, as well as adequate information for physicians on ADRs, which may explain 
the under-reporting of ADRs, including both serious and nonserious, by physicians in 
comparison to consumers. 
The SARF theory may elucidate the difference in risk perception between 
consumers and physicians. Consumers may perceive any ADR, whether nonserious or 
serious, as a risk based on media, marketing, advertisement, promotional materials, 
Internet, and even anecdotal evidence (Durrie et al. (2009). For instance, traditional 
media (television, newspaper, magazine, radio) coverage affects the propagation of drug 
safety information, thereby influencing warnings, alerts, and label changes to the drugs 
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that are issued by the FDA (Yong et al., 2009). According to findings from prior 
research, 100% of newspaper articles referenced a salubrious effect of a recently 
approved medicine, while only 32% mentioned at least one deleterious adverse effect 
from this drug (Cassels et al., 2003). Moreover, the Internet can serve a crucial role in 
contributing to behavioral changes to drug safety information, thereby influencing the 
risk perception of consumers since the message delivered by regulatory authorities, such 
as the FDA, is not akin to the one conveyed by the media (Cassels et al., 2003; Yong et 
al., 2009). 
Additionally, direct-to-consumer (DTC) advertising, which is as an effort 
undertaken by pharmaceutical companies to promote their prescription products directly 
to patients (currently only allowed in the US and New Zealand), plays a pivotal role in 
impacting the risk perception of consumers. Results from previous research have 
suggested that an increase in consumer reporting of ADRs to the FDA was evident thanks 
to the 2007 enactment of the print advertising requirement (Du et al., 2012), which 
mandated DTC advertisements to contain, in clear and conspicuous text, the following 
statement: “You are encouraged to report negative side effects of prescription drugs to 
the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.” (Kessler & Vladeck, 
2007). 
While investments have been made in digital promotion via Web sites, online 
display advertising, search engine marketing, social media campaigns, and mobile 
advertising, nearly two-thirds of promotional expenditure has been distributed to 
traditional media (television, newspaper, magazine, radio), including DTC advertising 
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(Gilchrist, 2016). Findings from the study conducted by Du et al. (2012), which 
investigated the relationship between DTC advertising expenditure and ADR 
reporting, have shown a positive relationship between the two variables (Du et al., 2012). 
According to the same authors, after the ratification of the Title IX of the Food and Drug 
Administration Amendments Act (FDAAA) in 2008, spending on DTC print ads resulted 
in more reports per drug on a monthly basis, of which nearly 65% might have resulted 
from the MedWatch enactment of the print advertisement requirement that mandates 
manufacturers to include toll-free reporting numbers in print DTC advertisements (Du et 
al., 2012). Furthermore, the same authors claimed that, based on their findings, a positive, 
statistically significant association existed between the number of patients and ADR 
reporting. According to the same authors, the influx of DTC ads contributed to an 
increase in ADR reporting by patients, which increased nearly 40% (from 1.28 monthly 
reports per drug to 1.74 monthly reports per drug) (Du et al., 2012). 
The difference in consumer reporting of ADRs to the FDA prior and subsequent 
to the 2007 print advertisement requirement was apparent. In 2004, nearly 18% of 
consumers submitted ADR reports to the FDA. One decade later, ADR reports were 
submitted to the FDA by approximately 42% of consumers (Aikin, et al., 2016). Hence, 
due to the collaborative efforts between the media and the FDA, the contribution of 
consumer reporting has been steadily increasing, as more consumers have been reporting 
ADRs. Therefore, the influence of media may explain the large amount of serious and 
nonserious ADR cases and events reported by the consumers in comparison to those 
reported by physicians, which was evident in this study. 
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 Moreover, consumers may also perceive an ADR as a risk based on the 
communication gap (either lack of or poor communication) between them and their 
physicians. The results from the study conducted by Golomb et al. (2007) have suggested 
that 87% of patients initiated communication with their physicians regarding a potential 
association between an AE and a drug that they were consuming. However, the 
physicians were less likely to corroborate the possible relationship and, therefore, were 
more reticent to report ADRs (Golomb et al., 2007). Even if physicians and their patients 
engaged in conversations regarding drug safety risks, which was evident in the study 
conducted by Enger et al. (2013), poor or insufficient communication still existed, 
thereby potentially contributing to a change in risk perception among consumers. The 
findings from the study performed by Enger et al. (2013) have suggested that only 33% 
of patients (who were using the anti-smoking patch varenicline reported having 
conversations with their physicians regarding the drug safety risks and the adverse effects 
they were experiencing from the drug (Enger, et al., 2013). Consequently, consumers 
were more likely to report ADRs while physicians were less likely to report them. 
Therefore, improper communication between consumers and their physicians may justify 
the large amount of nonserious ADR cases and events reported by the consumers in 
comparison to those reported by physicians, which was evident in my study. 
 Moreover, consumers may also perceive an ADR as a risk based on consumers’ 
reporting behaviors, which arise from consumers’ perception and experience of ADRs, 
especially serious ADRs, as well as their experiences in reporting ADRs directly to PV 
centers. In several studies conducted within the Netherlands and the UK, researchers have 
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explored the differences between ADR reports from patients and HCPs regarding the 
perception of the importance of ADR reporting, as well as the perception of the severity 
of the reported ADRs (van Hunsel et al., 2010; Anderson et al., 2011; & Krska et al., 
2011). The findings from the study conducted by Anderson et al. (2011) have suggested 
that patients perceived reporting ADRs directly to a PV center as significant, thereby 
resulting in more ADRs being reported in comparison to those reported by physicians. 
The findings from the studies performed by Anderson et al. (2011) and Krska et al. 
(2011) have demonstrated a difference in viewpoints between consumers and physicians 
with regards to the severity of the ADR. The same authors argued that the definition of 
“seriousness” or severity of the ADR may be dissimilar between patients and HCPs. For 
instance, patients considered ADRs resulting in disability as serious ADRs and, therefore, 
reported more ADRs resulting in disability in comparison to those reported by HCPs. 
Interestingly, the findings from my study have revealed that consumers also reported 
more ADR disability reports and ADRs resulting in disability than those reported by 
physicians. Therefore, the perception of seriousness of ADRs may justify the large 
amount of serious ADR cases and events reported by consumers in comparison to those 
reported by physicians, which was evident in my study. 
 Additionally, the findings from these studies conducted by van Hunsel et al. 
(2010) and Anderson et al. (2011) have suggested that patient reporting of ADRs is not 
only a consequence of patients’ perception of the seriousness of the ADR, but also the 
necessity to share their experiences of an ADR with others, especially the manner in 
which an ADR influences their quality-of-life on a daily basis. The same authors argued 
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that patients are eager to divulge their experiences of ADRs, as well as their perceptions 
and viewpoints regarding the significance of ADR reporting to a PV center. Hence, the 
authors concluded that altruism, viz., patients’ selfless concern for the well-being of 
others, was the primary motivation for reporting ADRs. Therefore, the potential 
inclination for consumers to report ADR cases and events out of sheer altruism may 
explain the large amount of serious and nonserious cases and events reported by 
consumers in comparison to those reported by physicians, which was evident in my 
study. 
The SARF theory may also justify the reason physicians reported less ADR 
reports and ADRs, including both serious and nonserious, in comparison to those 
reported by consumers. The findings from a systematic review performed by Lopez-
Gonzalez et al. (2009), which sought to identify knowledge and attitudes associated with 
ADR reporting, revealed that the lack of knowledge and certain reporting behaviors of 
HCP seem to be associated with under-reporting in over 90% of studies (Lopez-
Gonzalez, Herdeiro, & Figueriras, 2009). Specifically, the lack of knowledge regarding 
the functionality of SRS, as well as the attitudes (ignorance, in particular) to report 
ADRs, appear to be linked to under-reporting of ADRs by physicians. Findings from 
prior studies have suggested that numerous HCPs deemed that the sole purpose of SRS 
was to identify serious ADRs. Consequently, these HCPs Therefore, the ignorance of the 
ADR reporting requirements was prevalent among physicians, thus suggesting that 
insufficient knowledge and an oblivious attitude of physicians was evident. 
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Furthermore, Lopez-Gonzalez et al. (2009) claimed that certain attitudes of HCPs, 
such as diffidence, insecurity, complacency, lethargy, and fear, appeared to be related to 
the under-reporting of ADRs. The results from the same authors’ systematic reviewed 
have shown that diffidence (fear of appearing ridiculous) was an attitude related to under-
reporting in more than 70% of the studies reviewed. Moreover, insecurity, which may 
also be linked to diffidence, appeared in more than 65% of the studies reviewed by these 
same authors as a potential factor for under-reporting. The aforementioned attitudes are 
based on the inability for an HCP to establish a causal relationship between a drug and an 
ADR. The same authors stated that most HCPs are inclined to believe that only a causal 
relationship between a drug and an AE necessitates reporting of ADRs to an SRS. 
Therefore, such HCPs may be reluctant to report ADRs if they deem a non-causal drug-
ADR association. 
According to Lopez-Gonzalez et al. (2009), the attitude of fear may be aligned 
with the attitude of lack of confidence about confirming drug-ADR associations since 
HCPs may be less inclined to report an ADR when they feel less confident about the 
existence of a causal relationship between drugs and ADRs. This attitude may reflect the 
apprehensions of reporters “not to appear foolish”, a perception that may explain the 
reason why physicians reported less ADRs in comparison to those reported by consumers 
in my study. 
Lopez-Gonzalez et al. (2009) also claimed that the attitude of complacency, the 
belief that all ADRs of a drug are known when a drug enters the market and that only safe 
medications are marketed, seemed to be linked to under-reporting in about 67% of studies 
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they reviewed. This perception may be attributed to the lack of adequate or proper 
training and education received by HCPs, especially in epidemiology and pharmacology 
and at the clinical levels in undergraduate and medical schools. 
Moreover, Lopez-Gonzalez et al. (2009) identified the attitude of lethargy, viewed 
as a set of factors, including, lack of time and interest in rendering a diagnosis and 
reporting, which may impede or rationalize non-reporting of ADRs. The perception of the 
reporting process as a bureaucratic and challenging one was also identified as part of the 
attitude of lethargy and an additional factor contributing to under-reporting of ADRs by 
HCPs. If reporters are incognizant of the usefulness of the ADR data that may be reported 
to the system, then it is understandable, and perhaps to some extent justifiable that, 
despite any guarantee of confidentiality, those who were unfamiliar with the system 
would be less likely/less inclined to report ADR, due to an aversion to disclosing 
confidential information. Therefore, the findings from Lopez-Gonzalez et al. (2009) have 
shown that training and medical specialty appear to be related to reporting in nearly 
three-fourths of the studies that they reviewed. The same authors contended that such 
findings may yield the following insights: the greater the training, the better the attitudes 
toward ADR reporting (Lopez-Gonzalez et al., 2009). Hence, the findings from the study 
conducted by Lopez-Gonzalez et al. (2009) are critical to this study and may explain the 
need for adequate and necessary training and preparation, which may increase the 
knowledge and attitudes of physicians on ADR reporting, thereby potentially contributing 
to an increase in physician reporting of ADRs. These results may explain the under-
reporting of ADRs, including both serious and nonserious, by physicians in comparison 
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to those reported by consumers in my study. Thus, the increase in knowledge of 
physicians and the amelioration in physician attitudes may lead to an increase in ADR 
reporting. 
 In my study, I identified variations between physicians and consumers in terms of 
reporting ADRs (Aagaard et al., 2009). SARF was employed to elucidate the differences 
between HCPs and consumers’ reporting of ADRs. The perception of risk as it applies to 
the present issue involved the premise that different groups (HCPs and non-HCPs, 
researchers and the public, or HCPs and consumers) hold different views on the possible 
risks associated with some action or environment. In my study, I discovered that several 
factors contribute to the perception of risk, including factors related to the individual, the 
presentation of the risk, and the attributes of the risk (Aagaard et al., 2009). The findings 
from the studies conducted by Bongard et al. (2002), Durrie et al. (2009), and Lopez-
Gonzalez et al. (2009), which also employed the SARF framework and confirmed the 
aforementioned factors contributing to the risk perception, are important to my study and 
may explain the need for adequate education and training for physicians, as well as an 
educational intervention designed to ameliorate attitudes associated with under-reporting, 
especially among physicians, which may explain the differences in reporting of ADRs by 
physicians and consumers found in my study. Furthermore, the results from the study 
performed by Du et al. (2012), are also significant to my study and may justify the need 
to launch initiatives for consumers and physicians aimed at ameliorating patient-
physician communications, which may also explain the differences in ADR reporting 
between consumers and physicians found in my study. Hence, with respect to ADR 
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reporting and drug therapy, consumers frequently have contrasting views in their 
perception of risk versus HCPs (Aronson, 2006). Therefore, the SARF framework was 
appropriate for this study with regards to identifying under-reporting of ADRs since it 
was assumed that the consumer’s perception of risk differed from that of the physician. 
Limitations of the Study 
Despite the advantages of the FAERS database, which offers a solid structure for 
reporting of ADRs, the disadvantages of this system and its data are noteworthy to 
discuss. FAERS contains redundancies, reporting biases, and conflations (including, but 
not limited to, multiple entries and indications with ADRs) that are negatively impacting 
analysis and interpretation (McAdams et al., 2008). These biases can lead to conclusions 
of drug-ADR causal relationships where none exist and may also obfuscate potential 
drug-ADR relationships. Within the FAERs data, there is no evidence of a causal 
relationship between the drug and the reported event (FDA, 2017). Although consumers 
and HCPs are urged to submit ADR reports, the existence of the event may not 
necessarily be attributed to the drug, but rather to the condition being treated, other 
concomitant medicines or drugs, or other reasons. Therefore, the information in the ADR 
reports is indicative of the viewpoints of the reporter (FDA, 2017). 
Additionally, the FAERS data do not lead to a precise risk estimation relating to a 
drug. Risk estimation necessitates sufficient information associated with drug utilization 
to generate a numerical figure for the denominator of the risk estimate. However, this 
information is typically extracted from sales data, which may exaggerate the prescription 
and utilization levels (Hazell & Shakir, 2006). Since the denominator (number of patients 
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prescribed the product) may be unknown or erroneous, it is improbable to compute the 
incidence rate of ADR using the FAERS data (Rodriguez, Evelyn, Staffa, & Graham, 
2001). Hence, neither incidence rates nor an estimation of drug risk can be calculated 
from the FAERS data (FDA, 2017). 
An additional limitation of the FAERS database is its bias toward serious 
outcomes, in particular, the conflation of ADRs and serious outcomes (Maciejewski et 
al., 2017). This bias may have resulted from the lack of comprehension regarding the 
definition of the term “death”, specifically, whether death was listed as an ADR 
(resulting from the consumption of a medicinal product drug only) or an outcome (due to 
a disease). For instance, within the FAERS database, death was erroneously reported as 
an ADR rather an outcome resulting from the use of the drug thalidomide to treat a type 
of cancer known as complex myeloma multiplex (Maciejewski et al., 2017). Moreover, 
there are instances where the patient outcome of death may be over-reported, in relation 
to its prevalence among ADRs. Hence, the aforementioned limitation may contribute to 
over-reporting, especially among consumers. 
Since FAERS is a voluntary reporting system, not all reports for every AE or 
medication error that occurs with a product are submitted to the FDA. Moreover, 
duplicate reports may exist in which the same report was submitted by a consumer and/or 
by another reporter (the physician). Hence, the aforementioned limitations may result in 
an increase in risk associated with a product or drug (Chedid, Vijayvargiya, & Camilleri, 
2018). 
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 An additional limitation of the study that needs to be discussed is that one reporter 
may report more than one ADR event per case (report), thereby resulting in ADRs not 
being truly independent. Since my study was conducted at the ADR case and event level 
(modeled after the Danish study conducted by Aagaard et al. (2009)), the findings from 
these analyses were not at the patient/consumer level. Therefore, it was impossible to 
differentiate between ADRs, as the ADR events are identified by an ISR number instead 
of by reporter. Moreover, it was not possible to differentiate ADR events by reporter type 
and, consequently, it was not possible to designate an ADR event as primary (or 
secondary) for a reporter. Therefore, a reporter level analysis was not performed in this 
study. 
Limitations of the correlational cross-sectional research design, as well as the 
secondary data analysis in this study, must also be acknowledged. Since quantitative 
methods were employed, consumer perception of ADRs was not analyzed given that the 
latter requires qualitative methods. Qualitative data analysis of consumer reports would 
have been advantageous to this study in an effort to garner a fresh and alternate 
perspective of the consumer’s experience of ADRs. Since the correlational cross-
sectional research design was employed in this study, the secondary data may have 
resulted in implicit bias, reporting bias, and recall bias, which may yield misclassification 
or information bias (Gualano et al., 2015). Implicit bias among physicians may occur, 
thereby propagating disparities in healthcare and rendering clinical decisions, especially 
physicians’ inclination for certain drugs versus other drugs (Gawron & Bielefeldt, 2018). 
Under-reporting not only impacts older medicines and products as well as nonserious 
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ADRs, but also affects new drugs and serious ADRs (Hazell & Shakir, 2006). Reporting 
rate is also subject to fluctuate gradually and, therefore, be impacted by such aspects as 
media coverage, thereby contributing to reporting bias (Hazell & Shakir, 2006). 
Moreover, it can prove challenging to render statistical decisions on the relative risk of 
one product or indication versus another given that the rate of under-reporting may be 
different between the two medicines, thereby potentially concealing or overstating any 
statistically significant difference in toxicity profile (Hazell & Shakir, 2006). 
Furthermore, the use of this particular design provided a rather limited amount of 
information of the sample (Gualano et al., 2015). The correlational cross-sectional 
research design presented challenges regarding the determination of causal relationships 
between the distribution of ADRs by reporter (consumer versus physician) and patient 
outcome, as well as SOC and reporter demographics. The correlational cross-sectional 
design contained several limitations that are significant to examine, including internal 
validity, which is only germane to experimental designs, which attempt to establish a 
causal relationship (Frankfort-Nachmias, 2014). Since researchers do not alter the 
independent variables, they must render logical or theoretical inferences in terms of the 
direction of the causation by taking into account that correlation between variables does 
not imply causation (Field, 2013). Hence, in my study, it was challenging to make causal 
inferences when working with FAERS data for which quantitative methods were 
Recommendations 
With regards to the case- and event-based analyses performed in this study, in 
addition to analyzing consumer and physician ADR reports for severity of ADRs, it is 
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also noteworthy to assess such reports for nonserious ADRs in order to determine into 
which SOC groups they would fall and compare the findings to those with serious ADRs. 
Furthermore, it would be beneficial to assess the serious and nonserious ADRs based on 
ATC groups, which was not addressed or performed in my study. Additionally, it would 
be worthwhile to examine and analyze the chronological trends in spontaneous reporting 
of ADRs to the FAERS database by computing and comparing over time the reporting 
proportions for both serious and nonserious events, as well as the serious to nonserious 
ratio (Moulis et al., 2012). Although the seriousness of ADRs is a crucial factor to 
investigate in ADR reporting, the trends in reporting of serious versus nonserious ADRs 
have not been scrutinized, especially within the FAERS database. Therefore, additional 
research is needed and it is recommended that an observational, descriptive study is 
employed (Moulis et al., 2012). 
Additional research is needed to assess the quality of spontaneous reports, which 
is consequential for the precise assessment of drug safety signals. Crucial information 
that allows researchers to render causal inferences may potentially be omitted from ADR 
reports with inferior quality and those that contain insufficient details (Hazell & Shakir, 
2006). Moreover, ADR reports can be confounded by concurrent diseases or conditions, 
concomitant medication, or other factors. Consequently, “background noise” can emerge 
within the FAERS database, thereby rendering signal detection difficult or impossible or 
potentially creating false positive signals (Hazell & Shakir, 2006). 
To reduce the “noise” within the FAERS database, it may be worthwhile to map 
drug identifiers in FAERS to the chemical structures of these drugs’ ingredients, which 
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may yield information on the complete drug profile rather than the incomplete profile 
consisting of merely drug names and synonyms (Maciejewski et al., 2017). Moreover, 
given the millions of reports that are submitted to the FAERS database, it may be 
necessary to automate this process by utilizing machine learning methods. As a result, 
such an automated process may facilitate the identification of conflations in the data, such 
as multiple reports for the same ADR and consumer, or cases where ADRs were 
confounded with the conditions that the medicines or products are treating. For instance, 
diabetes was previously recorded as a side effect for medicines that treat diabetes 
(Maciejewski et al., 2017). 
Signals in FAERS database are obfuscated by redundancies in the chemical name, 
which yields incorrect statistical associations that lead to statistical insignificance on 
synonym aggregation, thereby concealing associations that would otherwise be 
statistically significant on aggregation (Maciejewski et al., 2017). To counteract this 
issue, it may be necessary to represent the active ingredients of drugs by their unique 
chemical structures by creating and embedding a readily searchable form within FAERS 
that enables users to easily search by the drugs’ chemical structures (Maciejewski et al., 
2017). Therefore, additional research is needed in this respect. 
Given the conflation of ADRs and outcomes, particularly the serious outcome of 
“death”, it is recommended to create a feature within FAERS that distinguishes between 
disease- and drug-related outcomes in an effort to correct the confusion as to when a 
medicinal product is utilized in different indications with distinct symptoms and 
outcomes (Moulis et al., 2012). Moreover, an additional feature to build and integrate 
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within the FAERS database is to automatically send an alert to the investigator to 
common indication biases, including high death rate in cancer, or baseline metabolic 
anomalies in diabetes (Moulis et al., 2012). Therefore, additional research is needed on 
this topic and subsequent statistical analysis on ADR reporting is recommended to 
distinguish between the outcomes associated with the disease or with the drug 
(Maciejewski et al., 2017). 
Additionally, within FAERS, the trends and biases, such as the conflation of 
ADRs and serious outcomes, in ADR reporting may hinder the reliability of drug-ADR 
associations (Maciejewski et al., 2017). Consequently, additional research on detecting 
drug-ADR associations is needed to monitor fluctuations in reporting patterns and trends. 
Since FAERS contains numerous types of conflation, these may be discovered via 
statistical analyses, such as a chemical structure and time-resolve analyses of ADR 
reporting (comparing ADR reports over time) (Maciejewski et al., 2017). Such analyses 
may be necessary to calculate time-resolved profiles of drug-ADR associations, which 
may divulge significant drug safety information relating to the comorbidities and 
similarities of ADRs between drugs and AEs across ATC, as well as their time evolution 
(the numbers of reports per month for individual ADRs observed across FAERS database 
for certain drugs) (Maciejewski et al., 2017). Moreover, the use of correlative studies 
may divulge additional features of the potential discrepancies between the clinical 
profiles of medicines or products that possess similar chemical structures (Maciejewski et 
al., 2017). 
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Consequently, ADR signals and their evolution can be observed and compared 
over time in an attempt to unveil biases that were otherwise difficult to detect. 
Furthermore, the use of time-resolved statistical analysis for drug-ADR associations can 
yield potential benefits in identifying biased reporting trends and biases within the ADR 
data (Maciejewski et al., 2017). Therefore, additional research is needed to demonstrate 
the value of performing chemical structure analysis and comparative analysis of ADRs 
over time (time-resolved analysis) in an effort to potentially divulge factors that have 
previously been undetected. 
The results from such additional research may provide unbiased classification of 
ADRs, indications, and drugs with similar clinical profiles. Once these biases and 
conflations are rectified, the molecular mechanism of previously hidden ADRs may 
ultimately be unveiled (Maciejewski et al., 2017). Therefore, the findings from such 
additional research may prompt investigators to avoid confounding associations based on 
chemical compounds and reporting biases in FAERS. 
Since FAERS is an instrumental database for consumers, physicians, 
pharmaceutical representatives and scientists, and other reporters, it can nonetheless be 
ameliorated in several ways to improve postmarketing pharmacovigilance. As was 
previously discussed in this chapter, it was recommended that an automated process is 
created to map drugs and synonyms to their unique chemical ingredients (Maciejewski et 
al., 2017). Moreover, alerts could be provided for indications where serious outcomes are 
frequent and challenging or impossible to detect or differentiate from ADRs. However, 
definitive drug-ADR associations necessitate exposure data, as the information on dosage 
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application and related pharmacokinetics (PK) data are crucial (Maciejewski et al., 2017). 
Currently, dosage information is not provided, and PK data can only be acquired from 
various sources, such as PharmaPendium, which contains both FAERS data and PK 
information (Maciejewski et al., 2017). However, these data are not directly mapped, and 
this resource cannot be accessible by the public. However, FAERS database could be 
linked to such public databases as DailyMed or drugs.com, which may yield information 
on PK, drug labels, formulations, and approved indications (Maciejewski et al., 2017). 
Therefore, it is recommended to invest in and perform additional research on acquiring 
information and performing statistical analyses that may offer further insight into drug-
ADR associations based on dose and PK data. 
One of the current disadvantages of the FAERS database is the lack of 
commentary by any reporter when submitting ADR reports. Several EU countries, 
including, but not limited to, Sweden and UK, enable any reporter to add free text case 
narratives of their ADR experiences when submitting suspected ADR reports online 
(Vilhelmsson, 2015). Therefore, it would be of utmost significance to ameliorate the 
FAERS surveillance system by introducing a feature that includes free text comments 
from all reporter types, especially consumers. Hence, such a feature may yield greater 
insight into consumer experiences with the drug and ADR. 
It would be beneficial to improve the FAERS database by creating and 
incorporating an automated reporting mechanism in FAERS that not only collects ADR 
information in a manner that would diminish inaccuracies and other errors relating to 
misclassification of ADRs and indications, but also interacts with the reporters in a user-
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friendly manner, especially with those who do not possess technical competence. 
Consequently, such qualities within the FAERS system would enable reporters to acquire 
feedback after submitting their entries, particularly with cases on the same or similar 
suspect drug, indication, patient population, and treatment programs that are most 
frequent or challenging. In addition to other advantages, the inclusion of such features 
may also assist investigators, physicians, and scientists to determine and define the 
“suspect drug” in treatment regimens, irrespective of the aim of the submitters/reporters 
(Maciejewski et al., 2017). Although such a development within the FAERS database 
would certainly necessitate funding, it is recommended that such a commitment and 
investment be a concerted public and private sector effort that would not only be 
advantageous to legislature and the scientific community, but also to the health and well-
being of the public. 
Under-reporting has been a significant problem that has plagued PV activities not 
only at a national scale, but also at a global scale. Although the reporting rate of ADRs 
has gradually improved over the years, ADRs are still under-reported in SRSs by 
consumers and physicians. Results from prior research have revealed that lack of training 
and education, as well as the lack of knowledge and certain attitudes on the part of 
physicians, contribute to under-reporting of ADRs by physicians (Lopez-Gonzalez et al., 
2009). Consequently, such findings may have potential significant impact given that 
knowledge and attitudes are factors that can be modified through proper trainings and 
educational efforts. HCPs, especially physicians, are encouraged to continue enhancing 
their comprehension regarding the objective and significance of PV in an effort to not 
132 
 
only submit ADR reports, but to ameliorate the amount and quality of ADR reports. If 
physicians are properly educated on the purpose of SRS and the benefits of ADR 
reporting, then it is possible that they may impart their knowledge upon their patients. 
Moreover, if physicians are thoroughly educated by the FDA and other regulatory 
agencies on the postmarketing safety risks, then they can also impart their teachings upon 
their patients and consumers on such risks. Therefore, it is recommended that physicians 
undergo additional training, especially at the undergraduate level of pre-medical 
education, that enhances their knowledge regarding observing and detecting ADRs at the 
clinical level, as well as increases their comprehension regarding the significance of ADR 
reporting. 
If an educational intervention is created to bridge the gap between HCPs’ 
knowledge and attitudes and under-reporting of ADRs, then the reporting rate among 
physicians may be ameliorated (Lopez-Gonzalez et al., 2009). Therefore, in an effort to 
increase reporting, it is recommended that observational studies be conducted to explore 
the utility and effectiveness of such interventions, and to assess whether a statistically 
significant relationship exists between attitudes and reporting. Subsequently, it is 
recommended to design and launch an educational initiative to ameliorate attitudes 
associated with under-reporting, particularly among physicians. Consequently, such an 
effort may contribute to an increase in signal detection, thereby allowing the health 
authorities and regulatory agencies to address and combat health disparities in a rapid 
fashion. 
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Prior research has shown findings suggesting the need for educational initiatives 
to foster efficient patient-physician communication in an effort to improve the poor 
communication between patients and their physicians. Findings from previous literature 
have demonstrated that efficacious communication between patients and their providers 
stems from the ability of HCPs to convey important information regarding their patients’ 
health, as well as the benefits and risks of drugs that patients may be consuming, in a 
manner that is precise, well-timed, thorough, and clear (Marcus, 2014). With regards to 
drug safety information, results from prior research have shown that a majority of 
patients prefer to have such information relayed to them in a manner and format that is 
accessible, easy to read, and facilitates comprehension of the material learned, with any 
new safety information clearly identified or marked. Accordingly, such a method may 
enable patients to be cognizant of new information regarding the advantages and 
jeopardizes of the drugs they are consuming, specifically for those who have been 
consuming medications for a long time and, therefore, do not feel the need to repeatedly 
check for new drug safety information (Marcus, 2014). Consequently, patients will be 
motived to actively partake in their care, thereby resulting in increased patient 
satisfaction, greater adherence to treatment guidelines and medication usage instructions, 
an amelioration in health outcomes, and a reduction in treatment times and expenditures 
associated with administering care (Marcus, 2014). 
Additionally, results from prior research have shown that physicians are more 
engaged during their conversations with their patients regarding their health when these 
physicians have drug safety information that is relayed to them in a well-timed, concise, 
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and authentic fashion, thus yielding stronger and more efficient patient-physician 
communications (Van de Wiel et al., 2011). Therefore, it is recommended to implement 
educational interventions that target efficient patient-physician communication in an 
effort to improve the poor communication between patients and their physicians. 
Previous literature findings have demonstrated findings that, although consumer 
reporting has increased globally, awareness of ADR reporting, especially among 
consumers, is still rather low (Margraff & Bertram, 2014). Findings from the UK study 
conducted by Avery et al. (2011) have revealed that only 8.5% of patients were cognizant 
of ADR reporting to SRS YCS despite patient contribution to ADR reporting since 2005 
within the UK (Avery et al., 2011). The duration between the inception of direct 
consumer reporting and the frequency of consumer ADR reporting to SRSs appeared to 
impact the reporting rate. Results from prior research have shown that those countries 
that have allowed for direct consumer reporting for a long period of time, including, the 
Netherlands, Denmark, and the UK, had a higher reporting rate (de Langen et al., 2008; 
Aagaard et al., 2009; Avery et al., 2011). Contrarily, those countries that have recently 
introduced direct patient reporting, such as Portugal, Malta, and Hungary, had a lower 
reporting rate (Inch, Watson, Anakwe-Umeh, & YC Study Collaboration, 2012; Margraff 
& Bertram, 2014). Although not the aim of the present study, it is unclear the manner in 
which physician reporting is evolving in the countries that have introduced patient 
reporting. Increasing consumer and physician awareness of ADR reporting should be at 
the forefront of national regulatory agencies, especially in countries with a low reporting 
rate. Therefore, additional research is needed to investigate the attributes of consumer 
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reporters, in particular, the psychological features that may elucidate the willingness to 
partake in consumer reporting. 
A recommended method to ameliorate under-reporting is to advertise the SRS to 
the general public and to stimulate not only HCPs, but also the consumers and their 
families who have experience with ADRs to submit ADR reports to regulatory health 
agencies, such as the FDA. Findings from a study conducted Arnott et al. (2013) have 
shown that promoting greater participation in pharmacovigilance activities will depend 
on raising public awareness, which should commence with strengthening patient-
physician communication and promoting education among consumers and HCPs, 
especially regarding drug safety risks and ADR reporting. Moreover, it is essential to 
embolden consumers to submit ADR reports and to encourage them that their actions will 
yield significance and value to their reports (Arnott et al., 2013). If communications 
between patients and their physicians are strengthened, then these conversations will 
involve discussions on the importance and value of ADR reporting, especially if both 
parties are aware of ADR reporting and its significance. While educational efforts may 
not necessarily lead to a change in reporting behaviors, such initiatives may nonetheless 
provide a better understanding of reporting behaviors among consumers and physicians. 
Thus, it may be possible to combat discrepancies in healthcare and improve the well-
being and safety of the public if concerted efforts are undertaken by researchers working 
with regulatory agencies, legislators, pharmaceutical companies, and the public. 
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Implications 
The results from this study have shown that consumer reports may not only have 
potential impact for positive social change at the individual level, but also at the greater 
level of public health. ADR reports from consumers are typically commensurate with the 
number of consumers who consume medication (Du et al, 2012). Irrespective of reporting 
an ADR, the chances of consumers being impacted by other consumers who experienced 
the same ADRs (particular if the occurrence of the ADR is infrequent and reportage of it 
has not been presented by the media) are rather low. Conversely, ADR reports from 
HCPs for a particular medicinal product may decline over time, which may be a 
consequence of HCPs’ failure to report the same ADR experienced by other patients (Du 
et al, 2012). Although the FDA mandates pharmaceutical companies to submit ADR 
reports, pharmaceutical companies may oftentimes be exempt by FDA for reporting 
certain nonserious ADRs. Therefore, the findings from this study have confirmed that 
consumer reporting is imperative to successful pharmacovigilance, especially in 
submitting ADR reports to SRSs, such as FAERs. 
Findings from this study have shown that consumer ADR reports may contribute 
to the early detection of safety issues (Hammond et al., 2007; Egberts et al., 1996). In a 
study conducted by Hammond et al. (2007), of a total 23 safety issues, 12 safety issues 
were detected by consumers at an early stage, eight issues were identified simultaneously, 
and only three issues were identified after analyzing ADR reports from consumers and 
HCPs (Hammond et al., 2007). Moreover, consumer reported ADRs may deter 
misdiagnosis and the potential exacerbation of potentially grave and fatal disorders 
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(Vihelmsson, 2015). Hence, by gathering as many consumer and patient experiences as 
possible, new and suspected ADRs may be detected, thereby enabling the analysis of 
potential causation at the population level in an effort to counteract unwarranted harm 
and suffering to levels, including, but not limited to, individual, family, organizational, 
and societal/policy (Vihelmsson, 2015). 
Additionally, the results from this study have corroborated findings from previous 
research suggesting that consumer ADR reports may yield novel insight and information 
different from that provided by reports from physicians and other HCPs. In the study 
conducted by Aagaard et al. (2009) in which an analysis of 6,319 ADR reports was 
performed, results from the study have revealed that, in comparison to other sources, 
patients were more likely to report ADRs associated with the following SOCS: “nervous 
system disorders,” “psychiatric disorders,” and “reproductive system and breast 
disorders.” (Aagard et al., 2009). 
Findings from this study have supported results from previous literature 
suggesting that consumer reporting may contribute to a greater amount of spontaneous 
ADR report submission, thereby augmenting SRSs and contributing to positive social 
change (Aagaard et al., 2009; de Langen et al., 2008; Blenkinsopp et al., 2007; van 
Hunsel et al., 2009). Results from published research have shown that consumers and 
patients are inclined to detect and report more ADRs in comparison to HCPs (Aagaard et 
al., 2009; de Langen et al., 2008; Blenkinsopp et al., 2007; van Hunsel et al., 2009). 
Similarly, the findings from my study have also demonstrated that consumers reported 
more ADRs and submitted more ADR reports than physicians. Since the number of 
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ADRs reported by consumers is higher in comparison to that of HCPs and other reporters 
(Van Grootheest, & de Graaf, 2003; Blenkinsopp, et al., 2007), and since the inclusion of 
consumer reports can provide value and additional insight beyond those reports submitted 
by HCPs, as evidenced in this study and previous studies, it would be justifiable to 
include consumer reports in the pharmacovigilance and signal detection activities of other 
countries in addition to those that currently accept consumer reporting of ADRs (Health 
Action International, 2015). Thus, by merging the reports from consumers with those of 
physicians and other HCPs, and injecting them into SRSs in a manner that enables causal 
relationships to be detected between the drugs and ADRs (and compared over time), the 
SRSs may ultimately contain informative and crucial data regarding ADRs, thereby 
contributing to the detection of signals and overall improvement in pharmacovigilance 
and drug safety (Health Action International, 2015). 
The findings from this study have an impact for positive change at the societal 
level. The FAERS SRS plays an integral role in postmarket surveillance. However, the 
system is in dire need of updates and standardizations in an effort to respond to, depict, 
and disseminate information contained within the dynamic environment and the digital 
age consisting of the Internet and social media (ISMP, 2018). To date, the FDA has stated 
that it continues to revise its critical guidelines for reporting ADRs, which is a document 
that previously updated circa 2001. No drafts for discussion have been released. 
Therefore, the results from this study may attract the attention of regulatory agencies to 
release important instructions regarding the proper and effective means of ADR 
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reporting, which may inevitably stimulate reporting of ADRs to regulatory health 
agencies by both consumers and physicians. 
Consequently, consumer reporting may actively be promoted to the general public 
not only through the official websites of drug regulatory agencies and via pamphlets and 
drug product information leaflet (for those who may not have access to the Internet), but 
also via public information. As indicated by the WHO, consumer reporting should be as 
easy and cheap as possible with, for instance, easy access to prepaid reporting forms 
(Vihelmsson, 2015). Findings from prior research have confirmed that consumer 
reporting leads to an increase in the frequency of ADRs reported to PV centers, thereby 
leading to signal detection (Vihelmsson, 2015). Furthermore, consumers who are 
cognizant of voluntary, SRSs, appeared to be knowledgeable and equipped in using such 
systems to directly report ADRs. However, increased promotion of and adequate training 
on how to utilize such systems, as well as accurate and precise ADR reporting 
requirements, are nonetheless needed (Vihelmsson, 2015). For instance, active promotion 
and increasing awareness of ADR reporting can be made at local pharmacies via 
brochures and information when a medicine that is prescribed or over-the-counter is 
purchased. These brochures may also contain easy accessible information of consumer 
ADR reports from which data have already been amassed and assessed, thereby 
presenting additional insight into potential drug-ADR associations. Within the current 
digital epoch, the utilization of social media data that is available for ADR monitoring is 
being increasingly discussed by researchers (Vihelmsson, 2015). The use of social media, 
especially Facebook and Twitter, has been recommended as one of the methods to 
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increase spontaneous ADR reporting (Vihelmsson, 2015). Currently, specific 
applications, such as MedWatcher, are available and accessible by consumers for 
reporting adverse effects resulting from drugs, vaccines, and medical devices 
(Vihelmsson, 2015). Hence, the results from this study can encourage additional research 
that may yield further insight and greater understanding of the aforementioned factors, 
which will ultimately transform into positive developments and practices given the 
necessity for more consumers to report their experienced suspected ADRs. 
Conclusion 
This study has shown that consumers reported more ADR reports and ADRs as 
well as more serious ADR reports and serious ADRs in comparison to those reported by 
physicians. Additionally, the study has revealed that consumers reported a large amount 
of nonserious ADR reports and ADRs in comparison to those reported by physicians. 
Moreover, the results from this study have revealed that female consumers reported more 
ADRs in comparison to female physicians. The results from this study have also 
demonstrated that consumers reported on different SOC groups than physicians. Based on 
the results from previous studies and from this study, consumer reports yield insight into 
not only the limitations of surveillance systems, but also the under-reporting of ADRs, 
both of which are persistent problems, especially in foreign countries and in those 
countries not currently accepting consumer reporting. The results from prior research 
have revealed that a majority of ADRs are under-reported, and the overall reporting rate 
of ADRs is circa 1% (although the rate considerably fluctuates due to the severity and 
type of reaction, as well as the characteristics of the drug). Additional findings from 
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studies have shown that only 6% of all ADRs are reported in the US (Alatawi & Hansen, 
2017). The information from consumer reports may offer additional understanding of the 
ADR experiences that consumers may have. Given the higher number of ADRs reported 
by consumers in comparison to those reported by physicians, which was evident from the 
results in this study, it would be judicious to incorporate consumer reports in the PV and 
signal detection processes, especially in foreign countries that are not currently accepting 
such reporting. Hence, the findings from this study may reveal the significance of 
consumer reporting in providing a deeper understanding and awareness of ADRs, thereby 
encouraging regulators and legislators from foreign countries to accept consumer reports 
and integrate them with physician reports within their PV practices. 
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